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Abstract 
Background: Sinusoidal obstruction syndrome (SOS) occurs in 50-70% of patients 
receiving oxaliplatin for hepatic metastasis. Patients suffering from SOS 
preoperatively are at increased risk of developing postresectional liver failure. To 
date, there is no ideal therapy to prevent SOS. Moreover, SOS delays liver 
regeneration following liver resections instigating the possible role of cell therapy. It 
is essential however to understand the dynamics of the transplanted cells. First, we 
studied the effect of a flavonoid (monoHER) on prevention of SOS. Second, we 
studied the role of a dual labeling technique for non-invasive tracking of stem cells 
in-vivo. Methods: A monocrotaline (MCT) induced SOS model was used in rats, 
with/without monoHER pretreatment. We studied hepatocellular damage and matrix 
metalloproteinase (MMP) expression. The potential inhibition of oxaliplatin-induced 
cytotoxicity by monoHER was tested in-vitro. In the second experiment, liver 
damage was induced in mice by acetaminophen. Green fluorescence protein (GFP) 
positive mouse embryonic stem cells (ESCs) were stained with a near infrared dye 
before transplantation. The distribution of the cells was monitored real-time. 
Immunohistochemistry was used to identify expression of GFP and albumin. 
Results: MonoHER ameliorated the increase in portal pressure after MCT and 
prevented hepatocellular damage. The liver damage score was lower in the 
monoHER group and was associated with less inflammation. Livers of MCT-treated 
rats had higher expression of MMP-9 when compared to monoHER group. 
MonoHER had no effect on in-vitro proliferation of colorectal cancer cells. In the 
second experiment, labeled ESCs were easily tracked by non-invasive technique.  
Within 24-hr of transplantation, homing of almost 90% cells was confirmed in the 
liver. Constitutively expressed GFP was used to study the cell distribution. 
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Conclusions: MonoHER prevented MCT induced portal hypertension and hepatic 
injury in rats. Dual labeling is an effective method for longitudinal monitoring of 
distribution, survival and engraftment of transplanted cells.  
  
6 
 
Acknowledgements 
 
It would not have been possible to take this study from the conceptual stages, at 
which I joined it three years ago, to the position that has been reached today, without 
the help and support of a great number of individuals. I cannot hope to provide an 
exhaustive record of the acknowledgments that are due, and take this opportunity to 
extend my thanks to anybody that I have omitted to mention directly. 
I would of course, firstly thank my three supervisors, Professor Massimo Malago, 
Mr. Steven Olde Damink and Dr Dipok Dhar for their help and guidance throughout 
the various stages of the project. It has been both a privilege and an inspiration to 
have been so closely supported. 
Without financial support from citadel capital scholarship foundation, and Dr Leslie 
Borthwick/ Ms.Anita Holme,Hertfordshire UK, this work would not have been 
completed. This is in addition to the clinical fellowship received by Mr. Steven WM 
Olde Damink from the Netherlands organization for health research and 
development (grant 907-06-177) and a Fast Track CRDC grant from University 
College London. 
I would like to express my deepest thanks to Professor Eddie Wisse, Maastricht 
University for his kind help and sincere guidance in conducting the electron 
microscopic study and to Prof D. Hochhauser, University College London for 
supplying the colorectal cancer cell lines. 
I would like to thank those working in the Biological Service Unit at both University 
College London and the Royal Free campus for their support, involvement and their 
continuous efforts to facilitate performing the required experiments. 
7 
 
Lastly, to my family I am truly indebted. My absence has been accepted with grace 
on numerous occasions and I have unfailingly been lifted by their smiling faces and 
laughter on my return home. To my father and mother who have been supportive 
throughout my career and have always provided me with the most sincere advice. To 
my darling wife, Sally, and to our children, Maryam and Hussein, I would like to 
express my eternal gratitude and love. 
 
 
 
 
 
 
 
  
8 
 
 
Table of contents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
Contents 
Title..........................................................................................................................................1 
Statement of originality ........................................................................................................... 2 
Dedication ................................................................................................................................ 3 
Abstract .................................................................................................................................... 4 
Acknowledgements .................................................................................................................. 6 
Table of contents ..................................................................................................................... 8 
Table of figures ...................................................................................................................... 12 
List of abbreviations ............................................................................................................... 19 
1.Introduction……………………………………………………………………………………………………………………23 
     1.1 Background…………………………………………………………………………………………………………….24 
1.2 Postresectional liver failure ......................................................................................... 25 
1.2.1 Chemotherapy induced liver damage ................................................................... 26 
1.2.2 Structural and Functional aspects of the Hepatic Sinusoid .................................. 28 
1.2.3 Pathogenesis of sinusoidal injury during oxaliplatin-based regimen ................... 31 
1.2.4 Role of SOS in development of PLF ....................................................................... 35 
1.2.5 Assessment and Detection of PLF ......................................................................... 36 
1.2.6 Prevention ............................................................................................................. 39 
         1.2.7 Treatment…………………………………………………………………………………………………………42      
1.3 Cell therapy for treatment of PLF ................................................................................ 42 
1.3.1 Liver regeneration following partial hepatectomy ............................................... 44 
1.3.2 Neoadjuvant chemotherapy and liver regeneration ............................................ 47 
         1.3.3 Hepatocyte Transplantation……………………………………………………………………………..49 
         1.3.4 What are stem cells?............................................................................................51 
1.3.5 Clinical applications of stem cells in regenerative medicine ................................ 55 
1.4 Stem cells and liver disease ......................................................................................... 56 
1.4.1 Embryonic stem cells ............................................................................................ 56 
1.4.2 Bone Marrow Stem Cells (BMSCs) ........................................................................ 59 
    1.5 Cell tracking……………………………………………………………………………………………………………..62     
2.Aims and experimental study design .................................................................................. 65 
    2.1 Section 1.…………………………………………………………………………………………………………………66 
    2.1.1 Experiment 1 ......................................................................................................... 66 
10 
 
 
       2.1.2 Experiment 2………………………………………………………………………………….…………….…….67 
    2.2 Section 2 ....................................................................................................................... 69 
3.Materials and methods ....................................................................................................... 71 
3.1 Animals ......................................................................................................................... 72 
3.2 Methods ....................................................................................................................... 72 
3.2.1 Measurement of portal pressure .......................................................................... 72 
3.2.2 Cell culture ............................................................................................................ 73 
3.2.3 Tracking of the transplanted cells using the in-vivo Imaging System (IVIS) .......... 76 
3.2.4 Cell proliferation assay .......................................................................................... 80 
3.2.5 Blood and tissue sampling/handling and storage ................................................. 81 
3.2.6 Analysis of Protein expression .............................................................................. 82 
3.2.7 Electron microscopy (EM) ..................................................................................... 87 
4.Development of a model of sinusoidal obstruction syndrome in rats ............................... 91 
4.1 Background .................................................................................................................. 92 
     4.2 Results…………………………………………………………………………………………………………………….94 
4.2.1 Portal pressure measurements ............................................................................. 94 
4.2.2 Biochemical evidence of monocrotaline induced liver injury ............................... 95 
4.2.3 Histological evidence of monocrotaline induced liver damage ............................ 98 
4.2.4 Electron microscopic examination of Monocrotaline induced liver damage ..... 103 
4.2.5 Role of Matrix Metalloproteinases in development MCT induced SOS ............. 107 
4.3 Discussion ................................................................................................................... 110 
5.Semi-synthetic flavonoid monoHER prevents development of sinusoidal obstruction 
syndrome in rats .................................................................................................................. 116 
5.1 Background ................................................................................................................ 117 
5.2 Results ........................................................................................................................ 119 
5.2.1 MonoHER reduces the portal pressure in SOS ................................................... 119 
5.2.2 Liver damage is attenuated by monoHER ........................................................... 120 
5.2.3 MonoHER reduces MMP-9 expression in the liver ............................................. 121 
5.2.4 Protective effect of monoHER on HUVEC cell line .............................................. 130 
5.2.5 MonoHER does not interfere with oxaliplatin cytotoxicity ................................ 133 
5.3 Discussion ................................................................................................................... 135 
6.Cell therapy and dynamic tracking in an experimental acute liver failure model ............ 141 
6.1 Background ................................................................................................................ 142 
11 
 
6.2 Results ........................................................................................................................ 143 
6.2.1 Dual labeling of mouse embryonic stem cells using the near infra red dye DiR 143 
6.2.2 MCT-SOS model could not be established in mice ............................................. 143 
6.2.3 Transplantation and in-vivo imaging ................................................................... 145 
6.2.4 Ex-vivo imaging ................................................................................................... 146 
6.2.5 Engraftment of the transplanted cells in the liver .............................................. 149 
6.2.6 Liver functions ..................................................................................................... 149 
6.3 Discussion ................................................................................................................... 154 
7.Discussion and future directions....................................................................................... 159 
Presentations arising from the studies contained in this thesis .......................................... 168 
Publications arising from the studies contained in this thesis ............................................ 169 
References ........................................................................................................................... 170 
Appendix-1………………………………………………………………………………………………………………………192 
Appendix-2………………………………………………………………………………………………………………………196 
Appendix-3 ........................................................................................................................... 203 
 
 
 
 
 
 
  
12 
 
 
Table of figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
 
Figure 1 Adopted with permission from Prof. Eddie Wisse (34). A schematic representation of 
the liver sinusoid showing the alignment of the SECs containing the fenestrae allowing the 
exchange of solutes with the hepatocytes-------------------------------------------------------------30 
 
Figure 2 Adopted with permission of Prof. Eddie Wisse. TEM x 6000 of normal hepatic sinusoid 
showing the fenestrae with size between 150-175 nm----------------------------------------------30 
 
Figure 3 Unpublished own group SEM images of liver SECs following oxaliplatin. Disruption of 
the SEC lining with gaps in the space of Disse can be detected (Top x5000). Exposure of the 
hepatocyte microvilli could be seen at higher magnification (Bottom x 10000)---------------33 
 
Figure 4 Unpublished own group TEM images of liver sinusoids. Normal liver showing intact 
sinusoids (Top). Following Oxaliplatin chemotherapy there is disruption in the space of 
Disse with extravasation of the erythrocytes from the sinusoidal lumen into the space 
(Bottom)-----------------------------------------------------------------------------------------------------  34 
 
Figure 5 Different sources of cellular therapy for postresectional liver failure--------------------- 43 
Figure 6 A schematic representation of the hepatic stem cells which are bipotential cells and 
may either be directed into a hepatocyte or cholangiocyte lineage.  Under certain conditions, 
Cholangiocytes, which are terminally differentiated cells, may differentiate into hepatocytes and 
regenerate the liver-----------------------------------------------------------------------------------------------46 
 
Figure 7 Steps of Embryoid body formation from undifferentiated embryonic stem cells.  The 
three most popular methods are illustrated.  In all methods, the principle is induction of 
aggregation of cells into a ball like mass which will lose the undifferentiated state in the 
absence of LIF and differentiate into ectoderm, mesoderm and endoderm from which 
hepatocytes arise-------------------------------------------------------------------------------------------58 
 
Figure 8 Schematic representation of the studied groups at the designated time points. 7  rats 
from each group were studied at 24, 48 or 72 hours following gavage with either MCT or 
vector--------------------------------------------------------------------------------------------------------- 66 
 
Figure 9 Schematic presentation of the two studied groups. Pre treatment with monoHER was 
started 24 hours before the MCT dose and was continued daily at the same time. (n=7) rats 
were sacrificed from each group at each time point------------------------------------------------68 
 
Figure 10 Experimental animal design.  40 mice were treated with APAP.  The animals were 
then divided into 2 groups Cell therapy group=Group1 with and control group=Group2.  
During the first 24 hours 19/40 animals died due to the effect of APAP.  Animals from both 
groups were then killed at 72 hours when the fluorescent signal started to decay and at two 
weeks when the signal could no longer be detected in-vivo----------------------------------------70 
 
14 
 
Figure 11  IVIS Lumina 2, computer and monitor--------------------------------------------------------76 
 
Figure 12 IVIS Lumina 2 and XFO-12 fluorescence equipment---------------------------------------77 
 
Figure 13 Portal pressure measurements in MCT treated rats compared to the control group. 
MCT administration caused a significant rise in portal pressure measurements when 
compared to the control group at all designated time points-------------------------------------94 
 
Figure 14 Serum ALT measurements in both groups.  Serum ALT was significantly higher in 
the MCT group at 48 and 72 hours, however no significant difference could be detected at 
24 hours------------------------------------------------------------------------------------------ ------------96 
 
Figure 15 Serum bilirubin measurements in both groups. Serum bilirubin levels were 
significantly higher in the MCT group when compared to the control group at 48 and 72 
hours however not at 24 hours--------------------------------------------------------------------------97 
 
Figure 16 Histological examination of the liver in both studied groups at 24 hours. Normal 
appearance of the liver in the control group with no dilatation of the hepatic sinusoids 
following gavage with DMSO (left). The effect of MCT on the liver could be seen in the 
form of sinusoidal dilatation that was extensive all over the liver (right low magnification) 
and showing the ballooning of the sinusoids and the presence of inflammatory cells  within 
the sinusoidal spaces (right high magnification) Low magnification x100, high 
magnificationx400-----------------------------------------------------------------------------------------99 
 
Figure 17 Histological examination of the liver in both studied groups at 48 hours. No liver 
damage could be detected at 48 hours in the control group (left); however in the MCT 
group there was severe congestion that was extensive over large areas of the liver (Right 
low magnification). This was associated with areas of peliosis and beginning of necrosis in 
some areas of the liver (Right high magnification). Low magnification x100, high 
magnification x400---------------------------------------------------------------------------------------100 
 
Figure 18 Histological examination of the liver in both studied groups at 72 hours. No damage 
could be detected in the control group at 72 hours (left). The liver in the MCT group shows 
extensive areas of coagulative necrosis in the centrilobular regions of the liver (right) with 
damage of the endothelial lining of the central vein and its separation from the basement 
membrane. (Right high magnification, solid arrow). Low magnification x100, high 
magnification x400---------------------------------------------------------------------------------------101 
 
Figure 19 Histological changes in the liver following oxaliplatin and MCT treatment. A very 
mild degree of SOS could be seen in the livers of oxaliplatin treated rats at 24 hours when 
compared to MCT treated rats at 24 hours (A, B). There was no progression of liver injury 
with time in the oxaliplatin group. At 72 hours oxaliplatin treated rats lacked 
hepatocellular necrosis and inflammatory cells unlike in the MCT group which progressed 
from sinusoidal dilatation at 24 hours to frank necrosis at 72 hours (C, D)-----------------102 
15 
 
 
Figure 20 Scanning Electron Microscopy images of both control and MCT treated rats at 72 
hours following gavage. The sinusoidal endothelial lining is intact in the control group 
receiving DMSO only with no detachment of the sinusoidal lining or gap formation 
(Ax2500). In the MCT treated rats, there is detachment of the sinusoidal endothelial lining 
occluding the blood flow in the sinusoid and congestion with erythrocytes (Bx5000). 
Dilatation of the fenestrae with formation of large gaps that develop in the sinusoidal 
lining of MCT treated rats (Cx2500, Dx5000 arrows pointing to gaps in sinusoids)------104 
 
Figure 21 Transmission Electron Microscopy images of the sinusoidal lining in both the control 
and MCT treated groups. The SEC lining is intact and basement membrane with normal 
sized fenestrae (Arrow) and abundant glycogen in the control group (A). There is 
ballooning and detachment of the SEC lining from the basement membrane with an 
increase in the size of the fenestrae due to gaping of the SECs (Arrow). This is also 
associated with glycogen depletion (B)---------------------------------------------------------------105 
 
Figure 22 Transmission Electron Microscopy images of the sinusoids in both the control and 
MCT treated groups. Dilatation of the sinusoid with detachment of the SEC lining from 
the basement membrane with disruption of the space of Disse could be clearly seen in the 
MCT group (B). Separation of the SECs which are floating in the sinusoid and obstruct the 
lumen leading to dilatation and direct contact of erythrocytes with hepatocytes that have 
lost their SEC lining with loss of hepatocyte microvilli (arrow) (C). The sinusoids appear 
normal in the control group following DMSO gavage with abundant glycogen compared 
with the MCT group and intact SEC lining (A)---------------------------------------------------106 
 
Figure 23 Difference in expression of MMP-2 and MMP-9 in control and MCT groups at 72 
hours. There was no marked difference in MMP-2 and MMP-9 expression in the control 
group at 72 hours (A, B). In the MCT group however, MMP-9 was markedly expressed 
when compared to MMP-2 which was similar to the expression in the control group (C, D)-
---------------------------------------------------------------------------------------------------------------108 
 
Figure 24 MMP-9 expression at different time points in the livers of the MCT group. A higher 
expression of MMP-9 could be detected in the MCT group when compared to the control 
group as early as 24 hours (A, B). Areas of MMP-9 expression included inflammatory cells 
and walls of the sinusoids (higher magnification C). An increase in the intensity of MMP-9 
expression could be seen at 72 hours (E) with strong expression in damaged hepatocytes 
that show vacuolation (higher magnification F)---------------------------------------------------109 
 
Figure 25 Portal pressure measurements in monoHER pre-treated rats compared to MCT rats. 
Pre-treatment with monoHER significantly reduced the portal pressure at all time points 
when compared to the MCT group-------------------------------------------------------------------119 
 
Figure 26 Representative samples showing morphological appearance of the liver at different 
time points. The congestion is evident at 24 hours in the MCT group (A), with appearance 
of punctuate hemorrhagic spots at 48 hours (B) and areas of frank necrosis in a deeply 
congested liver at 72 hours resembling the blue liver seen in the clinical scenario (C). 
16 
 
Congestion also occurred in the MCT+ monoHER group however was much less severe 
than in the MCT group and without the development of punctuate hemorrhages or frank 
necrosis-----------------------------------------------------------------------------------------------------122 
 
Figure 27 Serum ALT and bilirubin measurements in the two studied groups. Rats pre-treated 
with monoHER had significantly reduced serum ALT at 72 hours when compared to MCT 
treated rats. There was no difference between both groups at 24 or 48 hours. There was no 
significant difference in bilirubin levels in both groups------------------------------------------123 
 
Figure 28 Histological examination of the liver in both studied groups at 24 hours. Generalized 
sinusoidal dilatation could be detected in the MCT group with inflammatory cell 
infiltration (A, B). The sinusoidal dilatation is less pronounced in the monoHER group 
with less inflammation (C,D). Low magnification x100, high magnification x40-----------124 
 
Figure 29 Histological examination of the liver in both studied groups at 48 hours. Extensive 
areas of congestion could be seen in both groups (A, C). Inflammation is less severe in the 
monoHER group (C, D)--------------------------------------------------------------------------------125 
 
Figure 30 Histological examination of the liver in both studied groups at 72 hours. Massive 
areas of necrosis could be detected in the MCT treated liver (A), with detachment of the 
endothelial lining of the central vein and presence of subendothelial erythrocytes (B). No 
necrosis was detected in the monoHER liver at the same time point (C). Congestion was 
still present however the endothelial lining of the central vein was intact (D)---------------126 
 
Figure 31 Semi-quantification of liver damage in studied groups. The overall H&E liver damage 
severity score (A) and inflammatory cell count /HPF were significantly lower in the 
MCT+monoHER group only at 72 hours (B)------------------------------------------------------127 
 
Figure 32 Semi-quantification of MMP-9 expression in the liver samples of both groups. The 
MMP-9 expression was significantly higher in the MCT group at 24 and 48 hours-------128 
 
Figure 33 MMP-9 expression in both groups at different time points. The MMP-9 expression in 
the monoHER group was weaker than in the MCT group at all time points. The most 
striking difference could be seen at 72 hours where MMP-9 was greater in both extent and 
intensity in the MCT group----------------------------------------------------------------------------129 
 
Figure 34 Oxaliplatin effect on HUVEC cell line. Oxaliplatin reduced the viability of HUVEC 
cells which was dose dependant-----------------------------------------------------------------------131 
 
Figure 35 MonoHER attenuates the effect of oxaliplatin on HUVEC cells-------------------------132 
 
Figure 36  In-vitro analyses of proliferation of colorectal cancer cell lines. MonoHER did not 
interfere with the dose-dependent cytotoxic effects of oxaliplatin. MonoHER alone had no 
17 
 
effect on viable cell count as measured by optical density in either cell line 
(OXA=Oxaliplatin,MH=MonoHER)-----------------------------------------------------------------134 
 
Figure 37 IVIS images of GFP +ve cultured ESCs without DiR staining (LT) and with DiR 
staining (RT) showing background fluorescence using the GFP and CY5.5 filters, but not 
with the ICG filter---------------------------------------------------------------------------------------144 
 
Figure 38 Histological appearance of the liver following MCT administration in mice. No 
sinusoidal dilatation or hepatocellular damage could be detected in mice treated with MCT 
at 72 hours (A). When the mice were treated with APAP 300 mg/kg, marked hepatic 
necrosis was evident at 72 hours (B)-----------------------------------------------------------------145 
 
Figure 39 Labeling and tracking of the fluorescent ESCs following APAP administration. 
Images of a pair of mice (cell therapy group-RT) compared with the (control group-LT) 
using IVIS. At 30 min following transplantation, a strong signal could only be detected 
from the spleen where the cells were injected.  Between 3 and 24 hours following the cell 
transplantation, signal started to intensify between the spleen and the liver which is most 
probably the splenic vein owing to its tortuous course. A strong signal was detected over 
the liver 24 hours post-transplantation which faded out by 72 hour time period. At one 
week, the signal could not be detected over the liver but still strong was detectable over the 
spleen which completely disappeared by two weeks----------------------------------------------147 
 
Figure 40 Ex-vivo images showing the distribution of fluorescent cells in different organs as 
detected by the ICG filter of the IVIS. A signal was detected at the site of injection in the 
spleen however; the highest signal was noticed in the centre of the liver at 72 hours, which 
faded out after two weeks. A weak fluorescent signal was also detected in the lungs at 72 
hours and two weeks but not seen in kidneys at any of the designated time points (A). A 
graph showing the highest uptake of cells in the liver at all time points with a significant 
drop at two weeks (B)-----------------------------------------------------------------------------------148 
 
Figure 41 ESC liver engraftment following APAP induced damage. GFP +ve cells were present 
under the liver capsule (A-solid arrow) and around the central veins of the liver at 72 
hours as seen under direct fluorescence (A-dashed arrow) with no fluorescence detected in 
the control group (B). Characteristic pattern of APAP induced liver damage after 72 hours 
affecting mainly the centrilobular portions of the liver with marked damage of the 
pericentral hepatocytes in both the cell therapy and control groups although pericentral 
vacuolation was more evident in the control group (C and D). At 2wks, the GFP +ve cells 
could be detected using IHC in the hepatic parenchyma and within the sinusoidal lining 
(E). Localised colonies of GFP +ve cells were also detected in the spleen at 2 weeks (F). 
After 2 weeks the liver recovered in both groups with the liver sections from the cell 
therapy group (G) showing less inflammatory cells and congestion than in the control 
group (H)(Scale bar=200µ)-----------------------------------------------------------------------------151 
 
Figure 42 Serial sections examined for GFP and Albumin expressions. GFP +ve transplanted  
cells (A) showed very faint albumin expression at the cell periphery of dividing cells at 72 
18 
 
(B), whereas areas stained with anti-GFP antibody (C) were positive for albumin(D) at 2w 
following cell therapy (Scale bar=100µ)-------------------------------------------------------------152 
 
Figure 43 Serum levels of ALT, Albumin, Bilirubin and Urea are shown.  ALT level 
significantly dropped in both groups at two weeks when compared with the 72 hour time 
point. When compared with the 72 hours, there was a significant reduction in serum ALT 
level at two weeks in the ESC treatment group only but not in the control group (A). 
Albumin level also improved in both groups with level being significantly higher in the cell 
therapy group when compared with the control group at two weeks (B). The drop in urea 
levels was not significant in both groups. (C) Bilirubin levels dropped significantly from 72 
hours to two weeks with no significant differences between groups at similar time points 
(D)----------------------------------------------------------------------------------------------------------- 153 
 
Figure 44 Mir126 expression in the three studied groups at different time points.  A steady 
increase with time in the MCT group; however expression was five-fold lower in the 
MCT+ monoHER group when compared to the MCT group at 72 hours-------------------162 
 
Figure 45 well-formed EBs in culture using GFP+ C57BL6 mouse embryonic stem cells using 
the static suspension method (A)  Under fluorescence microscopy (B)-----------------------166 
 
Figure 46 The amplification plot following the PCR reaction-----------------------------------------195 
 
Figure 47 Primary cell culture of ligated bile duct epithelial cells showing organization of the 
cells at different time points. At day 10 the cells form a structure resembling a bile duct 
with a lumen and surrounded by polyhedral and rounded cells with another layer of 
fibroblasts and mesenchymal cells--------------------------------------------------------------------200 
 
Figure 48 A primary cell culture of bile duct epithelial cells with some cells of variable 
morphology expressing CD 133-----------------------------------------------------------------------201 
 
  
19 
 
 
List of abbreviations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
APAP:          Acetaminophen 
ALF:            Acute liver failure 
ALT:            Alanine aminotransferase 
ASCs:           Adult stem cells 
AST:            Aspartate aminotransferase 
APRI:           AST to platelet ratio index 
BDL:            Bile duct ligation 
BM:              Bone marrow 
BMSCs:        Bone marrow stem cells 
CCD:            Charge coupled device 
CASH:          Chemotherapy associated steatohepatitis 
CECs:           Circulating endothelial cells 
CRC:            Colorectal cancer 
CLM:           Colorectal liver metastasis 
DAB:           3,3’ –diaminobenzidine tetrahydrocholride 
DiR:             1, 1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide 
DMSO:         Dimethyl sulfoxide 
EM:              Electron microscopy 
EBs:             Embryoid bodies 
EGCs:           Embryonic germ cells 
ESCs:           Embryonic stem cells 
FBS:             Fetal bovine serum 
5 FU:            5-Flurouracil 
GFP:            Green fluorescent protein 
HSCs:           Haematopoietic stem cells 
H&E:           Haematoxylin and eosin 
HGF:            Hepatocyte growth factor 
21 
 
HT:               Hepatocyte transplantation 
HUVEC:      Human umbilical vein endothelial cell 
HA:               Hyaluronic acid 
ICC:              Immunocytochemistry 
IHC:             Immunohistochemistry 
ICG:             Indocyanin green 
iPS:              Induced pluripotent stem cells 
ID1:              Inhibitor of DNA Binding 1 
i.p:               Intraperitoneal 
IVIS:            Invivo imaging system 
LIF:             Leukemia inhibitory factor 
LT:               Liver transplantation 
MMP:           Matrix-metalloproteinase 
MSCs:          Mesenchymal stem cells 
MIR:            Micro RNA 
MCT:           Monocrotaline 
MCT-P:        Monocrotaline pyrrole 
MonoHER:  7-monohydroxyethylrutoside 
MTS:           3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-   
                   sulfophenyl)-2H-tetrazolium 
NIR:           Near infra red 
NO:            Nitric oxide 
NRH:          Nodular regenerative hyperplasia 
PBS:           Phosphate buffer solution 
PMN:          Polymorphonuclear 
PP:             Portal pressure 
PVE:           Portal vein embolization 
22 
 
PLF:           Postresectional liver failure 
SEM:         Scanning electron microscopy 
SECs:         Sinusoidal endothelial cells 
SOS:          Sinusoidal obstruction syndrome 
sTM:          Soluble thrombomodulin 
SDF-1:       Stromal derived factor-1 
SC:            Subcutaneous 
TEM:         Transmission electron microscopy 
VCAM:      Vascular cell adhesion molecule 
VEGF:       Vascular endothelial growth factor 
vWF:         Von willebrand factor 
 
  
23 
 
 
1-Introduction 
 
 
 
 
 
 
 
 
 
 
 
24 
 
1.1 Background 
 
Liver failure, which may either present in an acute or chronic form, is a growing 
health problem ranking as one of the leading causes of death worldwide. The 
etiology and presentation of liver failure differs according to age. In children, the 
leading identifiable cause of acute liver failure (ALF) is acetaminophen (APAP) 
induced hepatic toxicity followed by metabolic and autoimmune liver disease (1). 
Although APAP is the most common cause of ALF in adults in the UK, acute viral 
hepatitis is the leading cause worldwide (2). 
 In children, biliary atresia is the most common cause of chronic liver disease with 
excellent survival rates following liver transplantation (LT) (3). Liver cirrhosis 
however, remains the most common cause of end stage liver disease in adults with 
its two main etiologies; alcohol consumption and viral hepatitis C. The only 
established long-term successful treatment for these conditions is LT with long 
waiting lists of patients to be transplanted (4). Patients with liver tumours are not 
treated with LT but with liver resections and have excellent postoperative recovery; 
however liver failure may occur in about 2-5% of patients following liver resections 
with considerable mortality (5). LT  maybe used in critical situations to rescue the 
liver following postresectional liver failure (PLF) and has shown better survival rates 
than with any other method of treatment (6). There has been an ethical argument 
however, whether to put patients with PLF on a priority list for receiving an organ 
compared with other indications of ALF. Also, patients with PLF have very high 
mortality rates when compared to the other indications of LT. For these reasons, PLF 
represents a complex and challenging problem to most liver surgeons.  
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1.2 Postresectional liver failure 
 
Liver resection remains the gold standard of treatment for both primary and 
secondary liver tumours with the most common indications for liver resection being 
colorectal liver metastasis (CLM) (7), followed by hepatocellular carcinoma and 
cholangiocarcinoma (8).  
In the United Kingdom, colorectal cancer (CRC) is the third most common cancer 
after breast and lung with about 40,000 newly diagnosed cases and 16,000 deaths per 
annum (Cancer Research UK, 2008). CLM occurs in at least 30% of patients with 
CRC and accounts for more than two thirds of deaths (9), (10). Advances in 
chemotherapeutic drugs and changes in the resectability criteria have improved 
survival in patients after resection of CLM (11). In England, the liver resection 
population access rate was 1.82 and 2.95/100,000 general population in 2000-1 and 
2004-5, respectively, with a 62% increase during the 5-year study period (12). The 
incidence of short-term postoperative complications on the other hand has increased 
with the more aggressive approaches and more specifically the occurrence of PLF 
(13). 
PLF is a dreadful complication following major hepatic resections occurring once 
the remnant liver volume falls below a critical threshold. It presents a spectrum that 
ranges from mild liver dysfunction to ALF.  A similar problem occurs in patients 
following LT due to size mismatch between recipients and the graft resulting in a 
small-for-size syndrome (14). Several definitions for PLF exist; however the best 
quantitative definition with specificity of 96.6% is the 50-50 criteria, which 
describes PLF as prothrombin time <50% and serum bilirubin > 50% µmol on 
postoperative day 5. Serum bilirubin is preferred because prothrombin time may be 
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altered by administration of fresh frozen plasma and a peak bilirubin of 7.0 mg/dl 
has been considered a specific cut-off value for PLF related deaths (15),(16) 
To prevent PLF, the acceptable remnant liver volume following a resection should 
be at least 25% (17). However this may change if the remaining liver parenchyma is 
dysfunctional, where the required remnant volume of liver parenchyma would range 
from 30-40 % in patients with chemotherapy induced liver damage to 40-50 % in 
case of cirrhosis. When the remnant liver volume falls below this critical threshold, 
liver failure develops. 
 
1.2.1 Chemotherapy induced liver damage 
 
Until recently palliative chemotherapy was the main line of treatment for patients 
with unresectable CLMs with very few patients surviving for 5 years due to low 
tumour response rates (18). The revolution in chemotherapy regimens with the 
introduction of 5-Flurouracil (5-FU), Oxaliplatin and Irinotecan has converted non-
resectable liver metastases into resectable ones allowing a 10-30% increase in 
patients eligible for curative surgery with a 30-35% survival at 5-years (19), (10). 
Moreover, these powerful modern neoadjuvant chemotherapy protocols have 
allowed a reversal of the alternative approach with chemotherapy first, followed by 
liver resection and then resection of the CRC. This allows early treatment of the 
CLM which are the main cause of death in these patients. Also, it has the advantage 
of patient stratification into responders who have a good prognosis and non-
responders in which aggressive treatment should be avoided and would benefit from 
palliative treatment (20). There have been debates regarding the timing of surgery 
following neoadjuvant chemotherapy and the consensus is that surgery should be 
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performed once the CLM become resectable. This is due to the toxic effect of 
neoadjuvant chemotherapy on the normal hepatic parenchyma with an increase in 
development of PLF in these patients. Also, there is a risk of disappearance of small 
hepatic lesions with high impact chemotherapy. These lesions are difficult to treat 
and may lead to recurrence in the future (21) (20).  
 
Irinotecan 
 
Irinotecan inhibits topoisomerase I, resulting in single strand DNA breaks and 
inhibition of DNA synthesis. When used in combination with 5-FU and Leucovorin 
it leads to both an improved response rate and survival in patients with metastatic 
CRC (22). Unfortunately, Irinotecan-based regimens are associated with the 
development of chemotherapy associated steatohepatitis (CASH) in patients with 
CLM, independent of their body mass index (23). Simple steatotic hepatitis can 
develop into steatohepatitis after exposure to oxidative stress and reactive oxygen 
species. Irinotecan indeed induces oxidative stress leading to the development of 
CASH and is associated with increased 90-day mortality after liver surgery for CLM 
(23). 
Oxaliplatin 
 
Oxaliplatin is a third generation platinum containing antineoplastic agent which has 
a spectrum of activity that is different from first and second generation platinum 
compounds. Oxaliplatin has been shown to be effective against colon, breast and 
gastric cancers, in addition to sarcomas and renal cell carcinomas with the 
concentration and duration of exposure being important factors for its cytotoxicity 
(24), (25). Oxaliplatin exerts its activity by causing intra- and interstrand cross links 
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with DNA within 2 hours of its administration. This blocks DNA replication and 
transcription leading to apoptotic cell death (26). 
Oxaliplatin is associated with an improvement in disease free survival when used as 
an adjuvant in stage II or III CRC in combination with 5-FU and leucovorin (27). 
Oxaliplatin based regimen are highly effective but induce histologically proven 
sinusoidal injury in 50%-75% of patients with CLMs treated with oxaliplatin based 
chemotherapy prior to liver resection (28). The sinusoidal injury seen is 
characterized by damage to sinusoidal endothelial cells (SECs), hepatocellular 
atrophy, disruption of the sinusoidal membrane, sinusoidal dilatation, collagenization 
of the space of Disse, centrilobular or perisinusoidal fibrosis and resembles the 
injury observed in patients who have undergone myeloablative conditioning therapy 
before hematopoietic stem cell (HSC) transplantation (8, 9). This type of injury is 
described as the sinusoidal obstruction syndrome (SOS), formerly known as veno-
occlusive disease. However, up until now, no reliable methods have been developed 
for the detection of endothelial injury during oxaliplatin-based chemotherapy and 
prior to liver resection. 
Patients with oxaliplatin induced SOS present with increased bilirubin level, 
hepatomegaly, right upper quadrant pain and weight gain or development of ascites 
(29). Patients with histologically proven sinusoidal injury who have undergone 
major hepatectomy have a higher risk of post-resectional morbidity and longer 
hospital stay (30). 
1.2.2 Structural and Functional aspects of the Hepatic Sinusoid 
 
The hepatic sinusoids represent the principal site where blood regulation and solute 
exchange takes place between the blood and the space of Disse in the liver. The 
SECs which constitute the sinusoidal lining start to form between the 4
th
 and 6
th
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week of gestation. Initially they do not contain fenestrae and acquire the fenestrated 
architecture between the 10
th
 and 17
th
 week of gestation (31). The main afferent 
supply to the sinusoid is through small branches of the portal vein with a less 
consistent contribution from the arterial system. Following the exchange of blood 
and solutes, blood drains into the central venules (32). This transvascular exchange 
allowing better hepatocyte oxygenation and adequate clearance of toxic metabolites 
and chylomicron remnants is possible due to the unique structure of the SECs 
containing fenestrae measuring about 170 nm in diameter within their cytoplasm. 
This permits access of the solutes into the space of Disse where the hepatic 
microvilli project (33) (Fig.1 and 2). 
   Ultrastructural studies have shown that the fenestrae are dynamic structures 
supported by actin cytoskeletal filaments under paracrine control of vascular 
endothelial growth factor (VEGF) released from the hepatocytes and the stellate cells 
(35). Kupffer cells are resident macrophages that are anchored to the sinusoidal wall 
through interdigitations between the endothelial cells. They represent an important 
component of the sinusoidal lining and are responsible for clearance of 
macromolecules as well as toxic substances in the portal flow (32).  
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Figure 1 Adopted with permission from Prof. Eddie Wisse  (34). A schematic 
representation of the liver sinusoid showing the alignment of the SECs containing 
the fenestrae allowing the exchange of solutes with the hepatocytes. 
   
   
 
Figure 2 Adopted with permission from Prof. Eddie Wisse. TEM x 6000 of normal 
hepatic sinusoid showing the fenestrae with size between 150-175 nm. 
31 
 
 
1.2.3 Pathogenesis of sinusoidal injury during oxaliplatin-based regimen 
 
Microvascular injury to SECs is a key factor in the development of SOS. Drugs 
implicated in the development of SOS (e.g. oxaliplatin, azathioprine) deplete SEC 
glutathione and seem to be selectively toxic to SEC as depletion of hepatocyte 
glutathione has not been shown to occur (36). This is most probably due to a greater 
glutathione defensive capacity in hepatocytes with a higher turnover when compared 
to SECs, in addition to exposure of the circulating toxic metabolite at a much higher 
concentration than the hepatocytes (37). The resulting hepatocellular injury therefore 
seems to be more related to the SEC-induced microvascular events leading to 
hepatocyte ischemia rather than a direct hepatotoxic effect. The depletion of SEC 
glutathione has not yet been proven in-vivo or in-vitro for oxaliplatin, but several 
articles have already shown that one of the two main metabolites of oxaliplatin; the 
heavy metal DACH platin, reacts to and is detoxified by glutathione through adduct 
formation. It has been shown that high glutathione levels prevent injury induced by 
platinum-containing chemotherapeutics and that a decrease in glutathione 
concentrations induce cytotoxicity. SEC glutathione depletion is followed by toxicity 
to SECs (38).  
SOS is characterized by swelling and rounding up of SECs, sinusoidal injury 
including loss of SEC fenestration, formation of gaps between SECs (Fig.3). Red 
blood cells and inflammatory cells eventually penetrate beneath the swollen SECs 
into the space of Disse (Fig.4). In addition, swollen SECs block the sinusoidal lumen 
with redirection of blood flow into the space of Disse leading to complete dissection 
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of the sinusoidal lining wall. Kupffer cells, SECs and stellate cells embolize into the 
sinusoid and block sinusoidal flow (39). 
Also, nitric oxide (NO) plays a critical role in the pathogenesis of SOS. NO 
production is reduced due to Kupffer cell depletion (initially) and SEC injury. Due to 
the loss of NO, NO mediated inhibition of matrix-metalloproteinase-9 (MMP-9) 
synthesis declines and active MMP-9 separates SECs from the underlying basement 
membrane which leads to a further decrease in NO synthesis (40).  
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Figure 3 Unpublished own group SEM images of liver SECs. This patient had a 
liver resection following 6 cycles of oxaliplatin based neoadjuvant chemotherapy. 
Disruption of the SEC lining with gaps in the space of Disse can be detected (Top 
x5000). Exposure of the hepatocyte microvilli could be seen at higher magnification 
(Bottomx10000)
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Figure 4 Unpublished own group TEM images of liver sinusoids. Normal liver 
showing intact sinusoids (Top). Following oxaliplatin chemotherapy there is 
disruption in the space of Disse with extravasation of the erythrocytes from the 
sinusoidal lumen into the space (Bottom). 
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1.2.4 Role of SOS in development of PLF 
 
Several reports have shown that oxaliplatin-induced SOS is associated with an 
increased risk of PLF following major hepatic resections for CLMs. Karoui et al (21) 
compared two groups of patients with CLMs who had similar demographics and 
preoperative liver functions. Both groups were subjected to major hepatectomy with 
total vascular exclusion and the pathological examination of the non-tumorous liver 
revealed presence of SOS without steatohepatitis. There was a statistical significant 
increase in the incidence of PLF in patients who had received prolonged oxaliplatin 
based chemotherapy (21). Similarly, Nakano et al (30) showed that patients who 
developed oxaliplatin-induced SOS had higher preoperative aspartate 
aminotransferase (AST) and alkaline phosphatase levels with impaired functional 
liver reserve in the form of significantly higher values of indocyanin green (ICG)-
R15 when compared to patients with no SOS. Also, there was a significant 
association between SOS and PLF in patients undergoing major hepatic resections, 
and those with higher bilirubin levels and longer hospital stay. The authors 
concluded that a major hepatectomy should be delayed if SOS is diagnosed or even 
suspected preoperatively and if delay is not possible then other strategic options 
should be considered including portal vein embolization (PVE) or a two-stage 
hepatectomy (30). Although Nakano et al suggested a time interval between the last 
chemotherapy session and the operation; it still remains questionable whether or not 
SOS is a reversible condition. Indeed, Rubbia-Brandt et al showed that pathological 
evidence of SOS in the liver exists even after discontinuation of the chemotherapy 
(28). Soubrane et al (41) also reported that 74% of patients who received oxaliplatin 
within 4 months of the hepatectomy had impairment of the functional liver reserve 
when compared to the control group. Moreover, patients with severe SOS lesions 
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often developed ascites with possible mortality. (41). A recent report showed that 
patients who develop oxaliplatin-induced high-grade SOS not only have a higher 
incidence of PLF but also develop earlier intra-hepatic recurrences with a negative 
impact on survival (42). 
 
1.2.5 Assessment and Detection of PLF 
 
Estimation of the function of the remaining liver volume is an essential preoperative 
step in planning for a successful liver resection and is most commonly assessed by 
CT scan.  However, the function of the remaining liver may be compromised by 
cirrhosis, fibrosis or chemotherapy induced damage, and therefore functional studies 
are needed. ICG is a substrate whose extraction depends on both the functioning 
hepatocyte mass and the hepatic blood flow.  A safe resection would be considered 
when the ICG retention is 14% at 15 minutes (43). There are several scoring systems 
to predict PLF in patients with cirrhosis; most widely used is the Child-Pugh scoring 
system depending on the presence or absence of ascites, encephalopathy, and 
measurement of albumin, bilirubin and prothrombin time (44). An early diagnosis of 
SOS while patients are on chemotherapy or during the preoperative work up would 
be very beneficial to patients avoiding postoperative morbidity and mortality. 
 
Detection of endothelial damage 
 
Sinusoidal endothelial damage is the key feature of SOS of the liver following 
neoadjuvant chemotherapy treatment for CLM. A number of circulating markers for 
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endothelial function and activation of the coagulation cascade have been discovered 
in recent years: 
 Hyaluronic acid (HA) is a marker of endothelial function; It is a high-molecular 
weight polysaccharide, synthesized by mesenchymal cells throughout the body. 
It comes from peripheral tissues via the lymph into the circulation. Plasma HA is 
almost exclusively (85-90%) metabolized by liver SECs (45). HA uptake in 
SECs is achieved by means of receptor mediated endocytosis followed by 
degradation by lysosomal hyaluronidase, β-glucoronidase and β-N-acetyl-
glucosaminidase. The waste products are glucuronic acid and N-
acetylglucosamide. The plasma half life of HA is 2-5 minutes. Because the 
elimination capacity of HA is 10-times that needed for normal endogenous 
production, the serum HA levels are not influenced by increased input but 
depend predominantly on the scavenging function of SECs. Whether increased 
serum levels of HA are caused by increased production or decreased clearance 
capacity of the hepatic sinusoids, can be evaluated by means of a hyaluronan 
loading test (46) or [
11
C] hyaluronan positron emission tomography (47). 
Increased levels of HA might be seen during SOS because of decreased SEC 
function or increased vascular damage due to shunting of portal blood. HA has 
already been used in patients undergoing myeloablative conditioning therapy 
before HSC transplantation to detect the presence of SOS (48). Mean peak serum 
HA level was significantly higher in patients who had a diagnosis of SOS 
compared to those who did not, 1173 ± 982 ng/mL versus 445 ± 736 ng/mL 
(p=0.01). Serum levels increased in time in patients with severe SOS. 
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 Von Willebrand Factor (vWF) is an endothelial ligand for platelet glycoprotein 
and is endothelium-specific. It has an important role in mediating adhesions of 
platelets to the endothelium. When endothelial cells are damaged, vWF is 
released from Weibel-Palade bodies. vWF antigen can be measured in citrated 
plasma. Increased vWF levels are expected during and after oxaliplatin based 
chemotherapy resulting in sinusoidal damage (49). 
 Soluble Thrombomodulin (sTM) is a molecule specifically expressed by 
endothelial cells, a protein C cofactor with anticoagulant capacities. sTM can be 
released from damaged endothelial cells and measured in citrated plasma by 
means of an enzyme-linked binding assay. Increased sTM levels were observed 
in patients with multiple complications after bone marrow (BM) transplantation 
(50). 
CD146 positive circulating endothelial cells (CECs) are detached from their 
endothelial alignment and indicate severe endothelial damage. The necrotic CECs 
might cause an inflammatory reaction once phagocytosed by activated macrophages 
or bound to toll-like receptors. CECs can be detected by means of immune-magnetic 
isolation using anti-CD146 antibodies (51).  
The AST to platelet ration index (APRI) and the FIB-4 which combines standard 
biochemical values and age are two scoring systems that were originally used to 
predict development of liver fibrosis in hepatitis C patients (52), (53). Recently, 
these scoring systems have been used to predict high grade sinusoidal lesions 
following oxaliplatin chemotherapy with a sensitivity and specificity of 87% and 
69% respectively (41). The advantages of these scoring systems are that they are 
inexpensive and the parameters used for calculation are part of the standard liver 
investigations required preoperatively. More invasive investigations for preoperative 
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diagnosis of SOS have been suggested including preoperative diagnostic laparoscopy 
for detection of a blue liver. Also a preoperative liver biopsy has been suggested for 
diagnosis of SOS. Limitations are that a minimum of 25mm of liver tissue is 
required to provide accurate information using a semiquantitative score. This in 
addition to the variability of distribution of liver lesions in SOS makes a preoperative 
liver biopsy a less reliable diagnostic measure (54). 
 
1.2.6 Prevention 
The mainstay of management of PLF should be a preventive one.  
Preoperative 
 
Identifying problematic patients who are likely to develop PLF in the future is key in 
prevention of PLF. Preoperative correction of the patients’ co-morbidities is very 
important in prevention of PLF including special attention to the nutritional status. 
Parenteral nutrition provides adequate caloric intake and nitrogen support. Enteral 
nutrition on the other hand prevents gastrointestinal atrophy and preserves normal 
gut flora. No statistically significant differences could be detected between enteral 
and parenteral nutrition, however patients with enteral nutrition show better 
postoperative immune competence (55). There have been debates regarding the 
routine performance of percutaneous transhepatic drainage in all patients with 
jaundice as it has shown no benefit in patients with obstructive jaundice resulting 
from tumours (56). Recently, in a cohort of patients with tumours in the head of 
pancreas, it has been shown that preoperative biliary drainage is associated with a 
higher complication rate when compared to early surgery (57).  
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Oxaliplatin-induced SOS has a negative impact on postoperative recovery of liver 
function and is associated with an increased incidence of PLF. Several factors that if 
taken into consideration during the planning of the neoadjuvant chemotherapy might 
reduce the risk of SOS related PLF. The most important factor seems to be the 
number of chemotherapy cycles before the operation. Karoui et al (21) correlated the 
development of PLF with the number of chemotherapy cycles, where patients 
receiving a median number of five cycles had fewer postoperative complications 
than patients receiving a median number of 12 cycles. A recent report showed that 
more than nine cycles of oxaliplatin based chemotherapy was not associated with 
improvement in the pathological response and was considered an independent 
prognostic factor with patients having a four-fold risk of developing SOS and PLF 
when compared to patients receiving less than nine cycles (58). Soubrane et al 
showed that although the number of chemotherapy cycles might correlate with the 
development of SOS, this could not accurately predict the severity of SOS lesions 
and that a short interval period between the end of chemotherapy and operation time 
was a more important factor associated with high grade SOS lesions and PLF (41). If 
postponing surgery is not possible or there is fear that delaying surgery might be 
associated with cancer progression then preoperative PVE could be done to augment 
the volume of future remnant liver and thus circumvent PLF. 
Preoperative PVE is an effective measure to induce hypertrophy of the contralateral 
lobe of the liver.  The gain in the residual volume ranges between 4 and 21 ml/day 
with a parallel improvement of liver functions, and an average of 4-6 weeks is 
required before the operation to achieve adequate liver hypertrophy (59). This 
procedure has led to an increase in the percentage of patients undergoing extended 
hepatectomies with fewer complications and a shorter hospital stay.  This technique 
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however is not always successful and may result in an increase in the size of the 
existing tumour (60), (61).  
 
Intraoperative and postoperative 
 
Intra and postoperative hypotension also plays a role in prolonging the hepatic 
ischemia and this may result from either blood loss or sepsis; which has a 
suppressive effect on kupffer cell function (62). Neoadjuvant based oxaliplatin 
chemotherapy regimens have been associated with more intraoperative blood loss 
and packed red cell transfusions when compared to the control group. This has been 
hypothesised to be related to increased splenic sequestration of platelets leading to 
thrombocytopenia (63), (64).  
Several measures have been described to reduce excessive intraoperative blood loss 
including total vascular occlusion or lowering the central venous pressure (65). 
Patients who were subjected to ischemic preconditioning through intermittent 
vascular occlusion were associated with less morbidity when compared to 
continuous vascular occlusion. There was no difference between both groups in term 
of mortality or development of liver failure (66). Ischemic Preconditioning involves 
intermittent clamping of the hepatic pedicle for a short period (5-10) minutes 
followed by reperfusion (5-10) minutes. This renders the liver more tolerant to 
subsequent prolonged episodes of ischemia and has been shown to decrease the 
severity of liver necrosis through several mechanisms including the upregulation of 
cytokine TNF and IL-6 with downregulation of TGF-β (67). 
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1.2.7 Treatment 
 
Due to the low incidence of PLF, there is great difficulty in conducting a randomized 
controlled trial that would evaluate the effect of different treatment modalities in 
these patients (5). Patients with PLF should be treated in the ITU with intensive 
monitoring and support of the vital body functions.  Due to the strong association 
between sepsis and PLF, antibiotics should be administered empirically in the setting 
of PLF and later adjusted according to the results of the cultures taken (17). Several 
measures for liver support have been documented and could be divided into cell-free 
liver support systems and bioartificial livers. The former include plasma exchange 
(68) and the molecular adsorbent recirculating system (69), none of which seem to 
provide definitive treatment for PLF as they cannot replace the synthetic and 
metabolic functions of the failing liver.  
Bioartificial devices have been designed in the recent years to support functions of 
metabolic organs. They are basically extracorporeal bioreactors loaded with different 
cell types (70). The cells used in the liver model are either human or porcine 
hepatocytes (71). However more research needs to be conducted focusing on 
developing an ideal bioreactor which should resemble both the normal hepatic tissue 
structure and function (72). A more promising future management might be the 
application of stem cells or hepatocytes in the treatment of PLF. 
 
1.3 Cell therapy for treatment of PLF 
 
Cell based therapy is considered a new therapeutic tool that has shown great 
potential in the recent years and is expected to avoid whole-organ transplantation in 
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the future. The target of cell therapy is to replace the defective cells in order to 
substitute organ function through transplantation of cells (73). In case of larger tissue 
defects, cells alone would not be able to replace the function and tissue engineering 
is required to load cells on to 3-D biodegradable scaffolding system to support their 
growth and function (74). There are several sources of cells which can be used in 
prevention and treatment of PLF (Fig.5). 
 
Cell therapy 
sources for 
PLF
Hepatocytes Cholangiocytes
Stem cells
Embryonic Bone marrow
HematopoieticMesenchymal Endothelial
Induced 
Pluripotent
-Umbilical cord
-Placenta  
 Figure 5 Different sources of cellular therapy for postresectional liver failure. 
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1.3.1 Liver regeneration following partial hepatectomy 
 
The ideal way of increasing the functioning residual liver volume following major 
hepatic resections would be through increasing the number of functioning 
hepatocytes.  Replenishing the lost hepatocyte mass might occur through either 
stimulation of the endogenous hepatocyte population or through an exogenous 
supply of hepatocytes or cells with the potential to differentiate into hepatocytes.    
The liver has an enormous ability to regenerate dependant primarily on the 
proliferation capacity of hepatocytes. The hepatocytes are in a quiescent state in the 
intact liver and are non-responsive to growth factors. Following partial hepatectomy 
or hepatocyte loss, the hepatocytes are sensitized by TNF released from the non-
parenchymal cells which release a cascade of growth factors (75). Hepatocyte 
growth factor (HGF), epidermal growth factor and transforming growth factor-α are 
the primary mitogenic growth factors that initiate a powerful regenerative drive 
leading to rapid hepatic regeneration through proliferation of the hepatocytes.  This 
occurs in coordination with proliferation of non-parenchymal cells and the support of 
the extracellular matrix (76).  
Liver regeneration following partial hepatectomy requires two rounds of hepatocyte 
replication to restore the liver volume. The duration for complete restoration of the 
liver volume after a partial hepatectomy ranges from 5-7 days in rats and from 8-15 
days in humans (77). Hepatocytes have been shown to have their highest DNA 
synthesis 24 hours following the hepatectomy; followed by Kupffer cells at 48 hours 
and endothelial cells at 96 hours (78). 
With more extensive liver resections, the regenerative drive of hepatocytes is 
insufficient (79) and regeneration then depends on the stimulation of a second 
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compartment comprised of hepatic progenitor cells as described by Faber (80), (81). 
These are bipotential cells with the ability to differentiate into either hepatocytes or 
biliary epithelial cells (82). It is important to mention however that this only occurs 
when liver resection is associated with a background of chemical injury which is the 
situation following oxaliplatin chemotherapy and not following liver resection per se 
(83). These oval cells reside in four possible 3-dimensional niches, most important of 
which are the canals of Hering representing the small peripheral branches of the 
biliary tree (84). The interaction between the cells in these niches with hormones and 
growth factors adds to their flexibility and regenerative capacity (85). These oval 
cells have been postulated to be the progenitors of hepatic stem cells because they 
share cell surface markers with HSCs such as c-kit, Sca-1, Thy-1, and CD-34 (86). 
This may be clearly understood when looking at the common embryological origin, 
where hepatocytes, biliary epithelium and the pancreas originate from the endoderm 
of the foregut (87). Biliary epithelial cells appear capable of changing their 
phenotype and giving rise to hepatocyte-like cells, moreover gallbladder epithelial 
cells have been successfully engrafted in mouse recipient liver with similar 
morphological features and expression to hepatocytes (88).
 
 Whether this is due to 
the presence of bipotential stem cells or terminal transdifferentiation is yet to be 
investigated (Fig.6). 
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Figure 6 A schematic representation of the hepatic stem cells which are bipotential 
cells and may either be directed into a hepatocyte or cholangiocyte lineage.  Under 
certain conditions, cholangiocytes, which are terminally differentiated cells, may 
differentiate into hepatocytes and regenerate the liver. 
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1.3.2 Neoadjuvant chemotherapy and liver regeneration 
 
Hewes et al showed that hepatocytes from livers of patients who received 
neoadjuvant chemotherapy retained normal biochemical functions, however the 
authors did not show that SOS had occurred in the livers of the 12 patients who 
received oxaliplatin preoperatively, moreover the period between the last 
chemotherapy cycle received and the operation might have allowed recovery of the 
hepatocyte function (89). It has been shown more recently that liver regeneration 
was significantly impaired in an experimental model of SOS. Following partial 
hepatectomy with underlying SOS there was less increase in HGF mRNA levels with 
no evidence of hepatocyte proliferation following Ki67 staining which was strongly 
positive in the control group with no SOS (90). In a recent study comparing liver 
regeneration in patients with and without oxaliplatin induced SOS following partial 
hepatectomy and PVE, there was a significant reduction in liver hypertrophy in 
patients with SOS which was considered an independent factor associated with lower 
functional liver reserve and higher incidence of PLF (91). The mechanism through 
which SOS inhibits hepatocyte proliferation is still not completely understood.  
Oxaliplatin induced SOS is associated with splenomegaly and persistent 
thrombocytopenia mainly through splenic platelet sequestration and to a lesser extent 
through an immune-mediated mechanism (64). Platelets were shown to have a 
significant role in liver regeneration through a serotonin-mediated mechanism (92). 
Also, in order to initiate hepatocyte proliferation, platelets accumulate in the 
sinusoidal spaces in the acute phase following partial hepatectomy with translocation 
into the space of Disse where they maintain close contact with hepatocytes (93). 
Therefore, in addition to thrombocytopenia which has a negative impact on liver 
regeneration, the disruption in the sinusoidal architecture in SOS would limit the 
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selective contact of platelets with hepatocytes and hence inductive signals for early 
hepatocyte proliferation. 
The importance of SECs in liver regeneration has been recently investigated. The 
presence of SECs in culture media was essential for the inductive proliferative effect 
of VEGF on hepatocytes in-vitro. This is due to activation of VEGFR-1 on SECs 
leading to a release of HGF and other paracrine factors that stimulate hepatocyte 
proliferation. This VEGF-mediated HGF effect is specific to the liver SECs as it has 
not shown to occur in other vascular endothelial cell beds (94). Another more recent 
study investigated the role of VEGFR-2 and VEGFR-3 in SEC modulation and liver 
regeneration. It was shown that in the liver; VEGF-2 and VEGF-3 receptors were 
specific to SECs and were not expressed in any other liver cells (95). Inhibitor of 
DNA Binding 1 (IDI) factor is a transcription factor specific to endothelial 
progenitor cells and is beneficial in tracking endothelial cells in different vascular 
beds (96). Defective liver regeneration has been observed in ID1-deficient mice 
through decreased expression of SEC-mediated derived growth factors. Moreover 
ID1 upregulation occurred following partial hepatectomy driven liver regeneration 
through activation of the VEGF2 pathway. This leads to restoration of the liver mass 
in a biphasic mode where hepatocyte regeneration starts in close proximity to SECs 
in absence of vessel formation in days 1-3 following PH. As the liver mass increases, 
there is a demand for increased blood supply with a proliferative burst in SECs 
which starts at day four and returns to normal at day eight. These findings did not 
occur in the absence of the VEGF2-Id1 mediated pathways in mice leading to 
abnormal liver functions and delayed liver regeneration following partial 
hepatectomy highlighting the role of SECs in liver regeneration following liver 
resections (95). 
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1.3.3 Hepatocyte Transplantation (HT) 
The first HT was performed in an attempt to treat Crigler-Najjar syndrome in rats 
which are congenitally unable to conjugate bilirubin (97). More studies showed that 
HT is most successful in treating congenital metabolic diseases of the liver in 
children and in adults than other liver diseases (98). This might be explained by the 
low number of cells required to correct the underlying metabolic error, where 
replacement of 2-5% of the liver mass would improve the function dramatically (99). 
The main sources of hepatocytes are livers that were judged inadequate for 
transplantation (100). Other sources include fetal hepatocytes which show higher 
proliferation and engraftment rates than adult hepatocytes (101). Hepatocytes that 
were transplanted immediately seemed to provide better results than those that were 
cryopreserved, thawed and then transplanted (102). The quality of the transplanted 
cells is essential for efficient engraftment and is a major limiting factor for 
successful transplantation (103). Following injection there are three major steps that 
are required for liver repopulation which are deposition of hepatocytes into the 
hepatic sinusoids, traversing the sinusoidal endothelial cells which represent a 
physiological barrier to engraftment followed by integration into the liver 
parenchyma. Loss of cell viability in any of these steps would stimulate the 
phagocytic system to clear the non-viable cells (104). 
The cells are most often delivered by an intraportal infusion directly into the liver; 
however, cells also survive and retain their function when injected into the spleen 
which may be considered the best extra-hepatic organ for HT in animal models. 
Other sites include the thymus which has a good connective tissue network and 
adequate nutrient supply (105) and the peritoneal cavity for its large capacity and 
easy accessibility (99). 
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An important indication for HT is treatment of ALF which requires only temporary 
support until the liver regains its metabolic functions (106). The use of HT seems to 
be more effective with ALF than with chronic liver diseases because of the normal 
liver architecture and the better regenerative capacity of hepatocytes. 
Hepatocyte like cells known as NeoHeps that are derived from terminally 
differentiated peripheral blood monocytes also seem to be very effective in treating 
experimental ALF (107). There are very few clinical trials published, none of which 
provide evidence to show that patients who received HT for ALF showed better 
survival (102).  
In addition to limited availability, other problems in HT exist in that mature 
hepatocytes tend to de-differentiate in-vitro and that multiple transplantation 
procedures would be required to achieve meaningful liver repopulation (108). This 
problem may be bypassed through transplantation of immortalized hepatocytes based 
on the use of a clonal cell line that could be grown in culture and exhibit the 
characteristics of differentiated nontransformed hepatocytes.  Such cells could 
potentially provide an unlimited supply of well-characterized, pathogen-free liver 
cells (109). However, it is also thought that important interactions occur between 
hepatocytes and other cells in the body and this is difficult to replicate in standard 
culture conditions.  Attempts at developing sophisticated culture systems may help 
solve this problem (110). 
Currently, HT cannot present a reliable alternative to LT but might be able to bridge 
a period needed for regeneration or to stretch the waiting time for a suitable liver 
donation (111). Proper randomized clinical trials are needed to identify the 
appropriate number of cells required for a successful recovery from liver failure, and 
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the rate of engraftment of these cells. Stem cells on the other hand present an 
interesting therapeutic promise owing to their pluripotency and unlimited supply. 
1.3.4 What are Stem cells? 
 
Stem cells were first described by Becker in 1963 when he discovered that a 
macroscopic splenic colony developed from only one cell when transplanted into 
heavily irradiated mice (112). Stem cells are undifferentiated primal cells common to 
all multi-cellular organisms possessing two important properties, which are self-
renewal and unlimited progeny.  When a stem cell divides, it gives rise to an 
asymmetrical progeny; one cell being a new stem cell with similar self-renewal 
properties and another more differentiated cell type lacking the tissue regenerating 
ability.  
The division of stem cells is not restricted to one tissue type. The concept of 
plasticity where stem cells from one tissue may give rise to cell types of a 
completely different tissue has very important clinical implications both in the field 
of tissue regeneration and in cancer biology.   
 
According to the stages of mammalian development stem cells can be divided into: 
1) Totipotent cells that are produced from fusion of an oocyte and a sperm and 
are considered the ultimate stem cells as they can differentiate into all 
different types of human tissue. 
 
2)  Pluripotent stem cells which are descendants of totipotent cells and can 
differentiate into cells derived from the three major germ layers (113). 
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3) Multipotent stem cells can produce only cells of a closely related family of 
cells e.g. HSCs can differentiate into red blood cells, white blood cells, 
platelets (114). 
There have been several debates on how to measure pluripotency and how to define 
it. The gold standard would be the ability of the cells to functionally replace all cell 
types in the developing organism by introduction of these cells into the blastocyst 
(115). 
From the clinical point of view, it might be more relevant to classify stem cells into 
three categories: 
1) Embryonic germ cells (EGC) 
2) Embryonic stem cells (ESC) 
3) Adult stem cells (ASC) 
 
Embryonic germ cells  
 
EGCs are stem cells that are derived from the primordial germ cells which occur in 
the gonadal ridge, and which normally develop into mature gametes (eggs and 
sperm) (116). EGCs have less proliferative capacity in-vitro than ESCs which has 
limited its experimental use (117). 
 
Embryonic / Induced Pluripotent Stem cell derived hepatocytes 
 
ESCs were first described more than two decades ago, when they were isolated from 
the inner cell mass of the developing murine blastocyst and grown in the laboratory 
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(118). ESCs have since been shown to be totipotent cells that can differentiate into 
cells of all lineages, including the germ line and trophoblasts (119). The potential 
clinical application of ESCs is confronted however, with many practical and ethical 
concerns (120). Equivalent to the ESCs in gene expression are the induced 
pluripotent stem cells (iPS) which have been generated from adult mouse fibroblast 
cells by retroviral transduction of four transcription factors initially and then only 
three (121). Furthermore, iPS cells have been generated from primary hepatocytes 
and gastric epithelial cells in mice (122). Recently, iPS cells have also been derived 
from human skin (123). IPS cells involve a reversal of the developmental process 
removing most epigenetic marks laid down during development resulting in a 
pluripotent cell that must be differentiated into mature cells for therapeutic 
applications (124).
 
A pancreatic exocrine cell may be converted to a beta cell or an 
endocrine progenitor that produces all pancreatic endocrine cell types (124), or 
reprogramming a postnatal astroglia in the nervous system into a neuron or into a 
neural stem cell (125). However, the application of iPS cells in the clinic may also be 
a question of debate due to involvement of genetic manipulation that may lead to 
tumour formation in patients (115). 
 
Adult bone marrow derived hepatocytes 
 
There are less ethical issues with using ASCs, which are undifferentiated cells, found 
throughout the body to replenish dying cells and regenerate damaged tissue.  ASCs 
are stable cells and very rarely switch from one cell type to another, the occurrence 
of which may have serious consequences like metaplasia and cancer (126). There are 
several advantages in using ASCs in organ regeneration as they are 
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immunocompatible as long as they are from autologous tissue, readily available and 
pose no ethical considerations. 
The most readily available source of ASCs is the BM which contains 3 stem cell 
subpopulations, which are the Mesenchymal stem cells (MSCs), HSCs and 
endothelial progenitor cells (127). MSCs are clonogenic, non-hematopoietic cells 
that are capable of differentiating into multiple mesoderm-type cell lineages (128). 
They constitute about 0.01%-0.001% of bone marrow cells with the number being 
highest in neonates and decreasing with advancing age (129). When stimulated by 
specific signals, these cells can be released from their niche in the bone marrow into 
the circulation and recruited to the target tissues where they undergo in situ 
differentiation and integration and contribute to tissue regeneration and healing 
(130). 
Because of their extensive differentiation potential, MSCs were among the first stem 
cell types to be introduced in the clinic (131). 
 
Mechanism of action of MSCs 
 
Two possible mechanisms might explain the conversion of MSCs into more mature, 
well differentiated cell types. Why a MSC chooses one path over another is not 
entirely understood but may be related to the ploidies of the cells constituting the 
organ receiving the stem cells.  For organs containing cells of different ploidies 
which tend to form heterokaryons in severe organ injury like liver, pancreas and 
muscle, the external stem cells seem to fuse with the native cells and this has been 
evidenced by the expression of both donor and host genes in organs like the liver 
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(132). This may not be true, however in other organs like skin and lung, where 
terminal transdifferentiation seems to be a more likely mechanism (133). 
MSCs are not immortal and there is a limit to the time in which they can be cultured 
in-vitro, but this problem has been addressed by transducing them with the human 
telomerase reverse transcriptase gene in order to extend their life span and provide a 
large number of cells for therapeutic applications (134). Also, other sources of MSCs 
have been explored including the human placenta (135), and umbilical cord (136). 
Adipose derived stem cells are equally capable of differentiation when compared to 
BM MSCs; moreover they are abundant in many easily accessible sites which can be 
obtained under a local anaesthetic in a procedure similar to liposuction which is a 
relatively non painful procedure (137). 
 
1.3.5 Clinical applications of stem cells in regenerative medicine 
 
Due to the inability to harvest or expand stem cells from most adult organs especially 
heart, liver and brain, the majority of human stem cell trials have focused on clinical 
applications of MSCs, HSCs or both, which can be easily obtained in sufficient 
numbers from peripheral blood, BM, umbilical cord blood and placenta (138). In the 
past few years, extensive research has been carried out on treating spinal cord 
injuries using different types of stem cells. BM derived stem cells were 
transdifferentiated into neural tissue and resulted in functional improvement when 
transplanted into injured spinal cords of paraplegic animals (139). There are some 
clinical trials that are running but sufficient data is still lacking. 
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Recent stem cell research points to the potential of cell therapy as a future treatment 
strategy for heart failure. Cell types used include multipotent progenitor cells, 
skeletal myoblasts, smooth muscle cells, fetal and embryonic cardiomyocytes, and 
both BM stromal and HSCs.  A recent clinical trial suggests that transplanted BM 
derived progenitor cells injected into patients following acute myocardial infarction 
improved the cardiac function (140). 
The introduction of islet cell transplantation in contrast to whole organ 
transplantation in treating diabetes mellitus has the benefit of being minimally 
invasive, however the success rate of the approach is limited, and a very high percent 
of the patients would still require insulin after one year (141), and furthermore, 
advances are hampered by the shortage in cadaveric donor material.  Stem cells 
derived from the BM or reprogramming of the adult pancreatic cells into pancreatic 
progenitor cells which may be directed to secrete insulin may be possible through 
expression of certain transcriptional factors (142). 
 
1.4 Stem cells and liver disease 
 
Stem cells have been shown to improve liver functions and survival in liver diseases 
and present an interesting alternative or adjunct to LT and HT.   
 
1.4.1 Embryonic stem cells 
 
Differentiating ESCs into cells with hepatocyte properties that are metabolically 
active and immunologically inert is a major goal in the field of tissue regeneration.  
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When ESCs were injected in their undifferentiated state into mice, they resulted in 
teratomas that killed the animals (143). In addition, ESC derived hepatocytes were 
associated with improved survival when compared to undifferentiated ESCs in 
treating mice from ALF (144). From here, came the need to develop an in-vitro ESC 
differentiating system that would provide an unlimited source of functional 
hepatocytes without an increased risk of developing tumours. 
There are several methods for inducing differentiation of undifferentiated ESCs. 
Embryoid bodies (EBs) which resemble embryos in the early stages of development 
are formed when the culture conditions are changed to allow the ESCs to form three-
dimensional spherical structures (Fig.7), however, to induce differentiation, the 
leukemia inhibitory factor (LIF) which is essential to maintain the undifferentiated 
state needs to be taken out of the culture medium (145). ESCs that were cultured for 
more than 12 days, were capable of expressing both albumin and urea without the 
need for any additional growth factors at any stage of maturation, in addition, when 
cells were cultured for more than 9 days, they were not associated with teratoma 
formation when transplanted through the portal vein of mice (146). Other studies 
suggest that the addition of certain growth factors like Fibroblast growth factor, HGF 
and Oncostatin-M at different time points improve differentiation of ESCs into 
hepatocytes (147) and when transplanted, they significantly suppressed the onset of 
fibrosis and improved the survival rate among the recipient mice (148). 
Transplantation of undifferentiated ESCs also proved to be useful in treating CCL4 
induced fibrosis in mice without resulting in tumour formation (149). Developing co-
culture systems where ESCs are cultured with liver cells may present an alternative 
to adding exogenous growth factors. This has been established using hepatocytes 
(150) as hepatocytes secrete activin, which has been shown to induce endodermal 
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differentiation (151). However, activin alone cannot induce hepatocyte 
differentiation and in a more recent study it was used in combination with sodium 
butyrate and HGF for complete maturation of ESCs into hepatocytes (152). 
Unfortunately, there have been no clinical trials using human ESCs to treat liver 
diseases in patients because utilization of human ESCs is still under ethical debates.  
 
         
 
Figure 7 Steps of embryoid body formation from undifferentiated embryonic stem 
cells. The three most popular methods are illustrated.  In all methods, the principle is 
induction of aggregation of cells into a ball like mass which will lose the 
undifferentiated state in the absence of LIF and differentiate into ectoderm, 
mesoderm and endoderm from which hepatocytes arise. 
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1.4.2 Bone Marrow Stem Cells (BMSCs) 
 
Intensive research is being conducted to evaluate the efficacy of using MSCs as an 
alternative cell source to HT in treatment of liver disease. MSCs for transplantation 
ideally would be derived from the patient himself as this would avoid the problem of 
immunorejection. It has been shown, however, that even if BM derived MSCs were 
to be transplanted between different people, an exaggerated immunogenic response 
would not be elicited (153). This may be due to the lack of MHC molecules on 
MSCs (154), moreover, MSCs may exert an immunoregulatory effect through their 
inhibition of T-cell proliferation (155). 
Experimental data 
 
Several animal experiments have been conducted to understand the mechanism of 
action of BMSCs. Induced liver damage was an essential factor for cell recruitment 
and propagation in all experiments.  In an experimental murine model, infusion of 
MSCs following lethally induced ALF restored metabolic functions of the liver 
through differentiation into hepatocytes (156). The reduced cell requirement and the 
rapidity of rescue from ALF suggested a paracrine proliferative effect of MSCs on 
the endogenous hepatocytes rather than direct differentiation into hepatocytes. The 
paracrine effects of MSCs have also been studied in different organs where they 
exerted protective effect on the heart (157) and kidney (158). Also, systemic infusion 
of soluble factors secreted from MSCs provided a survival benefit and prevented the 
release of liver injury biomarkers (159). Another more recent study showed that 
transfer of the genetic material from MSCs to resident hepatocytes following 70% 
hepatectomy in rats improved hepatocyte proliferation and suppressed apoptosis both 
in-vitro and in-vivo (160). 
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MSCs have also been used for improving liver regeneration in liver-transplanted rats 
with small for size syndrome. It has been proven that the addition of HGF promotes 
cell uptake in the recipient grafts with production of albumin, improved liver 
function and survival (161). Both HGF and Stromal Derived Factor-1 (SDF-1) have 
been shown to play an important role in recruiting and homing of MSCs to damaged 
liver tissue (162). SDF-1 is a potent chemokine that binds to its CXC receptor 4 on 
HSCs. Expression of this receptor is higher in BM HSCs when compared to 
peripheral blood HSCs and elevation of the plasma levels of SDF-1 was found to be 
responsible for mobilization of stem cells from the BM to peripheral blood down an 
SDF-1 gradient (163).  In another study resident HSCs and CD-90+ BMSCs have 
been indentified in liver sections of rats where a small for size LT was conducted in 
an attempt to understand its effect on mobilizing stem cell populations.  This also 
proves that both the liver and the MSCs contribute to liver regeneration (164). 
Another theory is the mobilization of endothelial progenitors, which may be due
 
to 
the increased serum level of VEGF following the vascular
 
damage associated with 
LT. In animals, it has been shown that circulating
 
CD133
+ 
and CD34+ cells are 
known to contribute
 
to neo-angiogenesis after tissue ischemia and organ regeneration
 
in animal models (165). There is definitely a correlation between the type of injury 
and the mobilization of different cell populations to rescue the liver.  Whereas 
ischemia reperfusion liver damage associated with LT induced the extensive 
mobilization of several subsets of hematopoietic
 
and endothelial BM stem cells, liver 
resection regardless of extent was a weaker
 
stimulus to recruit significant numbers of 
BM cells despite the increase of the serum level of hematopoietic cytokine (166). 
SECs that are damaged in the setting of Oxaliplatin neoadjuvant chemotherapy 
originate from the BM and are key in liver regeneration (167), (95). A recent report 
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highlighted the role of BMSCs in SEC replacement following SOS in rats. It was 
shown that MCT not only damages the SECs in the liver but also suppresses the SEC 
progenitors in the BM leading to defective replacement. In addition, infusion of BM-
derived CD133
+ 
replaced a considerable portion of the liver SECs with improvement 
in both structural and functional hepatic elements (168). 
 
Clinical data 
 
The stimuli for stem cell mobilization from the BM and the resulting population of 
progenitor cells seem to be an important key in designing future therapies.  
Granulocyte colony stimulating factor and certain chemotherapy protocols have 
resulted in a significant mobilization of progenitor cells that were used for BM 
transplantation (169). The same principles have been applied in trials to treat patients 
with chronic liver diseases.  In one study, CD34+ cells were derived from the 
peripheral blood of nine patients with alcoholic liver cirrhosis.  These cells were 
expanded in-vitro and injected into the hepatic arteries of the patients resulting in 
significant improvement of the Child-Pugh score (170). This might not be possible 
however in liver resections for malignant tumours as granulocyte colony stimulating 
factor might enhance tumour growth and increase the risk of splenic rupture which 
might add to the mortality of PLF patients (167). It is of interest that liver donors 
showed a great increase of the circulating CD 133+ cell population 12 hours after a 
partial hepatectomy when compared to one day prior to the procedure. The origin of 
these cells is not known, but might be the liver itself because no increase was noted 
in other surgical procedures.   Moreover, these cells have the capacity to differentiate 
into hepatocytes in-vitro (171).  
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There have been only two clinical studies which were performed to assess the use of 
HSCs for PLF prevention. These studies were conducted on a small number of 
patients who were expected to undergo major hepatic resections for cancer. The 
infusion of the CD 133+ cells was combined with PVE which was important to 
induce a strong proliferative stimulus and to promote the uptake and engraftment of 
the cells.  CD 133+ cells were derived from the BM and highly enriched in-vitro 
then injected into the left lobe of the liver through the portal branches with 
subsequent PVE of the right liver segments to expand the left hepatic segments.  CT 
volumetric scans showed an increase in the proliferation rate of the left lobe when 
compared to the control group (172), (173). The main advantage of combining 
CD133+ cells with PVE would be to reduce the waiting time between PVE and the 
operation in patients with rapidly progressing tumours and to increase the liver 
reserve in patients with small left lateral liver segments. 
 
1.5 Cell tracking 
 
There is a lack of understanding of how stem cells behave in-vivo following 
transplantation with limited information on their capacity to migrate, engraft and 
differentiate in damaged tissue. Most studies were dependant on metabolic tests as 
indicators of successful organ regeneration and repair. It is essential, however to 
track the in-vivo fate of transplanted cells in addition to their functional capacity in 
order properly plan and optimize stem cell delivery techniques. 
Stem cell tracking in humans is faced with several challenges due to safety and 
technical considerations. The most successful human cell tracking technique is using 
the magnetic resonance imaging for tracking cells labeled with iron oxide (174). 
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Advantages of this method include high resolution and good anatomical localization 
however, in the liver due to large endogenous iron stores; it may not be possible to 
accurately localize transplanted cells due to iron overload whether spontaneous or 
induced. This has been shown to be a barrier in pancreatic-islet cell tracking which 
home to the liver (175). Another disadvantage is the engulfment of the iron oxide 
particle by resident macrophages following cell death with limiting ability to 
distinguish between viable and non-viable cells (176).  
Another promising modality is positron emission tomography imaging of cells radio 
labeled with glucose. It is a sensitive method with easy monitoring of biodistribution 
and cell quantification; however has a very short half-life which would not allow 
long term imaging (177). 
Experimental animal imaging is far ahead when compared to clinical imaging. The 
introduction of green fluorescent protein (GFP) as a cell marker in 1994 allowed 
both direct and indirect visualization of transplanted cells in tissue using fluorescent 
microscopes and anti-GFP antibodies respectively (178). A major problem in in-vivo 
cell tracking using fluorescent markers is the background autoflourescence. This is 
due to light absorption by hemoglobin and melanin pigments interfering with 
adequate cell localization (179). GFP has an emission/excitation wavelength of 
490/510 nm which is lower than the ideal optical window for precise cell 
visualization which is considered between 650-700 nm (179). This has lead to 
development of fluorescent dyes towards the near infra red (NIR) spectrum (650-
900) nm where tissue has minimal interference with transmitted signal allowing 
accurate imaging of deep tissue (180).  
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Although optical imaging using fluorescent dyes is not yet permitted for clinical use, 
ICG which is FDA-approved and emits in the near infra red (NIR) spectrum has been 
used to label ESC derived cardiomyocytes in-vitro with no interference with cell 
function (181). This carries great hope for future application of optical imaging in 
clinical trials with accurate localization allowing proper assessment of cell 
engraftment in damaged organs and hence successful therapy. 
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2-Aims and experimental study design 
 
The knowledge presented in the introduction formed the basis of the studies 
described in this thesis. From the overview of the literature it can be concluded that 
there are numerous possible research questions unanswered regarding the etiology, 
prevention and treatment of PLF. I decided to focus on two major topics during my 
research period. 1. The role of a novel semisynthetic flavonoid in prevention of 
sinusoidal obstruction syndrome which is a significant risk factor in PLF 
development. 2. The role of cell therapy in repopulating the liver in an ALF model. 
This is through developing an accurate cell tracking method with the possibility of 
both early and delayed monitoring. The two research topics will be described in 
separate sections in this thesis.  
Research hypothesis:  
1- Pre-treatment with the flavonoid monoHER would lead to a reduction in the portal 
pressure measurements when compared to the control group. This would be 
associated with improvement in both liver functions and the overall liver damage 
severity score. 
2-A novel dual labeling fluorescence technique would allow real-time cell tracking 
with a view to differentiation and cell fate.  
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2.1 Section 1 
 
2.1.1 Experiment 1 
AIM 
 
To establish a model of SOS in rats resembling the disease occurrence in patients 
following oxaliplatin administration. 
 
Experimental design 
 
The set-up of the experiment is depicted in Fig.8. Male Sprague-Dawley rats were 
divided into two groups (n=21). A model for SOS using a single gavage of 
monocrotaline (MCT) (MCT, Sigma Aldrich, St. Louis, MO) was used. Rats were 
gavaged with 160 mg/kg MCT in 0.5 mL dimethyl sulfoxide (DMSO) (182) and rats 
in the sham group received 0.5 ml DMSO only. After gavage, rats had free access to 
food and water. Rats were sacrificed 1, 2, 3 days after MCT gavage. 
 
 
Figure 8 Schematic representation of the studied groups at the designated time 
points. 7  rats from each group were studied at 24, 48 or 72 hours following gavage 
with either MCT or vector. 
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2.1.2 Experiment 2 
AIM 
 
1- To evaluate the protective effect of a novel semi-synthetic flavonoid 
(monoHER) on development of SOS following MCT administration in rats. 
2- To study the effect of monoHER and possible interactions with 
oxaliplatin/MCT in human CRC cell lines. 
 
Experimental design 
 
The set-up of the experiment is depicted in Fig.9. The animals were divided into two 
groups (n=21). A reproducible rat model for SOS using a single gavage of (MCT, 
Sigma Aldrich, St. Louis, MO) was used. Rats were gavaged with 160 mg/kg MCT 
in 0.5 mL dimethyl sulfoxide (DMSO) (182), rats had free access to food and water. 
7-monohydroxyethylrutoside (monoHER) was kindly provided by the Department of 
Pharmacology and Toxicology, Maastricht University Medical Centre. The required 
amount of monoHER was dissolved in distilled water 36mM NaOH (pH 7.8-8). The 
experimental animals received monoHER 500 mg/kg i.p., starting 1 day before MCT 
treatment and continuing once daily up until sacrifice. Sham animals received 
sodium hydroxide intraperitoneally (i.p), in equivalent volume. Rats were sacrificed 
1, 2, 3 days after MCT gavage. 
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Figure 9 Schematic presentation of the two studied groups. Pretreatment with 
monoHER was started 24 hours before the MCT dose and was continued daily at the 
same time. (n=7) rats were sacrificed from each group at each time point. 
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2.2 Section 2 
 
AIM 
 
To develop a tracking system for monitoring transplanted cells and their distribution 
in an ALF model. 
 
Experimental design 
 
Forty male C57/BL6 mice (Charles River laboratories) at 5-6 weeks of age with an 
average weight between 20-25g were used for this study. The animals were allocated 
into 2 groups.  Group 1 (n=20) with cell therapy and group 2 (n=20) with vehicle 
only. All animals received a single dose of APAP 300mg/Kg administered i.p (183). 
To ensure adequate dissolution, APAP was sonicated over night in a water bath at 
42°C and the temperature was maintained till injection time. APAP administration 
was preceded by a subcutaneous injection (SC) of 10% dextrose in order to prevent 
mortality from severe hypoglycaemia (184). The SC injection of dextrose 10% was 
repeated every 6 hours during the first day of the experiment. At selected time 
points, the animals were killed by exsanguination (Fig.10). Time points were 
selected to have an optimal evaluation of ESC cell homing in organs using ex-vivo 
imaging and for immunohistochemistry (IHC) studies. 
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Figure 10 Experimental animal design. 40 mice were treated with APAP. The 
animals were then divided into 2 groups, cell therapy group= group 1 and control 
group= group 2. During the first 24 hours, 19/40 animals died due to the effect of 
APAP.  Animals from both groups were then killed at 72 hours when the fluorescent 
signal started to decay and at two weeks when the signal could no longer be detected 
in-vivo.   
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3-Materials and methods 
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3.1 Animals 
All animal experiments were conducted according to Home Office guidelines under 
the UK Animals and Scientific Procedures Act 1986. All animals were housed in the 
respective unit and given free access to standard rodent chow and water, serially 
weighed, with a light/dark cycle of 12 h (the dark phase extended from 1900 to 
0700 h), at a temperature of 22–23 °C and approximately 50% relative humidity. 
Male Sprague–Dawley rats (Charles-Rivers, UK), weighing 230–280 g, were 
obtained from the Comparative Biology Unit at University College London. Male 
C57BL/6 mice, weighing 20-25 g, were obtained from the Biological Services Unit 
at the Royal Free Hospital, University College London. 
 
3.2 Methods 
 
3.2.1 Measurement of portal pressure 
 
Rats were anesthetized with inhalation of isoflurane (4% induction, 2.5% 
maintenance) and oxygen. The animals were placed in supine position and body 
temperature was maintained at 37°C using a heating pad. The abdomen was opened 
through a midline laparotomy and the portal vein was punctured and cannulated with 
a 25G needle without disturbing the surrounding structures. Portal pressure (PP) was 
continuously monitored and recorded using a pressure transducer, a pressure 
amplifier and a computer equipped with a data recording and analysis system 
(BIOPAC systems, Norfolk, UK). The average pressure over a five minute period 
was considered as the final PP. 
73 
 
3.2.2 Cell culture 
 
Embryonic stem cells 
Preparation of Coated Plates 
 
T-75 flasks (VWR, UK) were coated with enough 10 mL 0.1% gelatin solution 
(Millipore, Co Durham, UK) to cover the whole surface and left at room temperature 
to dry after aspirating the excess solution. The minimum incubation period was 30 
minutes. 
  
Thawing of Cells 
 
The vial of Milli Trace Constitutive GFP Reporter Mouse ESCs (1×10
6
) was 
removed from liquid nitrogen and incubated in a 37°C water bath to thaw the cells. 
The cells were closely monitored until only a small ice crystal remained as 
maximum cell viability is dependent on the rapid and complete thawing of frozen 
cells.  Also, important was not to vortex the cells to avoid cell killing. As soon as the 
cells were completely thawed, the outside of the vial was disinfected with 70% 
ethanol. Inside a laminar flow hood; a 1 mL pipette was used to transfer the cells to a 
sterile 15 ml conical tube. Care was taken not to introduce air bubbles. A 10 mL 
pipette was used to slowly add 9 ml of pre-warmed complete ESC media with 15% 
fetal bovine serum (FBS) and LIF (Millipore. ES-101-B) to the 15 ml conical tube in 
a dropwise fashion so as not to expose the cells to osmotic shock which might 
decrease the cell viability. The cell suspension was then gently mixed by slowly 
pipetting up and down twice. The tube was then centrifuged at 300 g for 3 minutes to 
pellet the cells. The supernatant was decanted to discard the DMSO 
cryopreservative. The cells were then resuspended in 10 ml of fresh ESC Media 
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containing 0.5 μg/mL puromycin was always added fresh and a concentration of 0.5 
μg/mL was obtained by adding 1μL of puromycin stock to 10 mL of ESC media. 
Cells were then plated in gelatin coated T 75 flask and incubated at 37°C and 5% 
CO2 in a humidified incubator. 
On the next day, the medium was exchanged once and then every other day. When 
the cells were approximately 80% confluent, they were dissociated with Accutase 
cell dissociation solution (Millipore, Co Durham, UK) and passaged or alternatively 
frozen for later use. 
Subculturing 
 
The medium was carefully removed from the gelatin-coated T 75 tissue culture flask 
containing the confluent layer of ESCs. This was followed by applying 3-5 mL of 
Accutase solution to detach the cells (Millipore, Co Durham, UK). The flask was 
then incubated at 37°C for three minutes during which the flask was frequently 
checked for detachment of the cells. Complete detachment of the cells was 
confirmed by gentle tapping with the palm of the hand. Five mL of FBS containing 
media was added to the plate to neutralize the effect of Accutase. The dissociated 
cells were transferred to a 15 mL conical tube for centrifugation at 300 g for three 
minutes to pellet the cells. After discarding the supernatant, 1 mL of fresh medium 
containing puromycin was added and the cells were resuspended thoroughly and this 
was assisted by repeated gentle pipetting.  
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Cell viability and counting 
 
Trypan blue was used to assess the cell viability. This dye cannot traverse the cell 
membrane of live cells as it is a bis-azo dye that is negatively charged at 
physiological pH. It can however pass through the cell membrane of dead cells 
staining them blue when inspected under microscope allowing determination of cell 
viability.  For counting the cells, a haemocytometer chamber was used with a cover-
slide.  A mixture of 50 µl Trypan blue and 50 µl cell suspension was pipetted under 
the cover-slide and viewed under the inverted microscope. The total number of cells 
in four corner 1mm
2
 squares with a total volume of 10
-4
 cm
3
 was counted. The 
average number of cells per square was then multiplied by 10
4
 and the dilution factor 
to give the number of cells in 1 ml. The cells were then plated at a density of (4×10
5
) 
and the remaining cells were frozen using freezing medium and stored in liquid 
nitrogen for future use.  
  
Maintenance of undifferentiated state of ESCs 
 
Undifferentiated C57/BL6 ESCs constitutively expressing GFP (Millipore, Co 
Durham, UK) were maintained in the undifferentiated state by using millitrace 
mouse ESC expansion medium (Millipore, Co Durham, UK) supplemented with 
15% FBS and LIF.  Puromycin was added to the media (0.5μg/ml) for selective 
growth of GFP-positive cells.  Cells were cultured on 0.1% gelatine coated T-75 cell 
culture flasks till 80% confluence. The undifferentiated state of the ESCs was 
confirmed by alkaline phosphatase expression in more than 90% of the ESC 
colonies. Cell fixation was performed with 4% paraformaldehyde for 2 minutes 
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followed by incubation with a mixture of fast red violet, naphthol AS-BI phosphate 
solution and water in a 2:1:1 ratio in a dark room for 15 minutes.  
 
3.2.3 Tracking of the transplanted cells using the in-vivo Imaging System (IVIS) 
 
The IVIS® Lumina 2 (Caliper life sciences, Cheshire, UK)   consisted of a charge 
coupled device (CCD) camera, an imaging chamber, the XFO-12 fluorescence 
equipment, and a preconfigured computer (Fig.11). 
 
 
 
Figure 11  IVIS Lumina 2, computer and monitor. 
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In-vivo imaging allowed cell monitoring within small animals. The cells were tagged 
with fluorescent particles which emitted light following their excitation. The emitted 
light was detected by the CCD camera maintained in a cooled state to minimize 
electronic background and maximize sensitivity, working in a range of 400-950 nm 
wavelength (Fig.12). 
 
 
Figure 12 IVIS Lumina 2 and XFO-12 fluorescence equipment. 
 
When the GFP +ve cells were used for in-vivo imaging, there was a considerable 
amount of autoflourescence which made it very difficult to identify the 
biodistribution of the transplanted cells. Autoflourescence is a fluorescent signal 
originating from substances other than the fluorophore of interest. The level of 
autoflourescence limits detection for fluorescent cells. Autoflourescence is primarily 
biological from the animal tissue with a smaller component arising from the 
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instruments. The GFP wave length is below that of haemoglobin and other animal 
proteins interfering with in-vivo cell tracking.  
In order to eliminate the background fluorescent effect another dye was used to label 
the cells. This dye emits light in the NIR wavelength, which is much higher than the 
animal autoflourescence and therefore, made it possible to precisely track the 
transplanted cells in mice. 
 
 
Dual labeling protocol 
 
In order to achieve in-vivo tracking of the GFP expressing ESCs, the cells were 
labeled with the fluorescent lipophilic tracer 1, 1-dioctadecyl-3,3,3,3-
tetramethylindotricarbocyanine iodide (DiR) (Invitrogen Ltd, UK). The excitation/ 
emission spectrum of DiR is in the NIR range (excitation 750 nm and emission 782 
nm). After preparation of the stock solution, 5ml of cell-labeling solution was 
directly applied to 1ml cell suspension, mixed and incubated at 37°C for 20 minutes. 
The labeled suspension was centrifuged at 1500 rpm for 5 minutes and the cell pellet 
was resuspended in warm fresh media. This procedure was repeated twice to ensure 
complete removal of any unbound dye. 
 
Cell preparation and transplantation 
 
Following labeling with DiR, 5x10
6 
cells were used for injection in a single mouse, 
which is equivalent to approximately 7.5-8% of the mouse liver hepatocytes (185). 
The cells were suspended in 100μl of sterile Phosphate Buffer Solution (PBS) drawn 
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into a 1 ml syringe and kept on ice till the transplantation. Cell transplantation was 
performed 4 hours following treatment with APAP in mice. Under adequate 
anaesthesia and strict aseptic technique, a one cm incision was made in the left flank 
of the abdomen and the spleen was delivered outside the incision. The cells were 
injected into the spleen over a period of 5-minutes to prevent any loss of the cells 
due to the overflow.  Following injection the needle was removed and fibrin glue 
was applied to the injection site to prevent bleeding and cell loss. After confirming 
haemostasis, the spleen was replaced back into the abdominal cavity and the 
abdominal wall was closed in single layer. The same procedure was performed for 
the control group with PBS only. 
 
Tracking of the transplanted cells 
 
The mice were anesthetized with inhaled isoflurane and placed into the IVIS 
chamber (Caliper life sciences, Cheshire, UK)  and sequential images were acquired 
using the CCD camera  at 30 minutes post transplantation, then at  3, 12, 24, 48 and 
72  hours, and after one and two week intervals.  Following sacrifice of the animals 
in groups at predetermined time periods, the spleen, liver, lung and kidney were 
retrieved and placed inside the IVIS and images were acquired. Data of the regions 
of interest of the illuminated cells were acquired to quantify the cell uptake in 
different organs. Three fluorescence filters (GFP, CY5.5 and ICG) were used to 
identify the filter with the least background autoflourescence. Data analysis was 
performed using the Living Image
TM
 Software 3.0 (Caliper life sciences, Cheshire, 
UK).   
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GFP fluorescence 
 
A Nikon fluorescence microscope (E501) was used for direct detection of GFP+ 
cells using the fluorescein isothiocyanate filter on frozen tissue sections. 
 
3.2.4 Cell proliferation assay 
 
Cell counting is possible using the haemocytometer; however for large scale cell 
quantification we required a more accurate method in order to measure the effect of 
monoHer on the cytotoxicity of oxaliplatin and MCT. The potential inhibition of the 
cytotoxic effect of oxaliplatin by monoHER was tested in-vitro in two different CRC 
cell lines (LoVo and LS174T, a gift from Prof D. Hochhauser, Cancer Research 
Institute, UCL).  This is in addition to studying the protective effect of monoHer on 
human umbilical vein endothelial cell (HUVEC) lines. We used the CellTitre
 
96 
Aqueous One Solution Reagent (Promega, Southampton, UK). It is an indirect 
colorimetric method involving the bioreduction of the 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
 
inner salt 
compound  (MTS) by cells into a coloured formazan product which is soluble in 
tissue culture medium. This conversion is presumably accomplished by NADPH or 
NADH produced by dehydrogenase enzymes in metabolically active cells. The 
quantity of formazan product as measured by the spectrophotometer at 490nm 
absorbance is directly proportional to the number of living cells in cell culture wells. 
Procedure 
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1- The CellTiter 96® Aqueous One Solution Reagent (Promega, Southampton, UK) 
containing MTS and an electron coupling reagent (phenazine ethosulphate) was 
thawed.  
2- Briefly, 2000 cells/well in a 96 well plate were incubated with increasing 
concentrations of (1) oxaliplatin 50-100-200 μM, (2) MCT 2-4-8 mM and (3) 
monoHER 25-50-100 mM or a combination of two of those. Following incubation 
for 48 hr, 20µl of CellTitre
 
96 Aqueous One Solution Reagent was added in each 
well and incubated for another 2 hr at 37°C in a humidified CO2 incubator.  The 
optical density was measured at
 
490 nm by means of LT-4000MS spectrophotometer 
(East Sussex, UK).  
 
3.2.5 Blood and tissue sampling/handling and storage 
 
Following the sacrifice of the animals at the designated time points, blood samples 
were taken from the abdominal aorta and liver tissue was cut from the median lobe at 
sacrifice. A part of the liver tissue was preserved immediately in liquid nitrogen and 
the remaining portion in 10% neutral formalin for downstream applications. Blood 
samples were drawn in pre-chilled tubes for EDTA-plasma, heparin-plasma and 
serum collection then centrifuged. Samples were stored at -80ºC until determination. 
Serum ALT was measured as a marker of liver damage using COBAS integra 400 
biochemistry analyzer (Roche, New York, USA).  
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3.2.6 Analysis of Protein expression 
 
IHC was used to examine protein expression in histological sections. Several steps 
were undertaken for routine histology/IHC: fixation, embedding, sectioning and 
staining. 
Fixation with a variety of chemicals allowed tissue to be stabilized and preserved for 
future examination. A solution of formaldehyde (formalin) was routinely used, 
which was buffered and osmotically balanced to minimize shrinkage, swelling and 
cellular damage. Embedding converted tissues into a solid form to allow sectioning 
into thin slices for staining and IHC. As most cells are essentially transparent with 
little or no intrinsic pigment haematoxylin and eosin (H&E) staining was used to 
outline the morphological appearances and IHC for protein expression that were 
examined under a microscope. 
 
Haematoxylin and eosin  
 
Apart from a primary dye to identify the structure of interest, it is a common practice 
to counter-stain with a secondary dye to give a contrasting colour to the nucleus. 
H&E is based on this principle. Haematoxylin is a basic stain with purple colour and 
stains cell nuclei and ribosomes, while eosin is an acidic stain which stains collagen 
fibers, red blood cells, muscle filaments and mitochondria. The combination of these 
two dyes allows morphological features of tissue samples to be examined in detail 
under the microscope. 
Histopathological examination was performed in a blinded fashion by two 
researchers. A conference microscope was used to reach a consensus regarding the 
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grading of tissue injury The degree of liver damage was quantified using a 
modification of the scoring system described by Rubbia-Brandt et al (186), including 
sinusoidal dilatation (scores; 0,1,2,3), perisinusoidal haemorrhage (scores; 0,1), 
peliosis (scores; 0,1), hepatocellular necrosis (scores; 0,1,2,3) and inflammatory cell 
infiltration (scores; 0,1,2,3). 
Mononuclear inflammatory cells were counted in three most densely populated areas 
in high power fields (x400) and the average number of cells was considered as the 
number of cells per high power field. 
 
Immunohistochemistry  
 
The Principle: 
IHC is an established method used in clinical diagnosis and research allowing 
localization and visualization of tissue and cell antigens. The principle involves 
attaching the primary antibody to the tissue antigen to be localized. The bound 
antibody is then detected by a variety of methods. 
Some antigenic sites become inactive during the formalin fixation and heat treatment 
during the paraffin-embedding process. This occurs due to cross-linking between 
lipoprotein membranes and extracellular material with fixatives forming a barrier 
preventing antibodies from binding the antigens.  It is important therefore to unmask 
the antigen through an antigen retrieval step to maximize the antigen-antibody 
reaction. The two most important factors for effective antigen retrieval are the 
heating conditions and the pH. 
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Non specific staining is also common in IHC and inhibition of the non-specific 
peroxidases is essential to avoid false positive results.  Therefore blocking of the 
endogenous active peroxidases highly expressed in the liver before adding the 
peroxides labeled antibody would eliminate any possibility of background staining 
due to tissue peroxidases. This could be achieved by adding hydrogen peroxide to 
deplete the endogenous peroxidases. 
Following this step, the primary antibody is applied which might be either 
monoclonal or polyclonal. Monoclonal antibodies are derived from a clone of single 
cells whereas polyclonal antibodies consist of several antibodies generated in-vivo 
following treatment with the antigen. The advantage of monoclonal antibodies is that 
they are more specific however less robust and more expensive than polyclonal 
antibodies. 
This is followed by incubation with the secondary antibody and development of the 
brown colour using 3,3’ –diaminobenzidine tetrahydrocholride (DAB). 
 
The procedure: 
 
1-Three to five m sections of tissue were cut and paraffin was removed by putting 
the slides in the oven for one hour to preheat and then four changes of fresh xylene 
each for 5 minutes. 
2- Sections were rehydrated by using: 
o One change of absolute ethyl alcohol, each for 5 minutes. 
o One change of 90% ethyl alcohol, each for 5 minutes. 
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o One change of 80% ethyl alcohol, each for 5 minutes. 
o One change of 70% ethyl alcohol, for 5 minutes. 
3-The slides were washed in PBS for 5 minutes 
4-For antigen retrieval: 
a) Plastic container was filled with sufficient citrate buffer (pH 6) (Dako, 
Cambridgeshire, UK) and placed in a microwave oven to bring the solution 
to boiling. 
b) The slides were placed in the antigen retrieval solution and placed in 
microwave oven to boil for 10 minutes at 800W. 
c) Container was removed from the oven and allowed to cool for 20-30 
minutes to reach the room temperature. 
5- Slides were placed in PBS for 2 minutes three times. 
6-Excess liquid was removed by careful tapping off the edge of each slide on paper 
towels.  It was important to dry the slides around sections using gauze pad without 
drying sections themselves. 
7-Endogenous peroxidase
 
activity was blocked for 30 min with 3% hydrogen 
peroxide. 
8- Slides were placed in PBS and washed for 2 minutes x three times. 
9-Excess liquid was removed by careful tapping off the edge of each slide with tissue 
paper.   
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10-The sections were incubated at 4°C overnight with primary antibodies; polyclonal 
rabbit anti-GFP (1:10, Millipore), and anti-albumin antibody (1:1000, Abcam). 
11- The slides were washed with PBS Tween twenty (0.05%) three times each 2 
minutes. 
12-The secondary antibodies were added and incubated for 30 minutes.  
13-The slides were washed with PBS Tween twenty (0.05%) three times each 2 
minutes. 
14-The DAB solution was prepared by mixing up 1 ml of substrate solution 
(Substrate in DAKO kit) with 20µL of buffer (Buffer for DAB and chromagen in 
DAKO kit) (Dako, Cambridgeshire, UK). The solution was mixed well and applied 
to the sections. 
15-The slides were washed with tap water for 5 minutes. 
16-Nuclear counter staining was done using Mayer’s Haematoxylin (Sigma, UK) for 
1-3 minutes. 
17- The slides were washed with tap water for 20 minutes to remove excess 
haematoxylin. 
18- After removing the excessive water, the cover glass slips were mounted with 
Aqueous mounting media (Dako, Cambridgeshire, UK) using a pair of forceps onto 
the tissue slides. Proper care was taken not to entrap any air bubbles between the 
cover glass and the tissue sections. The slides were left to dry for 30 minutes and 
then visualized under the microscope. 
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3.2.7 Electron microscopy (EM) 
 
EM allows obtaining images at a much higher resolution than those obtained by light 
microscopes. EMs use beams of electrons to examine specimens and the interaction 
of the electrons with the specimen gives information on morphology of the 
specimens. The EM consists of an electron source, an anode, magnetic lenses, 
apertures, specimen stage and image recording system all of which operate in a high 
vacuum. 
 
Preparation of the specimen for EM 
 
Perfusion fixation of total liver in situ 
 
Following anesthetizing the animal and opening the abdominal cavity the intestines 
were moved to the left side of the abdominal cavity and covered with saline soaked 
surgical gauze. The hepatic artery was ligated at the hilum with a 7-0 silk and 
divided. The portal vein was then exposed and a 23 gauge needle connected with a 
catheter and syringe was used to puncture the portal vein for perfusion. Perfusion 
was done with glutaraldehyde and the vena cava was incised to allow the infused 
fluid to escape. Hereafter the liver would change its consistency to firm or hard and 
its colour to yellow. The perfusion was completed in 5 minutes and small pieces of 
well perfused liver lobes were placed in the fixative solution. A razor blade was 
subsequently used to cut 1-mm slices of liver tissue without putting any pressure on 
the tissue while cutting.  Tissue slices were covered with glutaraldehyde all the time 
and several strips were cut for transmission electron microscopy (TEM) (1 mm × 1 
88 
 
mm × 1 mm) blocks or (1mm × 1 mm × 5 mm) strips for scanning electron 
microscopy (SEM). The samples were then processed for EM examination. 
 
Procedure for EM 
PROCESSING TISSUE FOR SCANNING ELECTRON MICROSCOPY 
 
The Procedure: 
 
The samples were fixed in 1.5% glutaraldehyde for a minimum of 2 hours, then 
washed with several changes of PBS (Oxoid, Basingstoke, UK) and postfixed using 
1% osmium tetroxide/1.5% potassium ferricyanide for 12 hours. 
Samples were washed with distilled water and dehydrated through graded acetone 
(30%, 50%, 70%, 90% and 100%, HPLC grade 2 x 15 minutes each). After 
dehydration the specimens were transferred to tetramethylsilane for 5 minutes and 
then allowed to air dry. 
They were then attached to aluminium stubs with double sided sticky tabs (TAAB, 
Berkshire, UK) or carbon dag and then coated with gold using an SC500 sputter 
coater (EMScope, UK) before being examined and photographed using a Philips 501 
SEM (FEI UK Limited, Cambridge, UK). 
 
Preparation of tissue for transmission electron microscopy 
 
The Procedure: 
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Tissue was fixed in 1.5% paraformaldehyde/1.5% glutaraldehyde in phosphate 
buffer, washed with phosphate buffered saline (Oxoid, Basingstoke, UK) and 
postfixed using 1% osmium tetroxide / 1.5% potassium ferricyanide, washed with 
distilled water and dehydrated using graded alcohols 30%, 50%, 2 x   70% and 3 x 
100%, followed by infiltration with 50% alcohol / 50% Lemix (TAAB, Berkshire, 
UK) epoxy resin mixture overnight. The next day tissue was infiltrated with 100% 
Lemix resin for a minimum of 6 hours, followed by a second day of infiltration with 
100% resin then polymerised at 70
o
 C overnight. 
Sections were cut on a Reichert-Jung ultracut E microtome (Reichert, NY, USA) and 
collected on 300HS, 3.05mm copper grids (Gilder, Manchester, UK). The sections 
were stained with saturated uranyl acetate in 50% ethanol (TAAB, Berkshire, UK) 
and Reynold’s lead citrate. Sections were viewed and photographed using a Philips 
201 TEM (FEI UK Limited, Cambridge, UK). 
Reagents for EM 
 
Glutaraldehyde (20mls 20% paraformaldehyde (VWR, Dorset, UK) + 16mls 25% 
glutaraldehyde (TAAB, Berkshire, UK) + 59mls PBS (Oxoid, Basingstoke, UK). 
Osmium tetroxide 1% osmium tetroxide (VWR, Dorset, UK)  + 1.5% potassium 
ferricyanide (VWR, Dorset, UK) in PBS (Oxoid, Basingstoke, UK). 
Toluidene blue stain 1% toluidine blue (Raymond Lamb, East Sussex, UK) with 
0.2% pyronine (Raymond Lamb, East Sussex, UK)  in 1% sodium tetraborate 
(VWR, Dorset, UK). 
Reynolds lead citrate  (Dissolve 1.33g lead nitrate (VWR, Dorset, UK) in 15mls 
distilled water and 1.76g sodium citrate (VWR, Dorset, UK) in 15mls distilled water, 
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mixed solutions were dissolved and the resulting precipitate mixed with 8 ml of 1M 
sodium hydroxide (VWR, Dorset, UK), made up to final volume of 50ml. 
Lemix epoxy resin (Lemix A (25mls) + Lemix B (55mls) + Lemix D (20mls). Poured 
into plastic resin bottle and added 2 ml of BDMA, and mixed well. 
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4-Development of a model of sinusoidal 
obstruction syndrome in rats 
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4.1 Background 
 
The treatment of CLM has been completely revolutionized by the introduction of 
oxaliplatin and irinotecan based chemotherapy. They play an integral role in 
downstaging advanced liver tumours rendering them more amenable to surgical 
resection. Moreover, these neoadjuvant chemotherapeutic agents also keep the 
systemic disease under control and identify the patient groups who would not benefit 
from surgery based on the progression of the disease during chemotherapy (187). 
Although these drugs have become the standard of care in this setting; oxaliplatin 
has been strongly associated with the development of sinusoidal injury in the non-
neoplastic liver. This well recognized side effect of oxaliplatin was first described by 
Rubbia-Brandt when 78% of post-chemotherapy hepatectomy specimens receiving 
oxaliplatin were found to demonstrate pathological evidence of striking sinusoidal 
damage (188).  
The sinusoidal changes occurring in the liver following oxaliplatin chemotherapy are 
pathologically similar to the SOS which is a well known complication of 
myeloablative therapy in patients receiving HSC transplantation for conditions like 
aplastic anaemia and inborn errors of metabolism (189). 
Patients who develop SOS due to oxaliplatin present clinically with manifestations 
of portal hypertension including hepatomegaly, ascites, splenomegaly and increased 
bilirubin levels. Portal hypertension can result in opening of the porto-systemic 
collaterals to decompress the portal system leading to haemorrhoidal and 
oesophageal varices which may rupture and cause fatal haemorrhages. Also the 
blood transfusion requirements for these patients during liver resections were higher 
when compared to patients receiving other regimens or no chemotherapy with a 
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higher postoperative complication rate and a prolonged hospital stay (64), (190), 
(191). 
In order to study the pathological effects of SOS and explore the possible therapeutic 
options to treat this serious overlooked condition it was essential to establish a 
reliable and reproducible animal model. Although oxaliplatin produces deleterious 
effects in human liver, similar effects could not be reproduced in rats. MCT is a 
pyrrolizidine alkaloid toxin that is known to induce hepatic and cardiopulmonary 
toxicities. It produces hepatic fibrosis and sinusoidal dilatation following ingestion 
due to its conversion to the active metabolite monocrotaline pyrrole (MCT-P) 
through the cytochrome P450 system (192). It has been extensively studied in the 
development of an animal model of pulmonary hypertension through its primary 
effect on the vascular bed (193). Also, Deleve et al used MCT to induce an animal 
model of liver sinusoidal injury similar to that occurring following HSC 
transplantation (182). 
 In the present study we investigated the effect of MCT in inducing SOS in rat liver 
with special emphasis on measuring the functional endpoint of PP changes in the 
animals that received MCT compared to the control group. This was the primary end 
point as elevation of PP is central in the pathogenesis of oxaliplatin induced SOS. 
Secondary endpoints included measurement of liver transaminases reflecting the 
degree of liver damage and examination of the histological sections of the liver both 
with light and EM. IHC was performed to study the expression of MMP. MMPs are 
endopeptidases that degrade collagen IV in the extracellular matrix of the basement 
membrane, and specifically MMP-2 and 9 are reported to be upregulated following 
SEC damage (194).  
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4.2 Results 
 
4.2.1 Portal pressure measurements 
 
Rats treated with MCT had significantly higher PP measurements when compared to 
the control group at all studied time points. The PP measurements were significantly 
higher in rats receiving MCT as early as 24 hours (9.37±0.99 vs. 6.50±0.70) mmHg 
MCT vs. control respectively (p=0.0001). The PP measurements in the MCT group 
also remained significantly higher than in the control group at 48 hours (10.19±1.30 
vs. 7.46±1.09) mmHg (p=0.005) and at 72 hours (11.36±2.97 vs. 6.63±0.51) mmHg 
(p=0.016) MCT vs. control respectively (Fig.13). 
 
 
 
Figure 13 Portal pressure measurements in MCT treated rats compared to the control 
group. MCT administration caused a significant rise in portal pressure measurements 
when compared to the control group at all designated time points. 
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4.2.2 Biochemical evidence of monocrotaline induced liver injury 
 
No mortality occurred in either group, however in the MCT treated rats there was 
blood-tinged ascitic fluid in the abdominal cavity which was not present in the 
control group at the time of sacrifice.  
Serum ALT levels were significantly higher in MCT treated rats when compared to 
the control rats at 48 hours and 72 hours reflecting the toxic effect MCT on 
hepatocytes (48h: 253.35±171.70 IU/L vs. 42.20±3.08 IU/L p=0.034, 72h: 
311.91±163.64 IU/L vs. 46.17±4.34 IU/L p=0.002) MCT vs. control respectively. 
There was no significant difference between both groups at 24 hours (24h: 
79.80±47.27 IU/L vs. 42.57± 6.89 IU/L p=0.109) MCT vs. control respectively 
(Fig.14). 
Also, there were significant differences in serum bilirubin levels when compared 
between both groups at 48 and 72 hour following gavage (48h: 1.96± 0.28 vs. 1.01± 
0.55 p=0.016, 72h: 5.37±2.70 vs. 1.16±0.35 p=0.01) MCT vs. control respectively, 
however, no significant differences could be detected at 24 hours (24h: 2.00± 0.69 
vs. 1.27± 0.15 Mmol/L p=0.054) MCT vs. control respectively (Fig.15). 
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Figure 14 Serum ALT measurements in both groups.  Serum ALT was significantly 
higher in the MCT group at 48 and 72 hours, however no significant difference could 
be detected at 24 hours. 
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Figure 15 Serum bilirubin measurements in both groups. Serum bilirubin levels 
were significantly higher in the MCT group when compared to the control group at 
48 and 72 hours but not at 24 hours. 
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4.2.3 Histological evidence of monocrotaline induced liver damage 
 
Light microscopic examination revealed normal large polygonal hepatocytes with 
prominent round nuclei and eosinophilic cytoplasm, and well spaced hepatic 
sinusoids arranged in-between the hepatic cords. The histology of the control group 
was consistent at different time points. 
In the MCT group, extensive sinusoidal dilatation with separation of the hepatic 
cords could be detected as early as 24 hours following MCT gavage. This was 
associated with inflammatory cell infiltration which was much denser than in the 
control group (Fig.16). At 48 hours, severe congestion was evident in the MCT 
treated group with inflammatory cells within the sinusoids (Fig.17). Massive areas of 
hepatic necrosis associated with inflammatory cell infiltration were evident at 72 
hours predominantly in the centrilobular regions of the liver with detachment of the 
endothelial lining of the central vein (Fig.18). 
However, treatment with Oxaliplatin did not produce any significant histological 
changes that were consistent with SOS when compared to the MCT group at of the 
time points (Fig.19). 
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Figure 16 Histological examination of the liver in both studied groups at 24 hours. 
Normal appearance of the liver in the control group with no dilatation of the hepatic 
sinusoids following gavage with DMSO (left). The effect of MCT on the liver could 
be seen in the form of sinusoidal dilatation that was extensive all over the liver (right 
low magnification) and showing the ballooning of the sinusoids and the presence of 
inflammatory cells  within the sinusoidal spaces (right high magnification) Low 
magnification x100, high magnification x400. 
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Figure 17 Histological examination of the liver in both studied groups at 48 hours. 
No liver damage could be detected at 48 hours in the control group (left); however in 
the MCT group there was severe congestion that was extensive over large areas of 
the liver (right low magnification). This was associated with areas of peliosis and 
beginning of necrosis in some areas of the liver (right high magnification). Low 
magnification x100, high magnification x400. 
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Figure 18 Histological examination of the liver in both studied groups at 72 hours. 
No damage could be detected in the control group at 72 hours (left). The liver in the 
MCT group shows extensive areas of coagulative necrosis in the centrilobular 
regions of the liver (right) with damage of the endothelial lining of the central vein 
and its separation from the basement membrane. (Right high magnification, solid 
arrow). Low magnification x100, high magnification x400. 
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Figure 19 Histological changes in the liver following oxaliplatin and MCT 
treatment. A very mild degree of SOS could be seen in the livers of oxaliplatin 
treated rats at 24 hours when compared to MCT treated rats at 24 hours (A,B). There 
was no progression of liver injury with time in the oxaliplatin group. At 72 hours 
oxaliplatin treated rats lacked hepatocellular necrosis and inflammatory cells unlike 
in the MCT group which progressed from sinusoidal dilatation at 24 hours to frank 
necrosis at 72 hours (C,D). 
 
 
 
 
 
 
103 
 
 
4.2.4 Electron microscopic examination of Monocrotaline induced liver damage 
 
EM was used to assess details that could not be detected using light microscopy. The 
EM study was conducted on liver samples preserved from both the control and the 
MCT treated rats at the 72 hour time point. This time point was chosen as it 
corresponded to the highest PP and enzymatic levels when compared to the other 
time points. On SEM it was possible to detect disruption of the sinusoidal 
endothelial lining and congestion of the sinusoids with erythrocytes in the MCT 
treated rats but not in the control group (Fig. 20A,B). Also an increase in the size of 
the fenestrae with gap formation was noted in the MCT treated group (Fig.20C,D). 
On TEM gaping of the SECs was evident in the MCT group with dilatation of the 
fenestrae. The sinusoidal endothelial lining was intact in the control group with 
normal fenestrae size when compared to the MCT group (Fig.21). Detachment of the 
SEC lining from the basement membrane and disruption of the space of Disse was 
evident in the MCT treated group and not in the control group (Fig.22B). The 
detachment of the SECs obstructed the lumen of the sinusoid and allowed direct 
contact between the erythrocytes and hepatocytes inducing hepatocyte damage 
(Fig.22C). Also, hepatocytes from MCT treated group showed more glycogen 
depletion when compared to the control group (Fig.21,22). 
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Figure 20 Scanning Electron Microscopy images of both control and MCT treated rats at 72 hours following gavage. The sinusoidal 
endothelial lining is intact in the control group receiving DMSO only with no detachment of the sinusoidal lining or gap formation (A 
x2500). In the MCT treated rats, there is detachment of the sinusoidal endothelial lining occluding the blood flow in the sinusoid and 
congestion with erythrocytes (B x5000). Dilatation of the fenestrae with formation of large gaps that develop in the sinusoidal lining of 
MCT treated rats (C x2500, D x5000 arrows pointing to gaps in sinusoids). 
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Figure 21 Transmission Electron Microscopy images of the sinusoidal lining in both the control and MCT treated groups. The SEC 
lining is intact and basement membrane with normal sized fenestrae (Arrow) and abundant glycogen in the control group (A). There is 
ballooning and detachment of the SEC lining from the basement membrane with an increase in the size of the fenestrae due to gaping of 
the SECs (Arrow). This is also associated with glycogen depletion (B). 
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Figure 22 Transmission Electron Microscopy images of the sinusoids in both the control and MCT treated groups. Dilatation of the 
sinusoid with detachment of the SEC lining from the basement membrane with disruption of the space of Disse could be clearly seen in 
the MCT group (B). Separation of the SECs which are floating in the sinusoid and obstruct the lumen leading to dilatation and direct 
contact of erythrocytes with hepatocytes that have lost their SEC lining with loss of hepatocyte microvilli (arrow) (C). The sinusoids 
appear normal in the control group following DMSO gavage with abundant glycogen compared with the MCT group and intact SEC 
lining (A). 
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4.2.5 Role of Matrix Metalloproteinases in development MCT induced SOS 
 
The role of MMP 2 and 9 was studied to determine their possible role in the 
pathogenesis of SOS. IHC was performed on liver samples with anti-MMP-2 and 
anti-MMP-9 antibodies. The basal expression of MMP-9 was slightly higher than 
that of MMP-2 in the control group (Fig.23A,B); however following MCT gavage 
MMP-9 expression was markedly higher than MMP-2 expression which did not 
seem to increase in response to MCT toxicity (Fig.23C,D). 
The extent of MMP-9 expression was similar at different time points following MCT 
ingestion. MMP-9 was mainly localized in SEC lining and the inflammatory cells at 
24 hours (Fig.24B,C). At 72 hours, in addition to expression in the SEC lining, 
MMP-9 was also expressed in hepatocytes in the vicinity of necrotic areas 
(Fig.24E,F). 
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Figure 23 Difference in expression of MMP-2 and MMP-9 in control and MCT groups at 72 hours. There was no marked difference in 
MMP-2 and MMP-9 expression in the control group at 72 hours (A, B). In the MCT group however, MMP-9 was markedly expressed 
when compared to MMP-2 which was similar to the expression in the control group (C, D).  
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Figure 24 MMP-9 expression at different time points in the livers of the MCT group. A higher expression of MMP-9 could be detected 
in the MCT group when compared to the control group as early as 24 hours (A,B). Areas of MMP-9 expression included inflammatory 
cells and walls of the sinusoids (higher magnification C). An increase in the intensity of MMP-9 expression could be seen at 72 hours 
(E) with strong expression in damaged hepatocytes that show vacuolation (higher magnification F).
110 
 
4.3 Discussion 
 
Oxaliplatin-based chemotherapy has been strongly associated with development of 
SOS when given as part of the neoadjuvant protocol to downstage hepatic CLMs 
prior to liver resections. The most serious complication of this condition is 
development of portal hypertension leading to splenomegaly resulting in 
thrombocytopenia due to platelet sequestration, ascites and variceal bleeding when 
the PP exceeds 12 mmHg (64), (195).  In this study we used MCT to induce SOS in 
rats; a model that is both reliable and reproducible and closely resembles both the 
histological and clinical features of SOS resulting from oxaliplatin based 
chemotherapy (182), (189).  
It was not possible to establish the SOS rat model following treatment with 
oxaliplatin as we could not detect the pathological lesions that correlate with clinical 
SOS including sinusoidal dilatation, inflammatory cell infiltration and hepatocellular 
necrosis. Similarly, Schiffer et al (90) and Narita et al (196) used MCT and not 
oxaliplatin to develop an experimental SOS model in rats relating the model to 
oxaliplatin induced SOS in patients. This is in addition to the description of the first 
rat SOS model by DeLeve et al who used using MCT to simulate the clinical SOS 
that develops following myeloablative chemotherapy for HSC transplantation (182). 
The reason oxaliplatin was not successful in inducing SOS in rats might be related to 
the difference in metabolic pathways between humans and rats especially concerning 
the cytochrome P450 system since platinum based drugs have been shown to 
suppress the expression of some cytochrome P450 isoenzymes in the rat but not in 
the human liver (197). 
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The primary end point of this experiment was to establish the role of MCT in 
developing portal hypertension related to hepatocellular damage in rats. An animal 
model with established portal hypertension and pathological changes that correlate 
with clinical SOS would be of great value in order to investigate the potential 
therapeutic effects of a target drug. We showed that the PP measurements were 
significantly higher in the MCT treated rats when compared to the control group at 
all time points. This was also associated with liver congestion, the presence of 
bloody ascitic fluid and congested bowels which were most evident at 72 hours in 
the MCT group. It has been previously reported that hepatic venous pressure 
gradient greater than 10 mm Hg is specific for SOS (198).  Hepatic venous pressure 
gradient is being used more frequently as an index for PPs as it is less invasive and 
correlates well with the direct PP measurements (199). In this study we measured the 
PPs directly through portal vein puncture with average values greater than 10 mm 
Hg at both 48 and 72 hour time points hence specific for SOS. 
The pathogenesis of MCT induced portal hypertension differs however according to 
different time points. DeLeve et al divided the changes occurring in the SECs 
following MCT toxicity into early or preclinical SOS during the first 12-48 hours 
and late or clinical SOS starting from day three for a period of three days where 
separation of the sinusoidal lining occurs (200). Accordingly PP elevation in the first 
two days has been hypothesized to be due to swelling and rounding up of the SECs 
leading to impedance of the blood flow with development of gaps within the 
sinusoidal wall lining. The erythrocytes then penetrate the space of Disse from 
beneath the sinusoids and through the gaps in the wall dissecting and completely 
separating the SEC lining blocking the sinusoidal lumen and inducing clinical SOS 
by day three (200). We performed an EM study at the 72 hour time point which 
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corresponds to clinical SOS to correlate the changes in PP with the ultrastructural 
damage changes. The SEM images on day three showed complete detachment of the 
SEC lining obstructing the blood flow. In addition, the TEM images showed 
dilatation of the sinusoidal cell fenestrae with loss of the SEC lining leading to direct 
contact between the erythrocytes and hepatocytes. Also, TEM images showed 
evidence of glycogen depletion in the perisinusoidal hepatocytes reflecting 
hepatocyte damage. This is similar to the early phase of APAP toxicity where 
glutathione depletion has been noticed (201), (202). 
Serum bilirubin levels were also significantly higher in the MCT group at 48 and 72 
hours. Schiffer et al reported decreased bile flow and bile excretion in livers of MCT 
treated rats and attributed this to the toxic effect of MCT on hepatocytes (90). 
Although serum bilirubin levels are sensitive in detecting SOS in the clinic; they are 
not specific due to the presence of several other causes of jaundice in these patients 
including extensive metastatic liver disease and enlarged lymph nodes in the porta 
hepatis (189), (203). Serum bilirubin levels however are very specific in predicting 
the development of PLF when their values are greater than 50% and a peak bilirubin 
of 7.0 mg/dl has been considered a specific cut-off value for PLF related deaths (16).  
Centrilobular sinusoidal dilatation with perisinusoidal erythrocyte extravasation 
could be detected on histological examination of the liver sections from the MCT 
group during the first 24 hours with progressive congestion, wide-spread 
haemorrhagic areas representing peliosis and extensive hepatocellular necrosis by 
day three. These findings were in-keeping with the pathological lesions seen in the 
non-neoplastic liver following oxaliplatin preoperative chemotherapy in patients 
(186). Drawbacks of the MCT-SOS model however included the extensive presence 
of coagulative hepatocellular necrosis which occurs less frequently in the liver 
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sections of patients following oxaliplatin treatment. Also, nodular regenerative 
hyperplasia (NRH) which is a common finding in a high percentage of patients could 
not be detected. In this study, the follow up period was only three days as we were 
interested in the acute phase of the disease and this time frame would not allow 
studying the NRH related to SOS. Moreover, even if we had longer follow up times 
it might still have not been possible to detect NRH due to the reversible nature of the 
model with complete resolution of SOS starting from day 10 in the animal model  
(182), (186).  
A substantial inflammatory cell response was observed in the regions of sinusoidal 
damage following MCT gavage at all time points. This histological evidence of 
inflammation was associated with biochemical evidence in the form of significantly 
higher serum ALT measurements at 48 hours when compared to the control group. 
The highest serum ALT levels however were detected at 72 hours and this correlated 
with the development of hepatocellular necrosis. Deleve et al (182) also reported the 
highest inflammatory response to occur on day three with mixed mononuclear and 
polymorphonuclear (PMN) cell populations. PMNs have been shown to play a role 
in hepatocellular necrosis in the MCT-SOS model through detection of increased 
myeloperoxidase activity in areas of coagulative necrosis. Myeloperoxidase is 
released following activation and degranulation of PMNs which yields hypochlorous 
acid which is a major oxidant formed through a reaction between hydrogen peroxide 
and chloride ions. (194), (196).  
Although inflammatory changes were not obvious in liver sections from patients 
with SOS, liver transaminases were significantly higher in high grade SOS lesions 
when compared to low grade SOS lesions (186), (204). Also, a recent study showed 
that acute phase pathway genes were upregulated in liver tissue following oxaliplatin 
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therapy including both the IL-6 pathway and STAT-1 gene which contribute directly 
to liver inflammation in clinical SOS (205), (206).  
We also showed an increased expression of MMP-9 but not MMP-2 in liver tissue of 
rats treated with MCT. MMPs are known to be produced by SECs when subjected to 
injury through actin disassembly (207). They may play a key role in SOS 
pathogenesis due to the discontinuous and scanty nature of the sinusoidal basement 
membrane in the liver comprised principally of collagen IV which is easily degraded 
with MMPs (208). Deleve et al (209) used gelatin zymography to study MMP 
expression in rat liver following MCT gavage and showed that MMP-9 expression 
was much higher than MMP-2 expression and that SECs were the major source of 
MMP production in the liver. We also showed that in addition to SEC expression; 
MMP-9 was expressed in the inflammatory cells as early as 24 hours. Borregaard et 
al (210) showed that PMNs are a source of MMP-9 in response to injury however the 
role of PMN-released MMP-9 might be less significant than SECs in development of 
SOS (194).  
The role of MMP-9 in pathogenesis of clinical SOS has been suggested when it was 
noticed that patients receiving bevacizumab in addition to oxaliplatin in the 
neoadjuvant chemotherapy protocol showed less severe SOS when compared to 
oxaliplatin alone (211). Bevacizumab is a monoclonal antibody directed against 
VEGF-A which has shown a higher expression in SOS following HSC 
transplantation (212). VEGF plays a role in maintenance of the fenestrae of the SECs 
and its expression is increased following SEC lining disruption and cellular hypoxia 
(213). VEGF is known to induce expression of MMP-9 by SECs, thus bevacizumab 
may lead to downregulation of MMP-9 resulting in less severe SOS. Surprisingly 
Rubbia-Brandt et al (205) showed that the VEGF-C mRNA levels were increased in 
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clinical SOS with no difference in VEGF-A levels when compared with the control. 
This would suggest that Bevacizumab has an anti-VEGF-C action as well. VEGF-C 
is responsible for lymphangiogensis and it has been reported that VEGF-C is 
released from macrophages activated via VEGF-A. In addition bevacizumab 
inhibited both angiogenesis and lymphangiogensis when added to the cornea 
suggesting a role of bevacizumab in VEGF-C suppression (214), (215). 
 
To conclude, we established an SOS animal model with special emphasis on the 
clinical implications of the model in terms of oxaliplatin induced SOS. We showed 
that the functional and structural damage changes in the MCT-SOS model resemble 
closely the clinical SOS with similar pathways and hence preventing SOS in this 
model could be prospectively used in a clinical trial to prevent and treat SOS in 
patients. 
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5-Semi-synthetic flavonoid monoHER 
prevents development of sinusoidal 
obstruction syndrome in rats   
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5.1 Background 
 
The main cause for development of SOS with its consequences of portal 
hypertension and increased incidence of PLF is the primary insult of the SECs with 
secondary hepatocellular damage. Prevention of SOS related PLF should focus 
primarily on identifying patients who are at high risk of developing SOS and who 
should be properly assessed before surgery. High risk patients include those who 
have received more than six cycles of neoadjuvant chemotherapy, patients with node 
positive tumours who received adjuvant chemotherapy following resection of the 
CRC, and those with a high APRI score which is considered a sensitive predictor of 
SOS (30), (216), (41). 
It has also been recently reported that patients with high grade SOS have a worse 
prognosis, not only in relation to postoperative morbidity but also in terms of early 
intra-hepatic recurrence and decreased survival (216). 
Prevention of the condition is of utmost importance and should focus on SEC 
protection. This should include both stabilization of sinusoidal endothelium and 
prevention of its detachment from the basement membrane in addition to inhibiting 
the upregulated inflammatory pathways associated with SOS. Prevention of SOS 
development has focused up until now on either inhibition of the coagulation 
cascade, deactivation of MMP activity which is upregulated in SOS, restoration of 
intracellular glutathione or preservation of sinusoidal perfusion (217), (40), (218). 
The flavonoid monoHER could have a potential protective agent against SOS 
because of its favourable effect on the microvascular endothelium and its antioxidant 
and anti-inflammatory capacities (219). MonoHER is a component of the registered 
drug Venoruton, which is used to treat chronic venous insufficiency. MonoHER has 
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been shown to provide a protective effect against doxorubicin-induced cardiotoxicity 
in mice without interfering with its antitumour activity (220), (221). More recently, it 
has been used in healthy volunteers in a phase I clinical trial without any serious side 
effects. This has encouraged investigators to study its cardioprotective effects in 
patients with metastatic cancer being treated with doxorubicin (222), (223). 
The aim of this study was to assess the protective effect of the semi-synthetic 
flavonoid monoHer on the development of MCT induced sinusoidal injury in rats. 
Furthermore, the effect of monoHER on cell growth of human CRC cells exposed to 
increasing concentrations of oxaliplatin was determined in-vitro. 
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5.2 Results 
 
5.2.1 MonoHER reduces the portal pressure in SOS 
 
In order to detect whether pretreatment with monoHER had an effect on reducing the 
PP, we compared PP measurements with the MCT group at all time points (Fig.25). 
The PP was significantly lower in rats pretreated with monoHER when compared to 
rats receiving MCT alone as early as 24 hours (7.43±0.93 vs. 9.37±0.99 mmHg 
respectively (p=0.005)). The PP measurements in the MCT+ monoHER group also 
remained significantly lower than in the MCT group at 48 hours (p=0.019) and 72 
hours (p=0.016) (48h: 7.91±1.26 vs.  10.19±1.30 and 72h: 7.31±2.65 vs. 11.36±2.97 
mmHg MCT+ monoHer vs. MCT respectively). 
 
 
Figure 25 Portal pressure measurements in monoHER pretreated rats compared to 
MCT rats. Pretreatment with monoHER significantly reduced the portal pressure at 
all time points when compared to the MCT group.  
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5.2.2 Liver damage is attenuated by monoHER 
 
Similar to the previous experiment no mortality occurred in either group. The livers 
of the MCT treated rats were more congested when compared to MCT+ monoHER 
group with multiple punctuate haemorrhagic spots at 48 hours and patches of 
necrosis at 72 hours  in MCT only group (Fig.26). 
No difference could be detected in serum bilirubin measurements at any time points 
between both groups. Serum ALT was significantly lower in MCT+ monoHER rats 
when compared to MCT rats at 72 hours (129.47±114.50 vs. 311.91±163.64) IU/L 
respectively, p=0.028). There was no significant difference in serum ALT levels 
between both groups at 24 hours (p=0.092) or 48 hours (p=1.00) (Fig.27). 
Histological examination of liver sections revealed extensive sinusoidal dilatation 
following MCT administration with inflammatory cell infiltration at 24 hours 
(Fig.28A). Sinusoidal dilatation was also present in the MCT+ monoHER rats, 
however to a much lesser extent with fewer inflammatory cells when compared to 
the MCT group (Fig.28B). At 48 hours, marked congestion was observed in both 
groups with a more extensive inflammatory response in the MCT group when 
compared to the MCT+ monoHER group (Fig.29B,D). Frank hepatic necrosis 
extending over most of the liver was observed in the MCT group at 72 hours with 
dense inflammatory cell infiltration (Fig.30A). Also, detachment of the SEC lining 
from the space of Disse could be seen in the central vein with evidence of 
subendothelial haemorrhage (Fig.30B). In the monoHER group, congestion was still 
present however there was no necrosis and the SEC lining remained intact 
(Fig.30C,D). 
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The overall liver damage severity score was significantly lower in MCT+ monoHER 
rats when compared to MCT treated rats only at 72 hours (10.33±0.51 vs. 4.8±3.56) 
MCT+ monoHER vs. MCT respectively (p=0.002) (Fig.31A). Inflammatory cell 
infiltration/HPF was also significantly lower in the MCT+ monoHER group when 
compared to the MCT group at 72 hours but not at other time points (20.6±8.32 vs. 
64.5±9.02) cells/HPF MCT+ monoHER vs. MCT respectively (P<0.0001) 
(Fig.31B). 
 
5.2.3 MonoHER reduces MMP-9 expression in the liver 
 
A scoring system based on both the intensity (0, 1, 2, 3) and extent of MMP-9 
expression (1=<33%, 2=33-67%, 3=>67%) was used as a semi-quantitative 
measurement of MMP-9 expression in both groups (224). Livers of MCT treated rats 
had a significantly higher expression of MMP-9 when compared to the MCT+ 
monoHER rats at both 24 hours (p=0.016) and 72 hours (p=0.0001) (Fig.32). Areas 
of highest expression included SEC lining and inflammatory cells to a lesser extent; 
in addition, MMP-9 was also expressed in areas of hepatocellular necrosis at 72 
hours (Fig.33). We could not detect significant differences in MMP-2 expression in 
MCT treated rats when compared to the sham group. Therefore MMP-2 expression 
was not used as a parameter to compare the liver damage between MCT and MCT+ 
monoHER groups. 
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Figure 26 Representative samples showing morphological appearance of the liver at different time points. The congestion is evident at 
24 hours in the MCT group (A), with appearance of punctuate hemorrhagic spots at 48 hours (B) and areas of frank necrosis in a deeply 
congested liver at 72 hours resembling the blue liver seen in the clinical scenario (C). Congestion also occurred in the MCT+ monoHER 
group however was much less severe than in the MCT group and without the development of punctuate hemorrhages or frank necrosis.
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Figure 27 Serum ALT and bilirubin measurements in the two studied groups. Rats 
pretreated with monoHER had significantly reduced serum ALT at 72 hours when 
compared to MCT treated rats. There was no difference between both groups at 24 or 
48 hours. There was no significant difference in bilirubin levels in both groups. 
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Figure 28 Histological examination of the liver in both studied groups at 24 hours. 
Generalized sinusoidal dilatation could be detected in the MCT group with 
inflammatory cell infiltration (A,B). The sinusoidal dilatation is less pronounced in 
the monoHER group with less inflammation (C,D). Low magnification x100, high 
magnification x400. 
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Figure 29 Histological examination of the liver in both studied groups at 48 hours. 
Extensive areas of congestion could be seen in both groups (A,C). Inflammation is 
less severe in the monoHER group (C,D). 
 
 
 
 
 
126 
 
 
 
 
Figure 30 Histological examination of the liver in both studied groups at 72 hours. 
Massive areas of necrosis could be detected in the MCT treated liver (A), with 
detachment of the endothelial lining of the central vein and presence of 
subendothelial erythrocytes (B). No necrosis was detected in the monoHER liver at 
the same time point (C). Congestion was still present however the endothelial lining 
of the central vein was intact (D). 
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Figure 31 Semi-quantification of liver damage in studied groups. The overall H&E 
liver damage severity score (A) and inflammatory cell count /HPF were significantly 
lower in the MCT+monoHER group only at 72 hours (B). 
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Figure 32 Semi-quantification of MMP-9 expression in the liver samples of both 
groups. The MMP-9 expression was significantly higher in the MCT group at 24 and 
48 hours. 
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Figure 33 MMP-9 expression in both groups at different time points. The MMP-9 
expression in the monoHER group was weaker than in the MCT group at all time 
points. The most striking difference could be seen at 72 hours where MMP-9 was 
greater in both extent and intensity in the MCT group. 
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5.2.4 Protective effect of monoHER on HUVEC cell line 
 
To determine the effective drug concentrations, HUVEC cells were treated with 
various concentrations of oxaliplatin ranging from (0.5 µg/ml-8 µg/ml). No 
difference could be detected between oxaliplatin concentrations of 0.5µg/ml and 
2µg/ml. With increasing the concentration to 8µg/ml, a sharp fall in cell number 
could be detected with less viable cells (Fig.34). 
When similar numbers of HUVEC cells were pre-treated with monoHER, a very 
slight variation could be detected even with higher doses of oxaliplatin indicating a 
possible protective effect of monoHER on the HUVEC cell line (Fig.35). 
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Figure 34 Oxaliplatin effect on HUVEC cell line. Oxaliplatin reduced the viability 
of HUVEC cells which was dose dependant. 
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Figure 35 MonoHER attenuates the effect of oxaliplatin on HUVEC cells. 
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5.2.5 MonoHER does not interfere with oxaliplatin cytotoxicity 
 
Both CRC cell lines incubated with oxaliplatin showed dose-dependent cytotoxicity. 
MCT and/or monoHER at different concentrations did not have an effect on cell 
numbers in both cell lines. Addition of monoHER to oxaliplatin even in high doses 
(100µM) did not interfere with the dose dependant cytotoxic effect established by 
oxaliplatin indicating that monoHER did not interfere with the anti-neoplastic 
properties of oxaliplatin (Fig 36). 
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Figure 36  In-vitro analyses of proliferation of colorectal cancer cell lines using the 
MTS indirect colorimetric method and a spectrophotometer at 490nm. MonoHER 
did not interfere with the dose-dependent cytotoxic effects of oxaliplatin. MonoHER 
alone had no effect on viable cell count as measured by optical density in either cell 
line (OXA= Oxaliplatin, MH= MonoHER)
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5.3 Discussion 
 
The primary goal of this study was to investigate the role of monoHER in preventing 
the development of portal hypertension following MCT administration. The PP 
measurements in the MCT+ monoHER group were significantly lower than in the 
MCT group at all time points. The protective effect of monoHER was also reflected 
in the macroscopic appearance of the livers in the MCT+ monoHER group which 
demonstrated much less congestion and less haemorrhagic ascitic fluid in the 
abdominal cavity when compared to the MCT group specifically at 72 hours. 
Moreover, we showed that monoHER has a protective effect on HUVEC cells when 
added to oxaliplatin in-vitro.  
This might be explained by understanding the role monoHER plays in endothelial 
cell stabilization since SEC detachment and occlusion of the sinusoidal lumen is the 
key factor in development of SOS and portal hypertension (200). MonoHER is the 
most potent constituent of Venoruton which has been shown to reduce the 
microvascular permeability and erythrocyte aggregation. Venoruton has also been 
shown to protect vascular endothelium and reduce the number of CECs which was 
considered as a marker of the severity of the disease in chronic venous insufficiency 
(225), (226). More recently, monoHER demonstrated a significant protective effect 
against doxorubicin-induced damage to human endothelial cells in-vitro (227).  
It is known that a common pathway between MCT and oxaliplatin in the 
development of SOS is formation of reactive oxygen species and subsequent 
glutathione depletion (228). MonoHER has been shown to possess potent antioxidant 
free radical scavenging properties (220) which might play a role in prevention of 
SOS through sweeping free oxygen radicals and preventing SOS both in the MCT 
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animal model and in patients. Recently, serious concerns have been raised however 
towards the oxidation product formed following oxidation of monoHER. Similar to 
quercetin which is another well-established flavonoid that forms oxidation products 
in the process of free radical scavenging with resultant cell damage, a phenomenon 
known as the quercetin paradox (229) monoHER forms oxidation products which 
have been obtained in-vitro through oxidation of monoHER via horseradish 
peroxidase. These oxidation products have been shown to react with the thiol group 
in glutathione producing a monoHER-glutathione conjugate ultimately leading to 
glutathione depletion. This would lead to paradoxical catastrophic consequences in 
patients with SOS since the primary insult is depletion of glutathione which is the 
primary defence in the SECs. Fortunately, this has not been shown to occur in 
patients owing to a structural difference between monoHER and quercetin. A major 
difference exists in the interplay of these two compounds with the refined 
antioxidant network in-vivo owing to an intrinsic difference in their chemical 
structure leading to two energetically different products. Unlike quercetin which is a 
soft electrophile which directly reacts towards the thiol group in the soft nucleophile 
glutathione leading to its depletion, oxidized monoHER is a hard electrophile and is 
reduced through its preferential faster reaction with hard nucleophile plasma 
ascorbate preventing its reaction with thiols of glutathione hence avoiding its 
depletion (230), (231). 
The structural damage changes seen by light microscopy in the H&E sections were 
significantly improved in the MCT+ monoHER group again only at 72 hours. This 
together with the significantly lower levels of both serum ALT and inflammatory 
cells at 72 hours is evidence that monoHER plays a role in reducing the 
inflammatory response elicited in the liver which has been shown to occur most 
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evidently between days three and five following  MCT administration in rats (182). 
It is known that the inflammation induced oxygen free radicals play a role in 
endothelial cell damage and an increase in their vascular permeability (232). The 
anti-inflammatory properties of monoHER against doxorubicin-induced 
inflammation have been previously demonstrated through inhibition of neutrophil 
adhesion to endothelial cells and inhibition of overexpression of doxorubicin-
induced VCAM and E-selectin (227). Narita et al has also demonstrated that 
inhibiting neutrophil adhesion to the sinusoids and hepatocytes is a key factor in 
prevention of SOS in rats. Moreover, the authors showed that the hepatic necrosis 
occurring following MCT intake was mainly due to both neutrophil infiltration and 
activation and that the resulting oncotic necrosis could be prevented by inhibiting the 
neutrophil-induced oxidative stress which leads to hepatocyte mitochondrial 
dysfunction (196), (233). 
We also showed the possible role of monoHER in inhibiting another important 
pathway in SOS development which is through inhibiting the expression of MMP-9. 
When MCT is converted into its active metabolite MCT-P through the cytochrome 
P-450 system, it interacts with F-actin in SECs leading to its depolymerisation. This 
leads to upregulation of MMP-9 which degrades the collagen in the basement 
membrane leading to SEC detachment and occlusion of the sinusoids. MMP-9 
upregulation may also be related to decreasing the NO concentration in the hepatic 
veins following MCT intake (40), (228). 
The main sources of MMP-9 expression are PMNs and SECs (234), (235). We 
showed that localization of MMP-9 was mainly within the SEC lining in the first 24-
48 hours, however at 72 hours, expression of MMP-9 could also be detected in areas 
of hepatocellular damage with significantly less expression in the MCT+ monoHER 
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group. Although we demonstrated that monoHER reduces the influx of inflammatory 
cells with a significantly lower inflammatory response, previous studies have 
undermined the role of PMNs in the pathogenesis of SOS following MCT (194). 
Hanumegowda et al showed that although infiltration and degranulation of PMNs 
occurs early in the MCT model, this seems to occur away from the centrilobular 
areas which represent the most heavily affected areas of sinusoidal damage. In 
addition, PMNs depletion did not prevent the occurrence of sinusoidal damage. 
Although PMNs might not apparently play a significant role in sinusoidal damage, 
they definitely play an integral role in hepatocellular damage when activated by 
thrombin which is released when the coagulation cascade is activated during the 
disease process (194). DeLeve et al also showed that MMP-9 and to a lesser extent 
MMP-2 were produced within the basement membrane of SECs and this allows for 
separation and dissection of the SEC lining by means of erythrocytes (218). This is 
also in-keeping with our findings as expression of MMP-2 was much weaker than 
MMP-9 and could not be quantified. Therefore monoHER plays a role in stabilizing 
the basement membrane of SECs early in the course of the disease and hence less 
expression of MMP-9 from SECs, and it also prevents hepatocytes damage which 
occurs as a later secondary event through inhibiting inflammatory cell infiltration 
and activation by means of its potent anti-oxidant and anti-inflammatory properties.  
The importance of MMP-9 inhibition has been highlighted when bevacizumab added 
to oxaliplatin lead to a significant decrease in the severity of SOS through its role in 
inhibiting MMP-9 upregulation though blocking VEGF-A (186). 
The cause of mortality in patients with severe SOS is usually multiorgan failure 
which is often triggered by a liver resection in a compromised patient. Treatment 
then requires a multidisciplinary team management and is mainly supportive, 
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maintaining the functions of vital organs with proper fluid and electrolyte balance. 
Specific drugs used in this setting include tissue plasminogen activators and heparin, 
however these patients are at risk of severe bleeding due to underlying 
thrombocytopenia (236), (237). Defibrotide is another drug that has been use for 
treatment of severe SOS with multiorgan failure with promising results in several 
uncontrolled trials (238), (239). It is a polydeoxoribonucleotide which increases 
PGE2, PGE1, thrombomodulin and tissue plasminogen activator with a decrease in 
plasminogen activator inhibitors that are released from the endothelial cells. 
Although beneficial, no randomized controlled trials exist up to the current date and 
therefore it cannot be recommended for use in established SOS (236).  A recent 
phosphodiesterase inhibitor has been recently used to prevent SOS and preserve 
remnant liver function following hepatectomy in a MCT rat model in-vitro (240). 
This study however did not address the effect of this inhibitor on the PP; in addition 
its role in cancer cell progression is yet uncertain.  
The ideal therapeutic agent therefore should be a preventive one, with low toxicity, 
and with no interference with the cytotoxic activity of the neoadjuvant 
chemotherapeutic agents. In the current study we used monoHER which is a potent 
semi-synthetic flavonoid and has been proven to be effective in reducing 
doxorubicin-induced cardiotoxicity both in-vivo and in-vitro (220), (221).  
MonoHER has the advantage over other experimental therapeutic agents in that it 
has shown no interference with the cytotoxicity of oxaliplatin in two CRC cell lines 
when added at different concentrations. This is in agreement with previous studies 
on doxorubicin-induced cardiotoxicity where monoHER achieved adequate 
intracellular concentration without interfering with the pharmacokinetics of 
doxorubicin or its conversion to its active compound doxorubicinol (241),(221). 
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MCT had no effect on cell proliferation in either CRC cell line in-vitro, probably due 
to the need for its conversion to its active metabolite MCT-P which occurs via the 
cytochrome P450 system in-vivo (192). In addition, monoHER has proved to be safe 
in a phase I clinical trial and is currently in a phase two clinical trial (222) (223) 
which might expedite its use for prevention of SOS following oxaliplatin treatment 
in patients. 
 
Conclusion 
We have shown that monoHER is a potential therapeutic agent to be used in 
prevention of oxaliplatin induced SOS owing to its potent antioxidant and anti-
inflammatory, without interfering with the cytotoxicity of the oxaliplatin.  
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6-Cell therapy and dynamic tracking in an 
experimental acute liver failure model 
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6.1 Background  
 
SOS is not only involved in the development of portal hypertension and its sequelae 
but it has also been shown to have a significant negative impact on liver regeneration 
with an increased risk of early postoperative complications following partial 
hepatectomy (29). In a recent report it has been shown that SECs are of BM origin 
expressing the CD 133 marker. Moreover, BM CD133+ cells were capable of 
replacing damaged SECs following infusion in an SOS model in rats with a 
therapeutic benefit (168). Cell therapy therefore might play a role in improving the 
outcome of oxaliplatin-induced SOS through replacement of damaged SECs. It may 
also prevent the occurrence of PLF through enhancing hepatocyte regeneration and 
increasing the remnant liver volume following partial hepatectomy. It would be of 
great importance however to understand the dynamics of cell uptake in an animal 
model and to track their distribution and integration into the hepatic parenchyma. 
Cell tracking in the animal model could be achieved through cell labeling with 
fluorescent dyes. 
We used mouse ESCs which are of unlimited potential and are capable of 
differentiating into several cell types. An obstacle which we faced was the inability 
to establish the SOS model in mice using MCT. We therefore used APAP which 
similar to MCT has an early primary insult to SECs with secondary effect on the 
hepatocytes (202). For the purpose of cell tracking in mice we established a novel 
dual labeling fluorescence system to enable in-vivo tracking of the transplanted cells 
without repetitive killing of the animals. 
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6.2 Results 
 
6.2.1 Dual labeling of mouse embryonic stem cells using the near infra red dye 
DiR 
 
For the purpose of a meaningful transplantation allowing the possibility to track the 
cells in-vivo using IVIS, we used ESCs which have an unlimited potential to divide 
and differentiate into different cell types. We used GFP +ve ESCs in order to allow 
IHC analysis of the tissue using the anti-GFP antibody. Immediate tracking of GFP 
+ve cells was not possible due to the low wave length of GFP which was associated 
with high background fluorescence. Therefore we used a NIR dye DiR which proved 
effective allowing accurate identification of the cells with low background noise 
using the ICG filter (Fig.37). 
 
6.2.2 MCT-SOS model could not be established in mice 
 
It was not possible to establish SOS in mice using MCT. There was no change in the 
naked eye appearance of the liver in the MCT mice when compared to the control 
group. Also, no sinusoidal dilatation or histological evidence of hepatocellular 
damage could be elicited at any of the time points (Fig.38A). We used APAP which 
is known to have an early toxic effect on the SECs followed by hepatocellular 
necrosis (202). At a dose of 300mg/Kg given i.p, it was possible to achieve 
histological evidence of hepatocyte damage and necrosis comparable to that of MCT 
in rats at 72 hours (Fig.38B). The mortality from APAP administration was 47.5% 
(19/40) at 24 hours in both groups and there was no mortality following the first 24 
hours.   
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Figure 37 IVIS images of two sets of cell culture plates with GFP +ve ESCs without 
DiR staining (LT) and with DiR staining (RT) showing background fluorescence 
using the GFP and CY5.5 filters, but not with the ICG filter. 
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Figure 38 Histological appearance of the liver following MCT administration in 
mice. No sinusoidal dilatation or hepatocellular damage could be detected in mice 
treated with MCT at 72 hours (A). When the mice were treated with APAP 300 
mg/kg, marked hepatic necrosis was evident at 72 hours (B). 
 
6.2.3 Transplantation and in-vivo imaging 
 
5x10
6 
GFP +ve labeled ESCs with DiR were used per transplantation in 20 mice. 
IVIS proved to be effective in precisely identifying the cells labeled with DiR in the 
liver and spleen at different time points. This was possible only using the ICG filter 
due to its high background passband of 665-695 nm with minimal background 
fluorescence. At 30 minutes post transplantation, the cells were confined inside the 
spleen and then gradually moved into the splenic vein and part of the liver at the 
three hour time point. By 24 hours, the cells spread out over almost all areas of the 
liver and residual signal was received over the spleen as well. The signal of DiR 
emitted from the liver faded out at 72 hours.  No signal could be detected in any of 
the other organs (Fig.39). 
  
146 
 
6.2.4 Ex-vivo imaging 
 
A very clear fluorescent signal was detectable from both the liver and spleen when 
the organs were taken out and imaged directly with the IVIS. Eliminating the barrier 
effect of the anterior abdominal wall allowed signal detection at time points when 
the signal could not be detected by in-vivo imaging. Similar to in-vivo imaging the 
ICG filter was the most accurate filter to localize the cells with no autoflourescence 
from the organs. A weak signal was also detectable in the lungs and kidneys in 
contrast to the in-vivo imaging (Fig.40A). DiR uptake in the liver was significantly 
higher than the sum of uptake in all other organs at 72 hours (p<0.0001). At two 
weeks, the total number of photons emitted from the liver decreased significantly 
from 3.67×10
10 
± 1.7×10
10
 photons/sec at 72 hours to 5.18×10
9
±1.58×10
9
 (p=0.002). 
However, in the liver, the emission was still significantly higher than the spleen 
(p=0.002), lungs (p<0.0001) and kidneys (p<0.0001) (Fig.40B).  
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Figure 39 Labeling and tracking of the fluorescent ESCs following APAP 
administration. Images of a pair of mice (cell therapy group-RT) compared with the 
(control group-LT) using IVIS. At 30 minutes following transplantation, a strong 
signal could only be detected from the spleen where the cells were injected.  
Between 3 and 24 hours following the cell transplantation, signal started to intensify 
between the spleen and the liver which is most probably the splenic vein owing to its 
tortuous course. A strong signal was detected over the liver 24 hours post-
transplantation which faded out by 72 hour time period. At one week, the signal 
could not be detected over the liver but still strong was detectable over the spleen 
which completely disappeared by two weeks. 
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Figure 40 Ex-vivo images showing the distribution of fluorescent cells in different 
organs as detected by the ICG filter of the IVIS. A signal was detected at the site of 
injection in the spleen however; the highest signal was noticed in the centre of the 
liver at 72 hours, which faded out after two weeks. A weak fluorescent signal was 
also detected in the lungs at 72 hours and two weeks but not seen in kidneys at any 
of the designated time points (A). A graph showing the highest uptake of cells in the 
liver at all time points with a significant drop at two weeks (B). 
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6.2.5 Engraftment of the transplanted cells in the liver 
 
Frozen liver sections were examined under the fluorescent microscope to detect GFP 
+ve transplanted cells in the liver parenchyma. This was to confirm that the signal 
detected using the IVIS was definitely emitted from the engrafted cells and not from 
the fluorescent DiR dye released following cell death. GFP fluorescence from the 
transplanted cells was easily detectable by direct fluorescence microscopy at 72 
hours, however, the signal was much weaker at two weeks and therefore, we relied 
on IHC using an anti-GFP antibody for detection. At 72 hours, discrete GFP +ve 
colonies were located under the liver capsule and around the central veins (Fig. 
41A). At two weeks, GFP +ve cells resembling hepatocytes were seen dispersed 
throughout the hepatic parenchyma with the presence of a larger number of GFP +ve 
cells incorporated within the sinusoidal endothelial lining (Fig. 41E). GFP +ve cells 
could still be detected after two weeks in the spleen, mainly around the central 
arteriole and the trabeculae (Fig. 41F). 
 
6.2.6 Liver functions 
 
All mortality occurred during the first 24 hours following APAP administration with 
10/40 (25%) mice in the control group and 9/40 (22.5%) in the cell therapy group. 
All animals surviving the initial 24 hours lived till the time of sacrifice. Liver 
damage was detected at 72 hours, most prominent in the centrilobular regions with 
hepatocyte necrosis and secondary infiltration of inflammatory cells in both the cell 
therapy and the control group (Fig.41C,D). Improvement in liver histology was 
noticed both in the cell therapy and the control groups at two weeks with less 
inflammatory cell infiltration in the treatment group (Fig.41G,H).  
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In order to identify the nature of the transplanted cells, we stained the sections with 
anti-albumin antibody which revealed very faint albumin expression in the GFP+ 
cells at 72 hours (Fig.42A,B). However, at two weeks cells positive for GFP were 
also strongly positive for albumin (Fig.42C,D). There was a significant improvement 
in serum levels of ALT, albumin and bilirubin in both groups at two weeks when 
compared to the 72 hour time point (Fig.43). Cell therapy itself had no effect on any 
of these parameters at the 72 hour time point when compared with the control group. 
However, at two weeks, serum ALT was significantly lower in the cell therapy group 
when compared to the control group (p=0.016) (Fig. 43A). Also, serum albumin 
level was significantly higher in the cell therapy group (p=0.009) (Fig.43B). No 
significant changes occurred in serum bilirubin or urea levels between both groups at 
two weeks. (Fig.43C, D)  
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Figure 41 ESC liver engraftment following APAP induced damage. GFP +ve cells were present under the liver capsule (A-solid arrow) 
and around the central veins of the liver at 72 hours as seen under direct fluorescence (A-dashed arrow) with no fluorescence detected in 
the control group (B). Characteristic pattern of APAP induced liver damage after 72 hours affecting mainly the centrilobular portions of 
the liver with marked damage of the pericentral hepatocytes in both the cell therapy and control groups although pericentral vacuolation 
was more evident in the control group (C,D). At 2wks, the GFP +ve cells could be detected using IHC in the hepatic parenchyma and 
within the sinusoidal lining (E). Localized colonies of GFP +ve cells were also detected in the spleen at 2 weeks (F). After 2 weeks the 
liver recovered in both groups with the liver sections from the cell therapy group (G) showing less inflammatory cells and congestion 
than in the control group (H)(Scale bar=200µ). 
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Figure 42 Serial sections examined for GFP and Albumin expressions. GFP +ve 
transplanted  cells (A) showed very faint albumin expression at the cell periphery of 
dividing cells at 72 (B), whereas areas stained with anti-GFP antibody (C) were 
positive for albumin (D) at 2 weeks following cell therapy (Scale bar=100µ).
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Figure 43 Serum levels of ALT, Albumin, Bilirubin and Urea are shown.  ALT level 
significantly dropped in both groups at two weeks when compared with the 72 hour 
time point. When compared with the 72 hours, there was a significant reduction in 
serum ALT level at two weeks in the ESC treatment group only but not in the 
control group (A). Albumin level also improved in both groups with level being 
significantly higher in the cell therapy group when compared with the control group 
at two weeks (B). The drop in urea levels was not significant in both groups. (C) 
Bilirubin levels dropped significantly from 72 hours to two weeks with no 
significant differences between groups at similar time points (D). 
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6.3 Discussion 
 
In this study we used mouse ESCs which have an unlimited supply and an enormous 
potential to differentiate into different cell types including hepatocytes. We also 
developed a novel model in which we were able to monitor both the immediate and 
late kinetics of transplanted ESC cells. In this way, we were able to track the cells 
real-time over days after the injection and had a better understanding of the 
dynamics of the cells in an experimental model of ALF without the need to sacrifice 
animals at different time points.  
Although it was possible to induce SOS in rats by using MCT, similar results could 
not be established in mice. It is known that MCT is converted into MCT-P which is 
the active metabolite produced by cytochrome P-450 3A (242). There are no studies 
that support the role of MCT in SOS development in mice, furthermore, when MCT 
was used to induce the pulmonary hypertension in mice the effects were much more 
attenuated when compared to rats and this again has been attributed to differences in 
metabolic pathways involved in MCT activation between rats and mice (243). We 
therefore used APAP to induce sinusoidal damage and ALF in mice. The sinusoidal 
damage in APAP similar to MCT precedes hepatocellular necrosis disrupting the 
space of Disse with gap formation in SEC lining eventually leading to SEC 
separation from the hepatocytes (244) (245). Also similar to MCT-induced SOS, 
MMP-9 is upregulated with APAP toxicity and its inhibition attenuated both the 
sinusoidal and hepatic parenchymal injury in C57BL/6 mice (246). 
So far, most of the existing animal models looked into the role of cell therapy in liver 
regeneration following partial hepatectomy or hepatocellular damage induced by 
CCL4, (247), (248),(249), (250). In these models the roles of cell therapy were not 
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studied in a pathophysiological milieu reciprocating the clinical scenario of ALF 
(251). For example, following liver resection the liver bed reduces drastically and 
resection itself mobilizes the CD 133+ subset of cells from BM into the circulation, 
which might have played an independent role in liver regeneration (252). Moreover, 
CCL4-induced liver damage builds up over a period of time and does not produce 
the similar profound effects of ALF (251). In this study, we used an ALF model 
induced by APAP at a relatively moderate dose of 300 mg/kg and transplanted the 
undifferentiated ESCs four hours following induction of injury so that most of the 
APAP would have been metabolized and would not interfere with ESCs survival 
(183). In order to track the cells in-vivo, we used a reproducible imaging system for 
continuous real-time monitoring of the injected cells following transplantation. The 
IVIS is a relatively new optical imaging system that is being widely used in the 
fields of oncology and immunology allowing non-invasive cell detection and 
migration (253). NIR dyes have been previously used for monitoring cells in-vivo 
with improved quality of signal detection through increasing the contrast between 
the signal and the background which is comprised mainly of water, oxyhaemoglobin 
and deoxyhaemoglobin (254). This has made it possible to track labeled cells located 
in deep seated organs with minimal background fluorescence. To achieve that goal, 
we labeled the ESCs with a NIR lipophilic tracer dye DiR which has the advantage 
of very low cell toxicity and laterally diffuses within the cell membrane, hence 
staining the whole cell. Very recently, Chois et al (255) used luciferase transfected 
fetal hepatocyte cells for repopulating liver in a MCT injected mice model and nicely 
showed the uptake of the cells by a CCD camera generated images. The advantages 
of the imaging we used in this study lies with the simplicity of the method. This 
technique is relatively cheap and easy to use without any necessity of genetic 
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manipulation of the cells. Also there is no necessity to inject any extra dye for 
visualisation of the cells which might interfere with body chemistry and prolong the 
anaesthetic duration for the animals. The cells could be clearly seen migrating from 
the spleen to the liver. The signal intensity in the liver was highest between the 
second and third days post-transplantation, possibly because cell proliferation is 
highest at that time (78). A rapid drop in the signal intensity was noticed after the 
third day and continued to fade till it completely disappeared at two weeks post 
transplantation. Similar to the DiR dye we used, the signal from firefly luciferase 
also dropped on day 10 following HT (255). However, visualisation and 
quantification of the transplanted cells was still possible at two weeks by DiR 
imaging when the organs were extracted and imaged directly under the IVIS.   
Because the ESCs were transfected with GFP; it was possible to observe the 
distribution of the transplanted cells in tissue sections directly under the fluorescent 
microscope or by IHC using the anti-GFP antibody. Engraftment of the ESCs was 
confirmed in liver tissue sections in the post-transplantation period by direct 
visualization of GFP+ cells, which appeared in the close vicinity of the central veins 
where the main brunt of the damage has occurred. The homed pericentral cells 
subsequently proliferated and spread throughout the liver parenchyma. The 
mechanism through which the ESCs integrate into the liver plate depends primarily 
on the disruption of the SECs (256). Although APAP overdose characteristically 
affects the centrilobular regions of the liver causing extensive necrosis; there is also 
a direct toxic effect on the SECs through glutathione depletion (202) and thus might 
have played a role  in uptake of cells into the liver parenchyma particularly since 
GFP +ve cells were also detected in the sinusoidal endothelial lining at two weeks.  
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ESC transplantation did not improve either survival or liver functions at 72 hours. At 
two weeks, some transplanted cells expressed albumin and morphologically 
resembled hepatocytes. In accordance, there was a significant reduction in serum 
ALT and an increase in serum albumin production at two weeks in the cell therapy 
group when compared to the control group. It is unlikely that the differentiation of 
transplanted cells into hepatocytes could explain the improved liver functions at two 
weeks in the cell therapy group since the cells were few and we did not perform 
additional studies to confirm differentiation as this was not the purpose of the study. 
The paracrine effect of the transplanted cells rather than direct differentiation seems 
to be a more possible reason for improved liver functions. MSC conditioned media 
has been shown to improve liver functions following induction of ALF in rats. (257), 
also proteins released from human undifferentiated ESCs was shown to improve 
cardiac functions (258). 
ESC therapy has been riddled with several problems including allogenic rejection, 
ethical concerns and most importantly, possibilities of malignant transformation. 
Although Moriya et al did not detect any teratoma formation following 
transplantation of undifferentiated ESCs in a liver cirrhosis model in mice (259), the 
transformation of undifferentiated ESCs into teratomas is very likely after a period of 
time. We used undifferentiated ESCs in this study to develop a suitable model to 
study the kinetics of transplanted cells in ALF; however, to study the therapeutic 
effect of ESCs in ALF, ideally we should have used differentiated ESCs, pluripotent 
stem cells or primary hepatocytes. Differentiation of ESCs in-vitro into hepatocytes 
has been extensively studied by several groups and could be achieved by formation 
of EBs (146), or directly by adding growth factors to the ESCs in monolayer cultures 
(147). However, full maturation of hepatocytes is not complete without the influence 
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of the intrinsic environment (260). Several studies have been conducted to simulate 
the inductive microenvironment in-vitro, either through co-cultures with hepatocytes 
(261) or using conditioned media in in-vitro cultures (262).  
We concluded that serial longitudinal tracking of transplanted cells in a mouse model 
of ALF induced by APAP is possible using IVIS and that dual labeling would allow 
both immediate and longterm tracking of the transplanted cells which would allow us 
to better understand their differentiation and fate. 
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7-Discussion and future directions 
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SOS is a serious clinical condition that has been known to result from myeloablative 
chemo-radiotherapy in preparation for HSC transplantation. SOS has also been 
shown to occur following oxaliplatin based neoadjuvant chemotherapy in order to 
downstage CLMs prior to liver resections. This condition leads to increased blood 
loss during liver resections with increased hospital stay and a higher occurrence of 
PLF in the immediate postoperative period with high morbidity and mortality. The 
only effective treatment of PLF is LT however may not always be possible due to 
shortage of liver donors and the high mortality associated with PLF and the problem 
of cancer and immunosuppression. Recent studies have also reported the important 
role of SECs in liver regeneration through the release of certain growth factors which 
stimulate hepatocyte regeneration. Moreover, in an experimental rat model of SOS, 
delayed liver regeneration following liver resection has been proven (189), (263), 
(64), (191), (90), (95). 
The ideal management of PLF should therefore be a preventive one with a strategy to 
eliminate the predisposing factors; one of which is oxaliplatin-induced SOS prior to 
liver resection for CLMs. There is also difficulty in estimating the functional liver 
reserve following liver resections as the non-tumorous liver may not have an 
adequate regenerative capacity owing to the SEC damage and delayed hepatocyte 
proliferation (90).  
From here comes the importance of planning a strategy to prevent the occurrence of 
SOS in addition to increasing the functional residual liver reserve to prevent the 
development of PLF. 
We used MCT to induce SOS in rats simulating clinical SOS, in addition to showing 
the structural and ultra-structural events that occur following MCT administration 
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through H&E and EM studies. We also studied the MMP pathways through IHC and 
showed that SOS is mainly related to upregulation of MMP-9.  
In order to prevent SOS, we used a semi-synthetic flavonoid monoHER which has 
been previously used in prevention of doxorubicin-induced cardiotoxicity. We 
showed that monoHER was effective in reducing SOS induced portal hypertension 
in rats with significantly lower ALT measurements especially at the 72 hour time 
point corresponding with the peak of MCT induced liver damage. We also showed 
that monoHER improved the liver damage score through a decrease in sinusoidal 
dilatation, hepatic necrosis and inflammatory cell infiltration. MonoHER proved to 
be effective in significantly downregulating the MMP-9 activity at 72 hours post-
MCT administration. The advantage of monoHER over other drugs is its safety to be 
used in patients and that it does not interfere with the cytotoxic effect of oxaliplatin 
which would make it an ideal preventive drug owing to its potent vascular protective 
and anti-inflammatory properties (225), (227). 
Predicting the subgroup of patients who are more likely to develop high grade SOS 
and hence PLF has been investigated by several groups, however with no convincing 
evidence. Importance of this would be to postpone surgery in patients who are at risk 
of high grade SOS in order to prevent SOS (51), (41). There is a growing interest in 
using Micro RNA (MIR) which is a short non-encoding RNA sequence for 
diagnostic purposes. We performed a preliminary experiment to investigate whether 
MIR-126 which is expressed in and specific to endothelial cells would be 
upregulated in SOS. We confirmed this by detecting a 26-fold increase in expression 
of MIR-126 in HUVEC cell lines when compared to normal control liver tissue. We 
showed that miRNA-126 expression in liver tissue increased with the severity of 
MCT injury but remained stable in the control group (Fig.44). Harris et al, showed 
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that MIR-126 was specific to endothelial cells as they were not expressed in vascular 
smooth muscle cells or in lymphocytic cells. They also showed that MIR-126 
regulates the expression of VCAM-1 which increases with damage to endothelial 
cells and is responsible for leukocyte adhesion to endothelial cells at the site of 
injury (264). Therefore MIR-126 expression might be related to the inflammatory 
response which was significantly higher at 72 hours in this study. When the rats were 
pretreated with monoHER, MIR-126 expression was lower in the MCT+ monoHER 
group when compared to the MCT group. This might be explained by the fact that 
monoHER reduces MIR-126-VCAM overexpression (227) (Fig.44). (Appendix 1). 
 
 
Figure 44 Mir126 expression in the three studied groups at different time points.  A 
steady increase with time in the MCT group; however expression was five-fold 
lower in the MCT+ monoHER group when compared to the MCT group at 72 hours. 
 
MIR-126 could serve as a potential marker to predict SOS development and patient 
stratification into low and high risk groups according to the expression. More 
experiments need to be conducted including isolating MIR-126 from the serum of 
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patients which if proved successful would be a simple non-invasive predictive 
marker. 
In addition to preventing the development of SOS, it would be important to increase 
the functional liver reserve following partial hepatectomy.  This would be possible 
through either stimulating the endogenous hepatocyte population or through an 
exogenous cell transplantation. Since the regenerative drive of hepatocytes is 
suppressed in the chemotherapy liver (90); therefore future therapies should focus on 
either hepatocyte or ESC transplantation with the potential to differentiate into 
hepatocytes either. It is important however to understand the dynamics of the 
transplanted cells and the time points at which they engraft in the liver and start to 
function which would dictate the time points when a cell transplantation would be 
effective.  
We developed a dual labeling tracking system in order to track the cellular events in 
an APAP model of ALF in mice. It was not possible to induce SOS using MCT in 
mice, however APAP-induced ALF has several advantages as it simulates the events 
occurring in SOS with early SEC damage followed by hepatocyte necrosis (265), 
(245). In addition, it represents a more acute liver damage model providing an 
adequate drive for cell engraftment. APAP-induced ALF therefore resembles PLF 
with chemical injury in the non-tumorous liver and serves as a good model for the 
purpose of cell tracking.  
We showed that cell tracking in the acute liver failure setting is possible with the real 
time events easily monitored using the IVIS without the need to sacrifice the animals 
at several time points. The dual labeling methodology allowed IHC studies on tissue 
sections once the animals were sacrificed. In this study we used ESCs in order to 
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achieve a meaningful population for transplantation. ESCs can be grown indefinitely 
in-vitro and provide sufficient numbers of cells for transplantation. We used DiR for 
labeling the ESCs which has an excitation peak at 750nm and an emission peak at 
782 nm which are well within the NIR range and higher than background tissue 
autoflourescence. Advantages of this dye include minimum lateral cell to cell 
transfer and very low toxicity. Although DiR has not been approved for use in 
patients; it shares very similar excitation/emission spectra with FDA-approved ICG 
which has been used for labeling human ESC derived cardiomyocytes (181). 
Although several studies have investigated the role of ICG in cell labeling in-vitro, 
there have been no studies to report its use in-vivo (266), (267). In the present study, 
we could track the migration of transplanted cells as early as three hours from the 
spleen to the liver with a signal appearing in the liver at 24 hours. There was decay 
in the transmitted signal starting from day three with complete loss of the signal at 
two weeks. This was not due to death of transplanted cells as a signal could be 
detected when the organs were displayed and imaged ex-vivo. Similar to our study, 
Boddington et al reported a rapid decay of the signal at 48 hours when the cells were 
imaged in-vitro using ICG labeling (181). Therefore labeling with NIR dyes is 
considered an efficient method for acute phase cell tracking providing useful 
information on cell migration and engraftment optimizing stem cell delivery 
schedules and techniques. This imaging technique carries great potential for clinical 
application in various fields of research including islet and stem cell transplantation.  
In terms of therapy, undifferentiated ESCs would not be optimal for rescuing 
patients with ALF as the amount of time required for differentiation would extend 
beyond the acute events of PLF. The improvement in liver functions following 
undifferentiated ESCs transplantation could not be explained by the small number of 
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albumin positive cells which have differentiated from the transplanted ESCs. This 
improvement might be related to certain factors released from the ESCs might have 
reduced the inflammatory response and stimulated the regenerative drive of the 
resident hepatocytes through HGF and VEGF production (258), (268). There is a 
significant risk of teratoma formation if ESCs were to be transplanted in the 
undifferentiated state (269). Alternative options might include the use of bile duct 
cells which share the common embryological origin with the liver and have been 
previously shown to transdifferentiate into hepatocytes (88). It would be ideal to 
isolate biliary epithelial cells from the gall bladders that would be removed at the 
time of partial hepatectomy and discarded. The isolated cell population would be 
expanded in-vitro and then transplanted back to the patient in the postoperative 
period preventing and/or stabilizing the developing PLF without the need for 
immunosuppression. We attempted a preliminary experiment to isolate rat bile duct 
cells and culture them in-vitro, however most cells were transformed into fibroblasts 
after 10 days of culture (Appendix-2). There are two main obstacles to using biliary 
epithelial cells in patients with acute liver failure; first of which is the need for a 
stressful stimulus to expand the oval cell population in the gall bladder which is 
achieved experimentally via bile duct ligation (BDL). Irie et al could not culture or 
identify cells with hepatocyte phenotypes when biliary epithelial cells were isolated 
from normal mouse and they showed that BDL was essential for the appearance of 
the C-Kit
+ 
epithelial cells which are considered hepatocyte progenitor cells (270). 
Lee et al used gallbladder cells from normal mice and transplanted into mice with 
induced liver failure to investigate whether these cells could acquire phenotypic 
characteristics of hepatocytes and whether these would repopulate the damaged liver. 
Of interest, is that partial hepatectomy was a weak stimulus for engraftment when 
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compared to chemical injury, in addition freshly transplanted cells had a much better 
engraftment rate than when cultured in-vitro and then transplanted. The overall 
percentage of engraftment however was very low and colonies were localized in 
discrete areas of the liver. A few of these cells acquired a hepatocyte phenotype 
however this occurred several months following transplantation (88).  
Another alternative would be in-vitro differentiation of ESCs into functional mature 
hepatocytes to achieve therapeutic benefit. Several methods of differentiation have 
been described (147), (262), (271), (272). We attempted in-vitro differentiation of 
ESCs into hepatocytes via formation of EBs (Fig.45) (Protocol for EB formation. 
Appendix 3).   
 
Figure 45 well-formed EBs in culture using GFP+ C57BL6 mouse embryonic stem 
cells using the static suspension method (A)  Under fluorescence microscopy (B). 
 
The next step would be a directed differentiation into definitive endoderm followed 
by hepatocyte differentiation and maturation. Directed definitive endoderm 
differentiation is essential step as visceral endoderm which may give rise to cells 
with hepatocyte markers would be fated to form tumours in-vivo (273). It is therefore 
essential also to achieve a large population of uniform cells which would be suitable 
for transplantation. These problems still need to be addressed as large numbers of 
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cells are lost during the differentiation process leading to a small cell yield that 
would not be sufficient for function replacement in the setting of PLF. 
 
Conclusions 
Surgeons are often confronted with a big challenge to perform partial hepatectomy 
for intended curative resections in patients with advanced tumours or with advanced 
cirrhosis. While neoadjuvant chemotherapy is effective in shrinking CLMs, it has 
deleterious effects on the non-tumorous liver predisposing to PLF. None of the 
current therapies have proven to be effective in treating PLF and LT which might be 
curative remains a debatable option due to the high mortality associated with the 
condition. Prevention of the condition from occurrence should therefore be the best 
approach and this may be through prevention of development of SOS through 
monoHER administration and by expanding the remnant liver volume following 
liver resection using cell therapy. Currently, HT is being effectively used to treat in 
born errors of metabolism especially in children, however in order to replace LT; 
greater numbers of differentiated cells from other sources with hepatocyte functions 
need to be used. The timing and degree of optimum differentiation of these cells and 
the capacity of the in-vivo inductive microenvironment to complete the 
differentiation process without tumour formation needs to be further investigated. 
 
 
 
 
168 
 
Presentations arising from the studies 
contained in this thesis 
 
1- Tarek Ezzat, Dipok Dhar, Steven OldeDamink, Massimo Malago. Dual labeling 
of embryonic stem cells for dynamic tracking in an acetaminophen induced model of 
injury in mice.  World congress of stem cells and regenerative medicine, San 
Francisco, USA. Jan 20-21/ 2010 
Winner of UCL poster award for faculty of biomedical sciences, 2010 
 
2- Tarek Ezzat, Dipok Dhar, Massimo Malago, Steven OldeDamink. Embryonic 
stem cells improve liver functions and express albumin following transplantation in a 
model of acute liver failure in mice. Stem cells, development and regulation, 
Amsterdam, NL. October 12-14, 2010 
 
3- Tarek Ezzat, Dhar D, Malago M, Steven OldeDamink. Novel semi-synthetic 
flavonoid prevents MCT Induced Sinusoidal Obstruction Syndrome in Rats. The 
Royal Free and University College London Medical School, Pearce Gould Visiting 
Professor, October 2010 
 
4- Tarek Ezzat, Dhar D, Malago M, Steven OldeDamink. The role of a novel semi-
synthetic flavonoid (MonoHer) in preventing monocrotaline induced sinusoidal 
obstruction syndrome in rats. SARS annual meeting, Dublin, January 4-5, 2011 
BRITISH JOURNAL OF SURGERY   Volume: 98   Pages: 20-20   Supplement: 
Suppl. 2   Published: APR 2011 
 
169 
 
Publications arising from the studies 
contained in this thesis 
 
 
1- Ezzat TM, Dhar DK, Newsome PN, Malagó M, Olde Damink SW. Use of 
hepatocyte and stem cells for treatment of post-resectional liver failure: are we there 
yet? Liver Int 2011;31:773-84.  
 
2- Ezzat TM, Dhar DK, Malagó M, Olde Damink SW. A simple and effective way 
for in-vivo dynamic tracking of embryonic stem cells in an acute liver failure model 
in mice. World Journal of Gastroenterology 2011;18:498-506 
 
3- Ezzat TM, van den Broek M, Davies A, Dejong C, Bast A, Malagó M, Dhar D, 
Olde Damink SW. The flavonoid monoHER prevents monocrotaline-induced hepatic 
sinusoidal injury in rats. Journal of Surgical Oncology 2012 Jan 27. doi: 
10.1002/jso.23046. [Epub ahead of print] 
 
 
 
 
 
 
 
 
 
 
170 
 
 
References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
171 
 
1. Squires RH Jr, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, et al. Acute 
liver failure in children: the first 348 patients in the pediatric acute liver failure study group. 
J Pediatr 2006;148:652-8. 
2. R, Williams. Classification, etiology, and considerations of outcome in acute liver failure. 
Semin Liver Dis 1996;16:343-8. 
3. Sokal EM, Goldstein D, Ciocca M, Lewindon P, Ni YH, Silveira T, et al. End-stage liver 
disease and liver transplant: current situation and key issues. J Pediatr Gastroenterol Nutr 
2008;47:239-46. 
4. Lucey MR, Schaubel DE, Guidinger MK, Tome S, Merion RM. Effect of alcoholic liver 
disease and hepatitis C infection on waiting list and posttransplant mortality and transplant 
survival benefit. Hepatology 2009;50:400-6. 
5. van den Broek MA, van Dam RM, Malagó M, Dejong CH, van Breukelen GJ, Olde Damink 
SW. Feasibility of randomized controlled trials in liver surgery using surgery-related 
mortality or morbidity as endpoint. Br J Surg 2009;96:1005-14. 
6. Otsuka Y, Duffy JP, Saab S, Farmer DG, Ghobrial RM, Hiatt JR, Busuttil RW. Postresection 
hepatic failure: successful treatment with liver transplantation. Liver Transpl 2007;13:672-
9. 
7. Mayo SC, Pawlik TM. Current management of colorectal hepatic metastasis. Expert Rev 
Gastroenterol Hepatol 2009;3:131-4. 
8. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis 
of cholangiocarcinoma. HPB (Oxford) 2008;10:77-82. 
9. Geoghegan JG, Scheele J.  Treatment of colorectal liver metastases. Br J Surg 
1999;86:158-69. 
10. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of 
hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:1271-
80. 
11. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver 
metastases. Oncologist 2008;13:51-64. 
12. Lytratzopoulos G, Tyrrell C, Smith P, Yelloly J. Recent trends in liver resection surgery 
activity and population utilization rates in English regions. HPB (Oxford) 2007;9:277-80. 
13. Cescon M, Vetrone G, Grazi GL, Ramacciato G, Ercolani G, Ravaioli M, et al. Trends in 
perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected 
cases over 20 years. Ann Surg 2009;249:995-1002. 
14. Kiuchi T, Kasahara M, Uryuhara K, Inomata Y, Uemoto S, Asonuma K, et al. Impact of 
graft size mismatching on graft prognosis in liver transplantation from living donors. 
Transplantation 1999;67: 321-7. 
172 
 
15. Mullen JT, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, et al. Hepatic 
insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J 
Am Coll Surg 2007;204:854-62. 
16. van den Broek MA, Olde Damink SW, Dejong CH, Lang H, Malagó M, Jalan R, et al. Liver 
failure after partial hepatic resection: definition, pathophysiology, risk factors and 
treatment. Liver Int 2008;28:767-80. 
17. Schindl MJ, Redhead DN, Fearon KC, Garden OJ, Wigmore SJ and (eLISTER), Edinburgh 
Liver Surgery and Transplantation Experimental Research Group. The value of residual liver 
volume as a predictor of hepatic dysfunction and infection after major liver resection. Gut 
2005;54:289-96. 
18. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al. Long-term 
survival of patients with unresectable colorectal cancer liver metastases following 
infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 
1999;10:663-9. 
19. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical 
pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94. 
20. Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant 
chemotherapy and resection of advanced synchronous liver metastases before treatment 
of the colorectal primary.  Br J Surg 2006;93:872-8. 
21. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al.  Influence of 
preoperative chemotherapy on the risk of major hepatectomy for colorectal liver 
metastases. Ann Surg 2006;243:1-7. 
22. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al.  Irinotecan plus 
fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl 
J Med 2000;343:905-14. 
23. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy 
regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for 
hepatic colorectal metastases. J Clin Oncol 2006;24:2065-72. 
24. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, et al. Oxaliplatin, tetraplatin, 
cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell 
lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 
1996;52:1855-65. 
25. Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD. Activity of oxaliplatin against 
human tumor colony-forming units. Clin Cancer Res 1998;4:1021-9. 
26. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular 
pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-35. 
173 
 
27. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall 
survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III 
colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16. 
28. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. 
Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in 
patients with metastatic colorectal cancer. Ann Oncol 2004;15:460-6. 
29. Pessaux P, Chenard MP, Bachellier P, Jaeck D. Consequences of chemotherapy on 
resection of colorectal liver metastases. J Visc Surg 2010;147:e193-201 
 
30. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al. 
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal 
liver metastases receiving preoperative chemotherapy. Ann Surg 2008;247:118-24. 
31. Collardeau-Frachon S, Scoazec JY. Vascular development and differentiation during 
human liver organogenesis.  Anat Rec (Hoboken) 2008;29:614-27. 
32. RS, McCuskey.  The hepatic microvascular system in health and its response to 
toxicants.  Anat Rec (Hoboken) 2008;291:661-71. 
33. Wisse E, De Zanger RB, Charels K, Van Der Smissen P, McCuskey RS. The liver sieve: 
considerations concerning the structure and function of endothelial fenestrae, the 
sinusoidal wall and the space of Disse. Hepatology 1985;5:683-92. 
34. Jacobs F, Wisse E, De Geest B. The role of liver sinusoidal cells in hepatocyte-directed 
gene transfer. Am J Pathol 2010;176:14-21. 
35. DeLeve LD, Wang X, Hu L, McCuskey MK, McCuskey RS. Rat liver sinusoidal endothelial 
cell phenotype is maintained by paracrine and autocrine regulation. Am J Physiol 
Gastrointest Liver Physiol 2004;287:G757-63. 
36. Wang X, Kanel GC, DeLeve LD. Support of sinusoidal endothelial cell glutathione 
prevents hepatic veno-occlusive disease in the rat. Hepatology 2000;31:428-34. 
37. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and 
monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of 
glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996;23:589-99. 
38. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with 
platinating agents.  Cancer Treat Rev 2007;33:9-23. 
39. LD, DeLeve.  Hepatic microvasculature in liver injury. Semin Liver Dis 2007;27:390-400. 
40. DeLeve LD, Wang X, Kanel GC, Ito Y, Bethea NW, McCuskey MK, et al. Decreased 
hepatic nitric oxide production contributes to the development of rat sinusoidal 
obstruction syndrome. Hepatology 2003;38:900-8. 
174 
 
41. Soubrane O, Brouquet A, Zalinski S, Terris B, Brézault C, Mallet V, et al. Predicting high 
grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based 
chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. 
Ann Surg 2010;251:454-60. 
42. Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B, et al. 
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases 
treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 2011;18:421-30. 
43. Morris-Stiff G, Gomez D, Prasad R. Quantitative assessment of hepatic function and its 
relevance to the liver surgeon. J Gastrointest Surg 2009;13:374-85. 
44. Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, et al. Improving perioperative 
outcome expands the role of hepatectomy in management of benign and malignant 
hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. 
Ann Surg 2004;240:708-10. 
45. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and 
turnover.  J Intern Med 1997;1:27-33. 
46. U, Lindqvist. Is serum hyaluronan a helpful tool in the management of patients with 
liver diseases? J Intern Med 1997;242:67-71. 
47. Lindqvist U, Westerberg G, Bergström M, Torsteindottir I, Gustafson S, Sundin A, et al. 
[11C]Hyaluronan uptake with positron emission tomography in liver disease. Eur J Clin 
Invest 2000;30:600-7. 
48. Fried MW, Duncan A, Soroka S, Connaghan DG, Farrand A, Peter J, et al. Serum 
hyaluronic acid in patients with veno-occlusive disease following bone marrow 
transplantation. Bone Marrow Transplant 2001;27:635-9. 
49. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist?  
Br J Haematol 1995;90:244-8. 
50. Nürnberger W, Michelmann I, Burdach S, Göbel U. Endothelial dysfunction after bone 
marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with 
multiple transplant-related complications. Ann Hematol 1998;76:61-5. 
51. Woywodt A, Haubitz M, Buchholz S, Hertenstein B. Counting the cost: markers of 
endothelial damage in hematopoietic stem cell transplantation. Bone Marrow Transplant 
2004;34:1015-23. 
52. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A 
simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with 
chronic hepatitis C. Hepatology 2003;38:518-26. 
53. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-
4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver 
biopsy and fibrotest. Hepatology 2007;46:32-6. 
175 
 
54. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis 
C.  Hepatology 2003;38:1449-57. 
55. Richter B, Schmandra TC, Golling M, Bechstein WO. Nutritional support after open liver 
resection: a systematic review. Dig Surg 2006;23:139-45. 
56. Sewnath ME, Karsten TM, Prins MH, Rauws EJ, Obertop H, Gouma DJ. A meta-analysis 
on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. 
Ann Surg 2002;236:17-27. 
57. van der Gaag NA, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ, et al. 
Preoperative biliary drainage for pancreatic head tumours. N Engl J Med 2010;14:129-37. 
58. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, et al. Extended 
preoperative chemotherapy does not improve pathologic response and increases 
postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann 
Surg Oncol 2010;17:2870-6. 
59. Broering DC, Hillert C, Krupski G, Fischer L, Mueller L, Achilles EG, et al. Portal vein 
embolization vs. portal vein ligation for induction of hypertrophy of the future liver 
remnant. J Gastrointest Surg 2002;6:905-13. 
60. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. Portal 
vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 
2003;237:208-17. 
61. Liu H, Zhu S. Present status and future perspectives of preoperative portal vein 
embolization. Am J Surg 2009;197:686-90. 
62. Mochida S, Ogata I, Hirata K, Ohta Y, Yamada S, Fujiwara K. Provocation of massive 
hepatic necrosis by endotoxin after partial hepatectomy in rats. Gastroenterology 
1990;99:771-7. 
63. Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, et al. Liver histology and 
surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in 
colorectal cancer liver metastases. J Clin Oncol 2006;24:4983-90. 
64. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, et al. Portal 
hypertension associated with oxaliplatin administration: clinical manifestations of hepatic 
sinusoidal injury. Clin Colorectal Cancer 2009;8:225-30. 
65. Vassiliou I, Arkadopoulos N, Stafyla V, Theodoraki K, Yiallourou A, Theodosopoulos T, et 
al. The introduction of a simple maneuver to reduce the risk of postoperative bleeding after 
major hepatectomies. J Hepatobiliary Pancreat Surg 2009;16:552-6. 
66. Gurusamy KS, Kumar Y, Pamecha V, Sharma D, Davidson BR. Ischaemic pre-conditioning 
for elective liver resections performed under vascular occlusion. Cochrane Database Syst 
Rev 2009;21:CD007629. 
176 
 
67. Gomez D, Homer-Vanniasinkam S, Graham AM, Prasad KR. Role of ischaemic 
preconditioning in liver regeneration following major liver resection and transplantation. 
World J Gastroenterol 2007;13:657-70. 
68. Onodera K, Sakata H, Yonekawa M, Kawamura A. Artificial liver support at present and 
in the future. J Artif Organs 2006;9:17-28. 
69. Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am J Gastroenterol 
2005;100:468-75. 
70. Chamuleau RA, Poyck PP, van de Kerkhove MP. Bioartificial liver: its pros and cons. Ther 
Apher Dial 2006;10:168-74. 
71. Selden C, Hodgson H. Cellular therapies for liver replacement. Transpl Immunol 
2004;12:273-88. 
72. Yu CB, Pan XP, Li LJ. Progress in bioreactors of bioartificial livers.Hepatobiliary Pancreat 
Dis Int 2009;8:134-40. 
73. JD, Sipe. Tissue engineering and reparative medicine. Ann N Y Acad Sci 2002;961:1-9. 
74. Ehnert S, Glanemann M, Schmitt A, Vogt S, Shanny N, Nussler NC, et al. The possible use 
of stem cells in regenerative medicine: dream or reality? Langenbecks Arch Surg 
2009;394:985-97. 
75. Fausto N, Laird AD, Webber EM. Liver regeneration. 2. Role of growth factors and 
cytokines in hepatic regeneration. FASEB J 1995;9:1527-36. 
76. N, Fausto. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. 
Hepatology 2004;39:1477-87. 
77. Flohr TR, Bonatti H Jr, Brayman KL, Pruett TL. The use of stem cells in liver disease. Curr 
Opin Organ Transplant 2009;14:64-71. 
78. Garcea G, Maddern GJ. Liver failure after major hepatic resection. J Hepatobiliary 
Pancreat Surg 2009;16:145-55. 
79. Sowa JP, Best J, Benko T, Bockhorn M, Gu Y, Niehues EM, et al. Extent of liver resection 
modulates the activation of transcription factors and the production of cytokines involved 
in liver regeneration. World J Gastroenterol 2008;14:7093-100. 
80. E, FARBER. Similarities in the sequence of early histological changes induced in the liver 
of the rat by ethionine, 2-acetylamino-fluorene, and 3'-methyl-4-
dimethylaminoazobenzene. Cancer Res 1956;16:142-8. 
81. Faris RA, Konkin T, Halpert G. Liver stem cells: a potential source of hepatocytes for the 
treatment of human liver disease.Artif Organs 2001;25:513-21. 
177 
 
82. Alison M, Golding M, Lalani EN, Nagy P, Thorgeirsson S, Sarraf C. Wholesale hepatocytic 
differentiation in the rat from ductular oval cells, the progeny of biliary stem cells.,J 
Hepatol 1997;26:343-52. 
83. Fausto N, Campbell JS. The role of hepatocytes and oval cells in liver regeneration and 
repopulation. Mech Dev 2003;120:117-30. 
84. Kuwahara R, Kofman AV, Landis CS, Swenson ES, Barendswaard E, Theise ND. The 
hepatic stem cell niche: identification by label-retaining cell assay. Hepatology 
2008;47:1994-2002. 
85. Gaudio E, Carpino G, Cardinale V, Franchitto A, Onori P, Alvaro D. New insights into liver 
stem cells. Dig Liver Dis 2009;41:455-62. 
86. S, Sell. Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology 
2001;33:738-50. 
87. Tremblay KD, Zaret KS.  Distinct populations of endoderm cells converge to generate 
the embryonic liver bud and ventral foregut tissues. Dev Biol 2005;280:87-99. 
88. Lee SP, Savard CE, Kuver R. Gallbladder epithelial cells that engraft in mouse liver can 
differentiate into hepatocyte-like cells. Am J Pathol 2009;174:842-53. 
89. Hewes JC, Riddy D, Morris RW, Woodrooffe AJ, Davidson BR, Fuller B. A prospective 
study of isolated human hepatocyte function following liver resection for colorectal liver 
metastases: the effects of prior exposure to chemotherapy. J Hepatol 2006;45:263-70. 
90. Schiffer E, Frossard JL, Rubbia-Brandt L, Mentha G, Pastor CM. Hepatic regeneration is 
decreased in a rat model of sinusoidal obstruction syndrome. J Surg Oncol 2009;99:439-46. 
91. Narita M, Oussoultzoglou E, Chenard MP, Rosso E, Casnedi S, Pessaux P, et al. Sinusoidal 
obstruction syndrome compromises liver regeneration in patients undergoing two-stage 
hepatectomy with portal vein embolization. Surg Today 2011;41:7-17. 
92. Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, et al.  Platelet-derived 
serotonin mediates liver regeneration. Science 2006;312:104-7. 
93. Murata S, Ohkohchi N, Matsuo R, Ikeda O, Myronovych A, Hoshi R. Platelets promote 
liver regeneration in early period after hepatectomy in mice. World J Surg 2007;31:808-16. 
94. LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, et al. Angiogenesis-
independent endothelial protection of liver: role of VEGFR-1. Science 2003;299:890-3. 
95. Ding BS, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks Z, et al.  Inductive 
angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 
2010;468:310-5. 
96. Mellick AS, Plummer PN, Nolan DJ, Gao D, Bambino K, Hahn M, et al. Using the 
transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor 
178 
 
cells offers novel strategies to inhibit tumor angiogenesis and growth. Cancer Res 
2010;70:7273-82. 
97. Groth CG, Arborgh B, Björkén C, Sundberg B, Lundgren G.  Correction of 
hyperbilirubinemia in the glucuronyltransferase-deficient rat by intraportal hepatocyte 
transplantation. Transplant Proc 1977;9:313-36. 
98. Fisher RA, Strom SC. Human hepatocyte transplantation: worldwide results. 
Transplantation 2006;82:441-9. 
99. Nussler A, Konig S, Ott M, Sokal E, Christ B, Thasler W, et al. Present status and 
perspectives of cell-based therapies for liver diseases. J Hepatol 2006;45:144-59. 
100. Baccarani U, Sanna A, Cariani A, Sainz-Barriga M, Adani GL, Zambito AM, et al. 
Isolation of human hepatocytes from livers rejected for liver transplantation on a national 
basis: results of a 2-year experience. Liver Transpl 2003;9:506-12. 
101. Allen KJ, Soriano HE. Liver cell transplantation: the road to clinical application. J Lab 
Clin Med 2001;138:298-312. 
102. Pietrosi G, Vizzini GB, Gruttadauria S, Gridelli B. Clinical applications of hepatocyte 
transplantation.  World J Gastroenterol 2009;15:2074-7. 
103. Sigot V, Mediavilla MG, Furno G, Rodríguez JV, Guibert EE. A simple and effective 
method to improve intrasplenic rat hepatocyte transplantation. Cell Transplant 
2004;13:775-81. 
104. Gupta S, Rajvanshi P, Sokhi R, Slehria S, Yam A, Kerr A , et al. Entry and integration of 
transplanted hepatocytes in rat liver plates occur by disruption of hepatic sinusoidal 
endothelium. Hepatology 1999;29:509-19. 
105. Mula N, Cubero FJ, Codesal J, de Andrés S, Escudero C, García-Barrutia S, et al. Survival 
of allogeneic hepatocytes transplanted into the thymus. Cells Tissues Organs 2008;188:270-
9. 
106. Mei J, Sgroi A, Mai G, Baertschiger R, Gonelle-Gispert C, Serre-Beinier V, et al. 
Improved survival of fulminant liver failure by transplantation of microencapsulated 
cryopreserved porcine hepatocytes in mice. Cell Transplant 2009;18:101-10. 
107. Glanemann M, Gaebelein G, Nussler N, Hao L, Kronbach Z, Shi B, et al. Transplantation 
of monocyte-derived hepatocyte-like cells (NeoHeps) improves survival in a model of acute 
liver failure. Ann Surg 2009;249:149-54. 
108. Rajvanshi P, Kerr A, Bhargava KK, Burk RD, Gupta S. Efficacy and safety of repeated 
hepatocyte transplantation for significant liver repopulation in rodents. Gastroenterology 
1996;111:1092-102. 
179 
 
109. Smalley M, Leiper K, Tootle R, McCloskey P, O'Hare MJ, Hodgson H. Immortalization of 
human hepatocytes by temperature-sensitive SV40 large-T antigen. In Vitro Cell Dev Biol 
Anim 2001;37:166-8. 
110. Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. 
Nat Biotechnol 2008;26:120-6. 
111. Ito M, Nagata H, Miyakawa S, Fox IJ. Review of hepatocyte transplantation. J 
Hepatobiliary Pancreat Surg 2009;16:97-100. 
112. Becker AJ, Mcculloch EA, Till JE.Cytological demonstration of the clonal nature of 
spleen colonies derived from transplanted mouse marrow cells. Nature 1963;197:452-4. 
113. Mitalipov S, Wolf D. Totipotency, pluripotency and nuclear reprogramming. Adv 
Biochem Eng Biotechnol 2009;114:185-99. 
114. Toma JG, Akhavan M, Fernandes KJ, Barnabé-Heider F, Sadikot A, Kaplan DR, et al. 
Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol 
2001;3:778-84. 
115. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced 
pluripotent stem cells. Nature 2007;448:313-7. 
116. Shamblott MJ, Axelman J, Wang S, Bugg EM, Littlefield JW, Donovan PJ, et al. 
Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl 
Acad Sci U S A 1998;95:13726-31. 
117. Shamblott MJ, Axelman J, Littlefield JW, Blumenthal PD, Huggins GR, Cui Y, et al. 
Human embryonic germ cell derivatives express a broad range of developmentally distinct 
markers and proliferate extensively in vitro. Proc Natl Acad Sci U S A 2001;98:113-8. 
118. Nagy A, Gócza E, Diaz EM, Prideaux VR, Iványi E, Markkula M, et al. Embryonic stem 
cells alone are able to support fetal development in the mouse. Development 
1990;110:815-21. 
119. Xu RH, Chen X, Li DS, Li R, Addicks GC, Glennon C, et al. BMP4 initiates human 
embryonic stem cell differentiation to trophoblast. Nat Biotechnol 2004;20:1261-4. 
120. Polak JM, Bishop AE. Stem cells and tissue engineering: past, present, and future. Ann 
N Y Acad Sci 2006;1068:352-66. 
121. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic 
and adult fibroblast cultures by defined factors. Cell 2006;126:663-76. 
122. Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K, et al. Generation of 
pluripotent stem cells from adult mouse liver and stomach cells. Science 2008;321:699-702. 
123. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human 
somatic cells to pluripotency with defined factors. Nature 2008;451:141-6. 
180 
 
124. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult 
pancreatic exocrine cells to beta-cells. Nature 2008;455:627-32. 
125. Berninger B, Costa MR, Koch U, Schroeder T, Sutor B, Grothe B, et al. Functional 
properties of neurons derived from in vitro reprogrammed postnatal astroglia. J Neurosci 
2007;27:8654-64. 
126. Colman A, Dreesen O. Induced pluripotent stem cells and the stability of the 
differentiated state. EMBO Rep 2009;10:714-21. 
127. Lyra AC, Soares MB, dos Santos RR, Lyra LG. Bone marrow stem cells and liver disease.  
Gut 2007;56:1640-1. 
128. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. 
Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7. 
129. Bobis S, Jarocha D, Majka M. Mesenchymal stem cells: characteristics and clinical 
applications. Folia Histochem Cytobiol 2006;44:215-30. 
130. Liu ZJ, Zhuge Y, Velazquez OC. Trafficking and differentiation of mesenchymal stem 
cells. J Cell Biochem 2009;106:984-91. 
131. Kassem M, Kristiansen M, Abdallah BM. Mesenchymal stem cells: cell biology and 
potential use in therapy.  Basic Clin Pharmacol Toxicol 2004;95:209-14. 
132. Vassilopoulos G, Wang PR, Russell DW. Transplanted bone marrow regenerates liver 
by cell fusion. Nature 2003;4226934:901-4. 
133. Harris RG, Herzog EL, Bruscia EM, Grove JE, Van Arnam JS, Krause DS. Lack of a fusion 
requirement for development of bone marrow-derived epithelia.  Science 2004;305:90-3. 
134. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, et al. 
Telomerase expression extends the proliferative life-span and maintains the osteogenic 
potential of human bone marrow stromal cells. Nat Biotechnol 2002;20:592-6. 
135. Huang YC, Yang ZM, Chen XH, Tan MY, Wang J, Li XQ, et al. Isolation of mesenchymal 
stem cells from human placental decidua basalis and resistance to hypoxia and serum 
deprivation. Stem Cell Rev 2009;5:247-55. 
136. D'Alessandro A, Liumbruno G, Grazzini G, Pupella S, Lombardini L, Zolla L. Umbilical 
cord blood stem cells: towards a proteomic approach. J Proteomics 2010;73:468-82. 
137. H, Mizuno. Adipose-derived stem and stromal cells for cell-based therapy: current 
status of preclinical studies and clinical trials.  Curr Opin Mol Ther 2010;12:442-9. 
138. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, et al. Clinical applications of 
blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 
2008;299:925-36. 
181 
 
139. Vaquero J, Zurita M. Bone marrow stromal cells for spinal cord repair: a challenge for 
contemporary neurobiology. Histol Histopathol 2009;24:107-16. 
140. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, et al. 
Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J 
Med 2006;355:1210-21. 
141. Witkowski P, Zakai SB, Rana A, Sledzinski Z, Hardy MA. Pancreatic islet transplantation, 
what has been achieved since Edmonton break-through. Ann Transplant 2006;11:5-13. 
142. Baeyens L, Bouwens L. Can beta-cells be derived from exocrine pancreas? Diabetes 
Obes Metab 2008;10:170-8. 
143. GR, Martin. Isolation of a pluripotent cell line from early mouse embryos cultured in 
medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A 1981;78:7634-
8. 
144. Liedtke C, Streetz KL. Hepatocytes from embryonic stem cells: Prometheus revisited? 
Hepatology 2007;45:829-30. 
145. Pan YL, Cai JY, Hu AB. Differentiation of hepatocytes from mouse embryonic stem cells 
and its significance. Hepatobiliary Pancreat Dis Int 2005;4:291-4. 
146. Chinzei R, Tanaka Y, Shimizu-Saito K, Hara Y, Kakinuma S, Watanabe M, et al. 
Embryoid-body cells derived from a mouse embryonic stem cell line show differentiation 
into functional hepatocytes. Hepatology 2002;36:22-9. 
147. Hamazaki T, Iiboshi Y, Oka M, Papst PJ, Meacham AM, Zon LI, et al. Hepatic maturation 
in differentiating embryonic stem cells in vitro.FEBS Lett 2001;497:15-9. 
148. umashiro Y, Asahina K, Ozeki R, Shimizu-Saito K, Tanaka Y, Kida Y, et al. Enrichment of 
hepatocytes differentiated from mouse embryonic stem cells as a transplantable source. 
Transplantation 2005;79:550-7. 
149. Moriya K, Yoshikawa M, Ouji Y, Saito K, Nishiofuku M, Matsuda R, et al. Embryonic 
stem cells reduce liver fibrosis in CCl4-treated mice. Int J Exp Pathol 2008;89:401-9. 
150. Moore RN, Dasgupta A, Rajaei N, Yarmush ML, Toner M, Larue L, et al. Enhanced 
differentiation of embryonic stem cells using co-cultivation with hepatocytes. Biotechnol 
Bioeng 2008;101:1332-43. 
151. Kubo A, Shinozaki K, Shannon JM, Kouskoff V, Kennedy M, Woo S, et al. Development 
of definitive endoderm from embryonic stem cells in culture. Development 2004;131:1651-
62. 
152. Zhou M, Li P, Tan L, Qu S, Ying QL, Song H. Differentiation of mouse embryonic stem 
cells into hepatocytes induced by a combination of cytokines and sodium butyrate.J Cell 
Biochem 2010;109: 606-14. 
182 
 
153. Chen L, Tredget EE, Liu C, Wu Y. Analysis of allogenicity of mesenchymal stem cells in 
engraftment and wound healing in mice. PLoS One 2009;4:e7119. 
154. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow 
mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells 
to their cognate peptide. Blood 2003;101:37223729. 
155. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. 
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular 
or nonspecific mitogenic stimuli. Blood 2002;99:3838-43. 
156. Taniguchi H, Toyoshima T, Fukao K, Nakauchi H. Presence of hematopoietic stem cells 
in the adult liver. Nat Med 1996;2:198-203. 
157. Tang YL, Zhao Q, Qin X, Shen L, Cheng L, Ge J, et al. Paracrine action enhances the 
effects of autologous mesenchymal stem cell transplantation on vascular regeneration in 
rat model of myocardial infarction. Ann Thorac Surg 2005;80:229-36. 
158. Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, et al. 
Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc 
Nephrol 2009;20:1053-67. 
159. van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW, et al. 
Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and 
regeneration in vitro and in vivo. Hepatology 2008;47:1634-43. 
160. Herrera MB, Fonsato V, Gatti S, Deregibus MC, Sordi A, Cantarella D, et al. Human liver 
stem cell-derived microvesicles accelerate hepatic regeneration in hepatectomized rats. J 
Cell Mol Med 2010;14:1605-18. 
161. Yu Y, Yao AH, Chen N, Pu LY, Fan Y, Lv L, et al. Mesenchymal stem cells over-expressing 
hepatocyte growth factor improve small-for-size liver grafts regeneration. Mol Ther 
2007;15:1382-89. 
162. Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, Ratajczak J, et al. 
Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by 
stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves 
matrix metalloproteinases. Stem Cells 2006;24:1254-64. 
163. Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh JH, et al. Plasma elevation of 
stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic 
progenitor and stem cells. Blood 2001;97:3354-60. 
164. Mao L, Qiu YD, Fang S, Wu YF, Liu H, Ding YT. Liver progenitor cells activated after 30% 
small-for-size liver transplantation in rats: a preliminary study. Transplant Proc 
2008;40:1635-40. 
183 
 
165. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. Expression of 
VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional 
endothelial precursors. Blood 2000;95:952-8. 
166. Lemoli RM, Catani L, Talarico S, Loggi E, Gramenzi A, Baccarani U, et al. Mobilization of 
bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver 
transplantation and liver resection. Stem Cells 2006;24:2817-25. 
167. Stutchfield BM, Rashid S, Forbes SJ, Wigmore SJ. Practical barriers to delivering 
autologous bone marrow stem cell therapy as an adjunct to liver resection. Stem Cells Dev 
2010;19:155-62. 
168. Harb R, Xie G, Lutzko C, Guo Y, Wang X, Hill CK, et al. Bone marrow progenitor cells 
repair rat hepatic sinusoidal endothelial cells after liver injury. Gastroenterology 
2009;137:704-12. 
169. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem 
cells. Blood 1997;89:2233-58. 
170. Pai M, Zacharoulis D, Milicevic MN, Helmy S, Jiao LR, Levicar N, et al. Autologous 
infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with 
alcoholic liver cirrhosis. Am J Gastroenterol 2008;103:1952-8. 
171. Gehling UM, Willems M, Dandri M, Petersen J, Berna M, Thill M, et al. Partial 
hepatectomy induces mobilization of a unique population of haematopoietic progenitor 
cells in human healthy liver donors. J Hepatol 2005;43:845-53. 
172. am Esch JS 2nd, Knoefel WT, Klein M, Ghodsizad A, Fuerst G, Poll LW, et al. Portal 
application of autologous CD133+ bone marrow cells to the liver: a novel concept to 
support hepatic regeneration. Stem Cells 2005;23:463-70. 
173. Fürst G, Schulte am Esch J, Poll LW, Hosch SB, Fritz LB, Klein M, et al. Portal vein 
embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial 
experience. Radiology 2007;243:171-9. 
174. Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, Lewis BK, et al. 
Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. 
Nat Biotechnol 2001;19:1141-7. 
175. Toso C, Vallee JP, Morel P, Ris F, Demuylder-Mischler S, Lepetit-Coiffe M, et al. Clinical 
magnetic resonance imaging of pancreatic islet grafts after iron nanoparticle labeling. Am J 
Transplant 2008;8:701-6. 
176. Budde MD, Frank JA. Magnetic tagging of therapeutic cells for MRI. J Nucl Med 
2009;50:171-4. 
177. Welling MM, Duijvestein M, Signore A, van der Weerd L. In vivo biodistribution of 
stem cells using molecular nuclear medicine imaging. J Cell Physiol 2011;226:1444-52. 
184 
 
178. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC. Green fluorescent protein as a 
marker for gene expression. Science 1994;263:802-5. 
179. K, König. Multiphoton microscopy in life sciences. J Microsc 2000;200(Pt 2):83-104. 
180. Koenig S, Krause P, Hosseini AS, Dullin C, Rave-Fraenk M, Kimmina S, et al. Noninvasive 
imaging of liver repopulation following hepatocyte transplantation. Cell Transplant 
2009;18:69-78. 
181. Boddington SE, Henning TD, Jha P, Schlieve CR, Mandrussow L, DeNardo D, et al. 
Labeling human embryonic stem cell-derived cardiomyocytes with indocyanine green for 
noninvasive tracking with optical imaging: an FDA-compatible alternative to firefly 
luciferase. Cell Transplant 2010;19:55-65. 
182. DeLeve LD, McCuskey RS, Wang X, Hu L, McCuskey MK, Epstein RB, et al. 
Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 
1999;29:1779-91. 
183. Saito C, Zwingmann C, Jaeschke H. Novel mechanisms of protection against 
acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine. Hepatology 
2010;51:246-54. 
184. Scorticati C, Prestifilippo JP, Eizayaga FX, Castro JL, Romay S, Fernández MA, et al. 
Hyperammonemia, brain edema and blood-brain barrier alterations in prehepatic portal 
hypertensive rats and paracetamol intoxication. World J Gastroenterol 2004;10:1321-4. 
185. Ponder KP, Gupta S, Leland F, Darlington G, Finegold M, DeMayo J, et al. Mouse 
hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic 
transplantation. Proc Natl Acad Sci U S A 1991;88:1217-21. 
186. Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. Sinusoidal 
obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-
associated liver lesions and partially prevented by bevacizumab in patients with hepatic 
colorectal metastasis. Histopathology 2010;56:430-9. 
187. Chun YS, Vauthey JN. Extending the frontiers of resectability in advanced colorectal 
cancer. Eur J Surg Oncol 2007;33:S52-8. 
188. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. 
Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in 
patients with metastatic colorectal cancer. Ann Oncol 2004;15:460-6. 
189. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal 
obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002;22:27-42. 
190. Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B, et al. Hepatic resection after 
rescue cetuximab treatment for colorectal liver metastases previously refractory to 
conventional systemic therapy. J Clin Oncol 2007;25:4593-602. 
185 
 
191. Dixon E, Datta I, Sutherland FR, Vauthey JN. Blood loss in surgical oncology: neglected 
quality indicator? J Surg Oncol 2009;99:508-12. 
192. Stegelmeier BL, Edgar JA, Colegate SM, Gardner DR, Schoch TK, Coulombe RA, et al. 
Pyrrolizidine alkaloid plants, metabolism and toxicity. J Nat Toxins 1999;8:95-116. 
193. Mathew R, Huang J, Shah M, Patel K, Gewitz M, Sehgal PB. Disruption of endothelial-
cell caveolin-1alpha/raft scaffolding during development of monocrotaline-induced 
pulmonary hypertension. Circulation 2004;110:1499-506. 
194. Hanumegowda UM, Copple BL, Shibuya M, Malle E, Ganey PE, Roth RA. Basement 
membrane and matrix metalloproteinases in monocrotaline-induced liver injury. Toxicol Sci 
2003;76:237-46. 
195. Koutras AK, Makatsoris T, Paliogianni F, Kopsida G, Onyenadum A, Gogos CA, et al. 
Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 
2004;67:179-82. 
196. Narita M, Hatano E, Tamaki N, Yamanaka K, Yanagida A, Nagata H, et al. Dai-kenchu-to 
attenuates rat sinusoidal obstruction syndrome by inhibiting the accumulation of 
neutrophils in the liver. J Gastroenterol Hepatol 2009;24:1051-7. 
197. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, 
dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert 
Opin Drug Metab Toxicol 2006;2:875-94. 
198. hulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer D, et al. Utility of 
transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty 
marrow transplant recipients. Transplantation 1995;59:1015-22. 
199. Thalheimer U, Leandro G, Samonakis DN, Triantos CK, Patch D, Burroughs AK. 
Assessment of the agreement between wedge hepatic vein pressure and portal vein 
pressure in cirrhotic patients. Dig Liver Dis 2008;37:601-8. 
200. DeLeve LD, Ito Y, Bethea NW, McCuskey MK, Wang X, McCuskey RS. Embolization by 
sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome. 
Am J Physiol Gastrointest Liver Physiol 2003;284:G1045-52. 
201. Hinson JA, Mays JB, Cameron AM. Acetaminophen-induced hepatic glycogen depletion 
and hyperglycemia in mice. Biochem Pharmacol 1983;32:1979-88. 
202. DeLeve LD, Wang X, Kaplowitz N, Shulman HM, Bart JA, van der Hoek A. Sinusoidal 
endothelial cells as a target for acetaminophen toxicity. Direct action versus requirement 
for hepatocyte activation in different mouse strains. Biochem Pharmacol 1997;53:1339-45. 
203. Youssef SS, Kumar PP. Jaundice secondary to isolated porta hepatis metastasis in 
colorectal cancer: case report and review of the literature. South Med J 2004;97:287-90. 
186 
 
204. Soubrane O, Brouquet A, Zalinski S, Terris B, Brézault C, Mallet V, et al. Predicting high 
grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based 
chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. 
Ann Surg 2010;251:454-60. 
205. Rubbia-Brandt L, Tauzin S, Brezault C, Delucinge-Vivier C, Descombes P, Dousset B, et 
al. Gene expression Profiling Provides Insights into Pathways of Oxaliplatin Related 
Sinusoidal Obstruction Syndrome in Humans. Mol Cancer Ther 2011;10:687-96 . 
206. B, Gao. Cytokines, STATs and liver disease.  Cell Mol Immunol 2005;2:92-100. 
207. Upadhya GA, Strasberg SM. Evidence that actin disassembly is a requirement for 
matrix metalloproteinase secretion by sinusoidal endothelial cells during cold preservation 
in the rat. Hepatology 1999;30:169-76. 
208. Griffiths MR, Keir S, Burt AD. Basement membrane proteins in the space of Disse: a 
reappraisal.  J Clin Pathol 1991;44:646-8. 
209. Deleve LD, Wang X, Tsai J, Kanel G, Strasberg S, Tokes ZA. Sinusoidal obstruction 
syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase 
inhibition. Gastroenterology 2003;125:882-90. 
210. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear 
leukocyte. Blood 1997;89:3503-21. 
211. ibero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, et al. Bevacizumab 
improves pathologic response and protects against hepatic injury in patients treated with 
oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007;110:2761-7. 
212. Iguchi A, Kobayashi R, Yoshida M, Kobayashi K, Matsuo K, Kitajima I, et al. Vascular 
endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic 
veno-occlusive disease (VOD) in stem cell transplantation. Bone Marrow Transplant 
2001;27:1173-80. 
213. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, et al. Hypoxia-
induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis 
in experimental cirrhosis. Hepatology 2002;35:1010-21. 
214. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, et al. VEGF-A 
stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via 
macrophage recruitment. J Clin Invest 2004;113:1040-50. 
215. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, et al. Bevacizumab as 
a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.  Invest 
Ophthalmol Vis Sci 2007;48:2545-52. 
216. Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B, et al. 
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases 
treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 2011;18:421-30. 
187 
 
217. Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL, et al. Prevention of hepatic 
veno-occlusive disease after bone marrow transplantation by continuous infusion of low-
dose heparin: a prospective, randomized trial. Blood 1992;79:2834-40. 
218. Deleve LD, Wang X, Tsai J, Kanel G, Strasberg S, Tokes ZA. Sinusoidal obstruction 
syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase 
inhibition. Gastroenterology 2003;125:882-90. 
219. Bast A, Haenen GR, Bruynzeel AM, Van der Vijgh WJ. Protection by flavonoids against 
anthracycline cardiotoxicity: from chemistry to clinical trials. Cardiovasc Toxicol 
2007;7:154-9. 
220. van Acker SA, Kramer K, Grimbergen JA, van den Berg DJ, van der Vijgh WJ, Bast A. 
Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity. 
Br J Pharmacol 1995;115:1260-4. 
221. van Acker SA, Boven E, Kuiper K, van den Berg DJ, Grimbergen JA, Kramer K, et al. 
Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the 
antitumor activity of doxorubicin. Clin Cancer Res 1997;3:1747-54. 
222. Willems AM, Bruynzeel AM, Kedde MA, van Groeningen CJ, Bast A, van der Vijgh WJ. A 
phase I study of monohydroxyethylrutoside in healthy volunteers. Cancer Chemother 
Pharmacol 2006;57:678-84. 
223. Bruynzeel AM, Niessen HW, Bronzwaer JG, van der Hoeven JJ, Berkhof J, Bast A, et al. 
The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients 
treated for metastatic cancer in a phase II study. Br J Cancer 2007;97:1084-9. 
224. Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, Tachibana M, et al. 
Expression of trefoil factor family members correlates with patient prognosis and 
neoangiogenesis. Clin Cancer Res 2005;11:6472-8. 
225. Wadworth AN, Faulds D. Hydroxyethylrutosides. A review of its pharmacology, and 
therapeutic efficacy in venous insufficiency and related disorders. Drugs 1992;44:1013-32. 
226. Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, et al. Circulating 
endothelial cells in venous blood as a marker of endothelial damage in chronic venous 
insufficiency: improvement with venoruton.  J Cardiovasc Pharmacol Ther 2006;11:93-8. 
227. Abou El Hassan MA, Verheul HM, Jorna AS, Schalkwijk C, van Bezu J, van der Vijgh WJ, 
et al. The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-
induced inflammatory effects in vitro. Br J Cancer 2003;89:357-62. 
228. Chun YS, Laurent A, Maru D, Vauthey JN. Management of chemotherapy-associated 
hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009:10:278-86. 
229. oots AW, Li H, Schins RP, Duffin R, Heemskerk JW, Bast A, et al. The quercetin paradox. 
BHaenen GR. Toxicol Appl Pharmacol 2007;222:89-96. 
188 
 
230. Jacobs H, van der Vijgh WJ, Koek GH, Draaisma GJ, Moalin M, van Strijdonck GP, et al. 
Characterization of the glutathione conjugate of the semisynthetic flavonoid monoHER.  
Free Radic Biol Med 2009;46:1567-73. 
231. acobs H, Moalin M, Bast A, van der Vijgh WJ, Haenen GR. An essential difference 
between the flavonoids monoHER and quercetin in their interplay with the endogenous 
antioxidant network. PLoS One 2010;5:e13880. 
232. Clark CJ, Boswell F, Greer IA, Lyall F. Treatment of endothelial cells with serum from 
women with preeclampsia: effect on neutrophil adhesion.  J Soc Gynecol Investig 
1997;4:27-33. 
233. Nieminen AL, Byrne AM, Herman B, Lemasters JJ. Mitochondrial permeability 
transition in hepatocytes induced by t-BuOOH: NAD(P)H and reactive oxygen species.  Am J 
Physiol 1997;272:C1286-94. 
234. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear 
leukocyte.  Blood 1997;89:3503-21. 
235. Upadhya AG, Harvey RP, Howard TK, Lowell JA, Shenoy S, Strasberg SM. Evidence of a 
role for matrix metalloproteinases in cold preservation injury of the liver in humans and in 
the rat. Hepatology 1997;26:922-8. 
236. DeLeve LD, Valla DC, Garcia-Tsao G and Diseases, American Association for the Study 
Liver. Vascular disorders of the liver. Hepatology 2009;49:1729-64. 
237. Bearman SI, Lee JL, Barón AE, McDonald GB. Treatment of hepatic venocclusive 
disease with recombinant human tissue plasminogen activator and heparin in 42 marrow 
transplant patients. Blood 1997;89:1501-6. 
238. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, et al. 
Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in 
response without significant toxicity in a high-risk population.  Blood 1998;92:737-44. 
239. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, et al. Multi-
institutional use of defibrotide in 88 patients after stem cell transplantation with severe 
veno-occlusive disease and multisystem organ failure: response without significant toxicity 
in a high-risk population and factors predictive of outcome. Blood 2002;100:4337-43. 
240. Narita M, Hatano E, Ikai I, Miyagawa-Hayashino A, Yanagida A, Nagata H, et al. A 
phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome 
through heme oxygenase-1 induction. Ann Surg 2009;249:806-13. 
241. The cardioprotector monoHER does not interfere with the pharmacokinetics or the 
metabolism of the cardiotoxic agent doxorubicin in mice. 4, 2003, Cancer Chemother 
Pharmacol, Vol. 51, pp. 306-10. 
242. Abou El Hassan MA, Kedde MA, Zwiers UT, Bast A, van der Vijgh WJ. Bioactivation of 
monocrotaline by P-450 3A in rat liver. J Cardiovasc Pharmacol 1997;30:124-9. 
189 
 
243. Molteni A, Ward WF, Ts'ao CH, Solliday NH. Monocrotaline pneumotoxicity in mice. 
Virchows Arch B Cell Pathol Incl Mol Pathol 1989;57:149-55. 
244. Ito Y, Bethea NW, Abril ER, McCuskey RS. Early hepatic microvascular injury in 
response to acetaminophen toxicity. Microcirculation 2003;10:391-400. 
245. Walker RM, Racz WJ, McElligott TF. Scanning electron microscopic examination of 
acetaminophen-induced hepatotoxicity and congestion in mice.  Am J Pathol, Vol 
1983;113:321-30. 
246. Ito Y, Abril ER, Bethea NW, McCuskey RS. Inhibition of matrix metalloproteinases 
minimizes hepatic microvascular injury in response to acetaminophen in mice. Toxicol Sci 
2005;83:190-6. 
247. Liu ZC, Chang TM. Transdifferentiation of bioencapsulated bone marrow cells into 
hepatocyte-like cells in the 90% hepatectomized rat model. Liver Transpl 2006;12:566-572. 
248. Gao Y, Mu N, Xu XP, Wang Y. Porcine acute liver failure model established by two-
phase surgery and treated with hollow fiber bioartificial liver support system. World J 
Gastroenterol 2005;, Vol. 11, pp. 5468-5474. 
249. Soloviev V, Hassan AN, Akatov V, Lezhnev E, Ghaffar TY, Ghaffar YA. A novel 
bioartificial liver containing small tissue fragments: efficiency in the treatment of acute 
hepatic failure induced by carbon tetrachloride in rats.  Int J Artif Organs 2003;26:735-42. 
250. Mark AL, Sun Z, Warren DS, Lonze BE, Knabel MK, Melville Williams GM, Locke JE, et 
al. Stem cell mobilization is life saving in an animal model of acute liver failure. Ann Surg 
2010;252:591-6. 
251. Tuñón MJ, Alvarez M, Culebras JM, González-Gallego J. An overview of animal models 
for investigating the pathogenesis and therapeutic strategies in acute hepatic failure. World 
J Gastroenterol 2009;15:3086-98. 
252. Gehling UM, Willems M, Dandri M, Petersen J, Berna M, Thill M, et al. Partial 
hepatectomy induces mobilization of a unique population of haematopoietic progenitor 
cells in human healthy liver donors.  J Hepatol 2005;43:845-53. 
253. Eisenblätter M, Ehrchen J, Varga G, Sunderkötter C, Heindel W, Roth J, et al. In vivo 
optical imaging of cellular inflammatory response in granuloma formation using 
fluorescence-labeled macrophages. J Nucl Med 2009;50:1676-82. 
254. R, Weissleder. A clearer vision for in vivo imaging.Nat Biotechnol 2001;19:327-31. 
255. Choi MS, Catana AM, Wu J, Kim YS, Yoon SJ, Borowsky AD, et al. Use of bioluminescent 
imaging to assay the transplantation of immortalized human fetal hepatocytes into mice. 
Cell Transplant 2008;17:899-909. 
190 
 
256. Gupta S, Rajvanshi P, Sokhi R, Slehria S, Yam A, Kerr A, et al. Entry and integration of 
transplanted hepatocytes in rat liver plates occur by disruption of hepatic sinusoidal 
endothelium. Novikoff PM. Hepatology 1999;29:509-19. 
257. van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW, et al. 
Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and 
regeneration in vitro and in vivo. Hepatology 2008;47:1634-43. 
258. LaFramboise WA, Petrosko P, Krill-Burger JM, Morris DR, McCoy AR, Scalise D, et al. 
Proteins secreted by embryonic stem cells activate cardiomyocytes through ligand binding 
pathways. J Proteomics 2010;73:992-1003. 
259. Moriya K, Yoshikawa M, Ouji Y, Saito K, Nishiofuku M, Matsuda R, et al. Embryonic 
stem cells reduce liver fibrosis in CCl4-treated mice. Int J Exp Pathol 2008;89:401-9. 
260. Imamura T, Cui L, Teng R, Johkura K, Okouchi Y, Asanuma K, et al. Embryonic stem cell-
derived embryoid bodies in three-dimensional culture system form hepatocyte-like cells in 
vitro and in vivo. iwara N, Sasaki K. Tissue Eng 2004;10:1716-24. 
261. Novik EI, Barminko J, Maguire TJ, Sharma N, Wallenstein EJ, Schloss RS, et al. 
Augmentation of EB-directed hepatocyte-specific function via collagen sandwich and SNAP.  
Biotechnol Prog 2008;24:1132-41. 
262. Min J, Shang CZ, Chen YJ, Zhang L, Liu L, Deng XG, et al. Selective enrichment of 
hepatocytes from mouse embryonic stem cells with a culture system containing cholestatic 
serum. Acta Pharmacol Sin 2007;28:1931-7. 
263. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. 
Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in 
patients with metastatic colorectal cancer. Ann Oncol 2004;15:460-6. 
264. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 
regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U 
S A 2008;105:1516-21. 
265. to Y, Bethea NW, Abril ER, McCuskey RS. Early hepatic microvascular injury in response 
to acetaminophen toxicity. Microcirculation 2003;10:391-400. 
266. Hay DC, Zhao D, Ross A, Mandalam R, Lebkowski J, Cui W. Direct differentiation of 
human embryonic stem cells to hepatocyte-like cells exhibiting functional activities. Cloning 
Stem Cells 2007;9:51-62. 
267. Yamada T, Yoshikawa M, Kanda S, Kato Y, Nakajima Y, Ishizaka S, et al. In vitro 
differentiation of embryonic stem cells into hepatocyte-like cells identified by cellular 
uptake of indocyanine green. Stem Cells 2002;20:146-54. 
268. Fatma S, Selby DE, Singla RD, Singla DK. Factors Released from Embryonic Stem Cells 
Stimulate c-kit-FLK-1(+ve) Progenitor Cells and Enhance Neovascularization. Antioxid Redox 
Signal 2010;13:1857-65. 
191 
 
269. Nussbaum J, Minami E, Laflamme MA, Virag JA, Ware CB, Masino A, et al. 
Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma 
formation and immune response. FASEB J 2007;21:1345-57. 
270. Irie T, Asahina K, Shimizu-Saito K, Teramoto K, Arii S, Teraoka H.  Hepatic progenitor 
cells in the mouse extrahepatic bile duct after a bile duct ligation. Stem Cells Dev 
2007;16:979-87. 
271. Ren M, Yan L, Shang CZ, Cao J, Lu LH, Min J, Cheng H. Effects of sodium butyrate on 
the differentiation of pancreatic and hepatic progenitor cells from mouse embryonic stem 
cells. J Cell Biochem 2010;109:236-44. 
272. Teratani T, Yamamoto H, Aoyagi K, Sasaki H, Asari A, Quinn G, et al. Direct hepatic fate 
specification from mouse embryonic stem cells. Hepatology 2005;41:836-46. 
273. Asahina K, Teramoto K, Teraoka H. Embryonic stem cells: hepatic differentiation and 
regenerative medicine for the treatment of liver disease. Curr Stem Cell Res Ther 
2006;1:139-56. 
274. Garcia-Pagan JC, De Gottardi A, Bosch J. Review article: the modern management of 
portal hypertension--primary and secondary prophylaxis of variceal bleeding in cirrhotic 
patients. Aliment Pharmacol Ther 2008;28:178-86. 
275. Kauffman CR, Mahvash A, Kopetz S, Wolff RA, Ensor J, Wallace MJ. Partial splenic 
embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. 
Cancer 2008;112:2283-8. 
276. Fried MW, Connaghan DG, Sharma S, Martin LG, Devine S, Holland K, et al. 
Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive 
disease following bone marrow transplantation. Hepatology 1996;24:588-91. 
277. Rapoport AP, Doyle HR, Starzl T, Rowe JM, Doeblin T, DiPersio JF. Orthotopic liver 
transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone 
marrow transplant.  Bone Marrow Transplant 1991;8:421-4. 
 
 
 
 
 
 
192 
 
 
Appendix-1 
 
 
 
 
 
 
 
 
  
  
193 
 
Micro RNA-126 as a diagnostic marker for SOS 
 
MicroRNA (miRNA) isolation (Applied Biosystems, Warrington, UK) 
 
Sample disruption and organic extraction 
1- Homogenization of frozen live samples and addition of 600µ of lysis buffer 
2- The mixture was then vortexed and 1/10 volume of miRNA Homogenate was 
added to the homogenate, vortexed and the mixture left on ice for 10 minutes 
3- Addition of Acid-Phenol: Chloroform that is equal to the lysate volume 
before addition of the miRNA Homogenate Additive and vortexed for 30-60 
sec to mix 
4- Centrifugation for 5 min at maximum speed (10,000 x g) at room temperature 
to separate the aqueous and organic phases resulting in a compact interphase 
5- The aqueous (upper) phase was carefully removed without disturbing the 
lower phase, and transferred it to a fresh tube 
 
Final miRNA isolation 
1- Addition of  1.25 volumes of room temperature 100% ethanol to the aqueous 
phase  
2- Pipetting of the lysate/ethanol mixture onto the filter cartridge and 
centrifuged to maximum speed and repeat till all of the lysate/ethanol mixture 
was drained through the filter 
3- Application of 700 μL miRNA wash solution 1 (working solution mixed with 
ethanol) to the filter cartridge and centrifuge for approximately 5–10 sec 
4- Application of  500 μL Wash Solution 2/3 (working solution mixed with 
ethanol) 
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5-  Repeated with a second 500 μL aliquot of Wash Solution 2/3 
6- After discarding the flow-through from the last wash, the filter cartridge was 
replaced in the same collection tube and the assembly spinned for 1 min to 
remove residual fluid from the filter 
7- The filter cartridge then was transferred into a fresh collection tube. 
Application of 100 μL of pre-heated (95°C) nuclease-free water to the center 
of the filter, and the cap closed and spinned for ~20–30 sec at maximum 
speed to recover the RNA. 
8- The eluate was then collected (which contains the RNA) and stored at –20°C 
 
RNA quantification 
We used the Nanodrop 2000 spectrophotometer (Wilmington, USA) to calculate the 
concentration of miRNA in the solution.  
 
Reverse transcription (RT) (TaqMan MicroRNA Reverse Transcription Kit) 
(Applied Biosystems, Warrington, UK) 
1- The kit components were thawed on ice 
2- In a polypropylene tube, the RT master mix was prepared. RNA was diluted 
to reach a final concentration of 10ng/15 µL of RT reaction. Each 15 µL of 
RT reaction consisted of 7µL master mix, 3 µL primer, and 5 µL RNA sample 
3- The tubes were sealed and mixed gently to bring the solution to the bottom of 
the tube 
4- The tubes were incubated on ice for 5 min and kept till ready to load the 
thermal cycler (Quanta Biotech 2, Surrey, UK) 
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PCR amplification 
1- For preparation of the PCR reaction plate, a master mix volume of 20 
µL/reaction was prepared containing Taqman 2X Universal PCR Master Mix 
(10 µL), Taqman miRNA assay (1 µL) and nuclease free water (5 µL). The c-
DNA was then added to each well to make a total of (20 µL) 
2- The target primer used was miRNA-126 and the endogenous control u-87 
3- The microamp plates were sealed and loaded to the 7500 fast real time PCR 
(Applied Biosystems, Warrington, UK) and an amplification plot was 
performed (Fig.46) 
 
 
Figure 46 The amplification plot following the PCR reaction. 
 
4- The fold difference in gene expression was calculated plotted in a graph 
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Establishing a primary cell culture of bile duct epithelial cells in 
rats 
 
We studied the possibility of using bile duct epithelial cells which have been shown 
to be the primary source of hepatic stem cells (84). We performed Bile duct ligation 
(BDL) in order to increase the number of cells that would make it possible to 
establish a primary cell culture of BDL cells  
 
Surgical technique for bile duct ligation in rats 
 
Under general anaesthesia, the hair of the anterior abdominal wall was shaved with a 
clipper and the animal was placed in a supine position on the operating table.  The 
skin was prepared with povidone iodine 10% and draped using sterile towels. 
An upper midline skin incision was made followed by incision of the anterior 
abdominal wall musculature and peritoneum. Care was taken in this step not to injure 
any bowel which might be very superficial. Also, the left lobes of the liver are 
almost very close to the anterior abdominal wall and care was taken not to cut 
through the liver which might lead to uncontrollable bleeding. 
Once the peritoneal cavity was open, the liver lobes were gently pushed upwards by 
the means of sterile cotton balls. Using cotton buds, the duodenum was retracted 
downwards to expose the portal vein and the bile duct. The bile duct was then 
carefully separated from the portal vein by sharp dissection using very fine forceps 
and a silk suture 4/0 was passed to ligate the lower end of the duct immediately 
above the duodenum. It is important not to include the duodenum in the ligature or 
this would lead to bowel obstruction. The silk suture was left long to assist in the 
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downward pull exposing the upper part of the bile duct which was ligated twice. The 
bile duct was divided between the two ligatures without injuring the closely related 
portal vein. 
Haemostasis was checked and any bleeding points were cauterized using a hand held 
cautery device. The cotton ball was removed and the liver was replaced back in 
position. The peritoneum and the anterior abdominal wall musculature were closed 
using 4/0 continuous Vicryl suture.  The skin was closed using interrupted 4/0 silk 
with the ties cut close to the knot to avoid other animals from biting on it leading to 
abdominal dehiscence. 
The wound were then sprayed with opsite and animals were kept in recovery under 
observation till they were fully active. 
 
Killing of the animals and collection of the ligated bile ducts and gall 
bladders 
 
At the designated time points (1, 2 and 4 weeks) the animals were killed under 
general anaesthesia by means of exsanguination. Retrieval of the dilated bile duct 
was performed carefully due to multiple adhesions between the bowel and the dilated 
duct. Also the bile duct needed to be carefully dissected from within the liver lobes.  
It was important not to puncture it as the plane of dissection would be lost making 
the procedure very difficult. 
Once the dilated bile duct was excised, it was washed with cold sterile PBS 5X and 
then placed in a 50 ml tube containing Hanks Balanced Saline Solution. The tube 
was kept on ice and taken immediately to the lab. 
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Rats unlike mice lack a gallbladder and hence in order to achieve a considerable 
number of cells that might be used for purposeful transplantation, we performed 
BDL. We sacrificed the rats at different time points following BDL and we 
performed a primary cell culture at each time point. The one week time point was the 
most appropriate in terms of the highest number of cell, least adhesions intra-
operatively and least number of fibroblasts when cultured on collagen coated plates. 
It was possible to achieve a primary cell culture from bile duct cells following 
scraping of mucosal surface. After 10 days, we could see a configuration similar to 
the bile duct with polygonal/polyhedral cells surrounding a lumen and surrounded by 
some fibroblasts (Fig.47). We performed Immunocytochemistry (ICC) using CD-
133 marker which is a stem cell marker and were able to detect very few positive 
cells within the cultured BDL cells. This did not occur without BDL (Fig.48). 
After 10 days in culture, the polygonal cells could not maintain their architecture and 
were converted into fibroblasts with very few numbers of polygonal cells. 
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Figure 47 Primary cell culture of ligated bile duct epithelial cells showing 
organization of the cells at different time points. At day 10 the cells form a structure 
resembling a bile duct with a lumen and surrounded by polyhedral and rounded cells 
with another layer of fibroblasts and mesenchymal cells. 
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Figure 48 A primary cell culture of bile duct epithelial cells with some cells of 
variable morphology expressing CD 133. 
 
Protocol for Immunocytochemistry (ICC) 
 
ICC was performed in order to assess the presence of a certain antigen expressed by 
cells within cell culture flasks following similar principles of IHC. We used ICC to 
detect the presence of CD-133 cells within a cell culture of bile duct and gall bladder 
epithelial cells. 
Procedure: 
1- In order to achieve this, an 18 x22 mm cell culture tested coverslip (VWR, UK) 
was placed using sterile forceps in each well of a 6-well cell culture flask. The wells 
with the coverslips were then coated with rat tail collagen (Invitrogen, UK) and 
incubated for one hour at room temperature. 
2-Excess collagen was aspirated immediately before cell culture and the wells were 
rinsed well using PBS.  
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3-The cells were then plated with confirmation that the cells were also covering the 
coverslips by visualization under the inverted microscope and then placed into the 
CO2 incubator. 
4-After culturing for the appropriate duration, the media was aspirated and the 
coverslips side by side on the coverslip-basket that soaked in the 37ºC-warmed 
medium. 
5-The coverslips were then incubated at 37 degrees for more than 30 minutes 
(recovery culture). 
6-The fix solution was prepared (4% paraformaldehyde in PBS) and the coverslips 
were placed into the 37 degree pre-warmed fix-solution and incubated at room 
temperature for more than 20 minutes. This was followed by PBS wash (4 min × 3 
times). 
7- The coverslips were then soaked in 0.1％ Triton-X100 in PBS at room 
temperature for 20 min to ensure permeabilization of plasma membranes which is 
required for the easy access of antibody molecules to the target molecules in the cell. 
This was followed by PBS wash (4 min × 3 times). 
8-Drops of the primary antibody CD 133 (1:500, Abcam, UK) were then placed on a 
parafilm (50-100ML) and the coverslips were transferred on the drops of the primary 
antibody with the cellular surface down. After incubation for one hour, the coverslips 
were transferred to the wells with the cell surface up and washed with PBS x3. 
9-Drops of the secondary antibody were then placed on fresh parafilm and the 
coverslips places cell surface down and incubated for 30 minutes. This was followed 
by PBS wash (4 min × 3 times). 
10- Steps 14-18 as in IHC (Chapter 3) 
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Embryoid body formation 
 
Mouse C57BL/6 GFP+ ESCs (Millipore, Co Durham, UK) were used for EB 
formation. 
Mouse ES cells were grown in proper cell culture conditions for at least three 
passages before attempting to form embryoid bodies. 
 
1. The medium used to culture mouse ESCs was carefully removed from the tissue 
culture flasks and the plates were washed twice with 1X PBS. 
2. 5 mL Accutase (Millipore, Co Durham, UK) was applied to the cells and 
incubated in a 37°C incubator for 3-5 minutes. 
3. The flasks were carefully inspected to ensure the complete detachment of cells by 
gently tapping the side of the flask with the palm of the hand. 
4. 5 mL of EB formation medium (Millipore, Co Durham, UK) pre-warmed to 37°C 
was applied to each flask. 
5. The cells were then pipette into a conical tube and centrifuge t at 300 xg for 2-3 
minutes to  
   pellet the cells. 
6. The supernatant was discarded and 2mmL EB formation medium was added to the 
conical tube to resuspend the cells thoroughly without vortexing. 
7. The number of cells were counted using a haemocytometer. 
8. 3 x 10
6 
cells were aliquoted in 10 ml EB formation medium and placed in a sterile 
10-cm  
9. Aliquot 2 to cells in 10mL Embryoid Body Formation Medium and place in a 
ultra low attachment Petri dish (VWR, Leicestershire, UK) 
205 
 
10. Cells were then incubated at 37°C, 5% CO2 incubator for two days. 
11. The cells were carefully collected using a 10 mL serological pipette, (both 
aggregated EBs and non aggregated cells) into a 15 mL conical tube and allowed to 
settle by gravity for 15 minutes. 
12. The supernatant was then carefully removed and the cells resuspended 10 mL 
fresh EB Formation Medium. 
13. The cell suspention was then transferred to a fresh sterile 10-cm low attachment 
plate and incubate at 37°C in a 5% CO2 incubator for 2 days. 
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